metoclopramide has been researched along with Emesis in 743 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the clinical efficacy of prophylactic metoclopramide in reducing the incidence of nausea and vomiting in emergency department (ED) patients with acute pain who were treated with intravenous tramadol." | 9.69 | The efficacy of prophylactic metoclopramide in preventing nausea and vomiting in patients with acute pain treated with intravenous tramadol: a randomized double-blinded, placebo-controlled trial. ( Lokeskrawee, T; Patumanond, J; Phinyo, P; Sriwiset, H; Wongyikul, P, 2023) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 9.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 9.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| " Maropitant (MRP) and metoclopramide (MCP) prevent emesis attributable to the opioid agent apomorphine in dogs." | 9.24 | A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. ( Himelfarb, MA; Invaldi, SH; Litterio, NJ; Lorenzutti, AM; Martín-Flores, M; Zarazaga, MP, 2017) |
| "The aim of the study was to evaluate the efficiencies of selected anti-emetic drugs (metoclopramide, ondansetron and maropitant) in preventing vomiting in the treatment of canine parvoviral enteritis." | 9.24 | Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs. ( Keser, GO; Yalcin, E, 2017) |
| "Eligible patients were those who were mechanically ventilated and over 20 years old, with delayed gastric emptying (DGE), defined as a gastric residual volume ≥250 ml or vomiting, and who failed to respond to first-line prokinetic treatment of 3 doses of 10 mg IV metoclopramide over 24 h." | 9.22 | A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastr ( Allan, K; Brown, J; Greenwood, R; Manara, A; McWilliam, H; Taylor, SJ; Toher, D, 2016) |
| " The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis." | 9.20 | Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. ( Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F, 2015) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 9.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| " The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0." | 9.17 | Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? ( Abdul Kassim, MS; Keat, CH; Phua, G; Poh, WK; Sriraman, M, 2013) |
| "During the 72-h observation period, 39 out of 56 (70%) patients receiving olanzapine had no emesis compared to 16 out of 52 (31%) patients with no emesis for patients receiving metoclopramide (p < 0." | 9.17 | The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Gray, SE; Nagy, CK; Navari, RM, 2013) |
| " Parents or caregivers should be given more detailed discharge instructions about vomiting and diet considering the relatively long time to resuming a normal diet after ketamine sedation and the fact that KAV often occurred after ED discharge." | 9.16 | Adjunctive atropine versus metoclopramide: can we reduce ketamine-associated vomiting in young children? a prospective, randomized, open, controlled study. ( Choi, SC; Jeon, WC; Jung, YS; Kim, GW; Lee, JS; Min, YG; Park, EJ, 2012) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 9.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "To compare the efficacy and safety of ondansetron versus less expensive metoclopramide in the treatment of children with persistent vomiting with acute gastroenteritis." | 9.15 | Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. ( Abdulateef, H; Al-Ansari, K; Alomary, S; Alshawagfa, M; Kamal, K, 2011) |
| "We aimed to compare the relative efficacy of tropisetron and metoclopramide in treating nausea/vomiting in undifferentiated ED patients." | 9.15 | Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial. ( Chae, J; Frauman, AG; Taylor, DM, 2011) |
| "This study assesses the effects of ginger on nausea and vomiting caused by pregnancy and compares it with metoclopramide medicine." | 9.15 | Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea. ( Farhadifar, F; Mohammadbeigi, R; Rezaiie, M; Shahgeibi, S; Soufizadeh, N, 2011) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 9.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "The aim of this study was to compare the incidence of nausea and vomiting in patients with acute pain treated with morphine along with prophylactic metoclopramide or placebo." | 9.12 | Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial. ( Bradshaw, M; Sen, A, 2006) |
| "This study demonstrates that betamethasone does not prevent nausea, vomiting and increase of vasopressin induced by apomorphine, whereas metoclopramide prevents apomorphine-induced emesis." | 9.12 | Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine. ( Axelsson, P; Lövqvist, A; Thörn, SE; Wattwil, L; Wattwil, M, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 9.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "To determine whether intermediate dose metoclopramide is more effective than standard dose metoclopramide for patients who present to the ED with nausea and vomiting." | 9.11 | Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study. ( Basire, M; Cham, S; Kelly, AM, 2004) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 9.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "Aim of this study was to demonstrate that intravenous metoclopramide can reduce pain, nausea and discomfort during nasogastric tube (NGT) insertion in ED." | 9.11 | Effectiveness of pre-emptive metoclopramide infusion in alleviating pain, discomfort and nausea associated with nasogastric tube insertion: a randomised, double-blind, placebo-controlled trial. ( Karaca, MA; Ozucelik, DN; Sivri, B, 2005) |
| "In daily practice, a combination of oral dexamethasone and oral granisetron achieves an extremely high control of acute emesis (86% protection)." | 9.10 | A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. ( Aapro, MS; Bernhard, J; De Pree, C; Maibach, R; Sessa, C; Thuerlimann, B, 2003) |
| " The number of patients who were emesis free (no nausea, retching, or vomiting) was significantly higher in patients who received granisetron (88% [2225]) than in those who received droperidol (64% [1625]; P = 0." | 9.10 | A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial. ( Fujii, Y; Kawasaki, T; Tanaka, H, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 9.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 9.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "Although combination antiemetics prevent vomiting during the initial 24 h after high-dose (> or =100 mg/m2) cisplatin, many patients experience delayed emesis 24-120 h afterwards despite receiving prophylactic dexamethasone and metoclopramide during this time." | 9.09 | Oral cisapride for the control of delayed vomiting following high-dose cisplatin. ( Baltzer, L; Grant, SC; Hinckley, L; Kris, MG; Miller, VA; Pisters, KM; Pizzo, BA, 1999) |
| "Several studies have confirmed the efficacy of high-dose metoclopramide and, more recently, serotonin antagonists, with and without dexamethasone, in the prophylaxis of cisplatin-induced nausea and vomiting." | 9.09 | Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. ( Hussain, M; Khan, Z; Malik, I; Moid, I, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 9.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "Complete control of established postoperative nausea and vomiting, defined as no emesis and no need for another rescue antiemetic medication, was more frequent among the patients who had received granisetron (88%) than among those who had received droperidol (55%) or metoclopramide (50%) (P <." | 9.09 | Granisetron, droperidol, and metoclopramide for the treatment of established postoperative nausea and vomiting in women undergoing gynecologic surgery. ( Fujii, Y; Somekawa, Y; Tanaka, H, 2000) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 9.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 9.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "A single 5-minute infusion of 3 mg granisetron was more effective and produced a less adverse effect than multiple doses of metoclopramide in controlling chemotherapy-induced emesis, both in the first 24 hours and over a 6-day period." | 9.08 | Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Wei, CH, 1995) |
| " Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combination of metoclopramide, dexamethasone phosphate and lorazepam to assess the comparative efficacy of the two regimens in the control of irradiation-induced nausea and vomiting." | 9.08 | Granisetron in the prevention of irradiation-induced emesis. ( Collis, C; Cunningham, J; Cunningham, S; Gandhi, L; Hamon, MD; Prentice, HG, 1995) |
| "Metoclopramide was significantly more effective at preventing both nausea and vomiting (20/44 (45%) compared with 32/47 (68%), p < 0." | 9.08 | Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. ( Appelgren, L; Haglind, E; Thune, A, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "To compare the efficacy of oral droperidol versus oral metoclopramide, or both oral droperidol and metoclopramide, on postoperative vomiting when used as a premedicant for strabismus surgery." | 9.08 | The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery. ( Brown, RE; Jones, E; Kymer, PJ; Lawhorn, CD; Pearce, L, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 9.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 9.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy." | 9.08 | Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996) |
| "Of the patients treated with metoclopramide plus methylprednisolone (n = 92), 53% had complete protection from delayed emesis, 16% a major response, 15% a minor response, and 15% no response." | 9.08 | Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A; Tirrito, ML; Valenza, R, 1995) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 9.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "We conducted a prospective randomized study to compare granisetron, a 5-hydroxytryptamine-3 receptor antagonist with standard anti-emetics (control group) consisting mainly of metoclopramide, in the prophylaxis of emesis induced by conditioning prior to stem cell transplantation." | 9.08 | Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. ( Asano, S; Ikeda, Y; Kimura, Y; Miyawaki, S; Oh, H; Okamoto, S; Onozawa, Y; Sakamaki, H; Takahashi, S; Tanosaki, R; Toyama, K, 1996) |
| " The recurrence of retching or vomiting was higher with propofol (58%) than with droperidol (4%) or metoclopramide (24%) (P < 0." | 9.08 | Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide. ( Lacroix, G; Lessard, MR; Trépanier, CA, 1996) |
| "The purpose of this retrospective study is to assess the frequency and intensity of chronic nausea in patients admitted to the Palliative Care Unit and the results of a metoclopramide-based treatment regimen." | 9.08 | Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. ( Babul, N; Bruera, E; Darke, A; Harsanyi, Z; Seifert, L; Suarez-Almazor, M; Watanabe, S, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 9.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "To compare the antimetic efficacy of prophylactic ondansetron, metoclopramide, and placebo for prevention of postoperative vomiting in pediatric tonsillectomy or adenotonsillectomy patients." | 9.08 | Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. ( Bohnsack, LE; Bostrom, BC; Seay, RE; Stene, FN; Young, LA, 1996) |
| "The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens." | 9.08 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. ( Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL, 1997) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 9.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "To evaluate the combined effect of granisetron and methylprednisolone against acute emesis induced by cytotoxic agents, we investigated the clinical response and the urinary excretion of 5-HIAA in 85 patients with ovarian cancer who received the same anticancer chemotherapeutic regimen in a prospective randomized trial." | 9.08 | Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents. ( Cheng, X; Itamochi, H; Kigawa, J; Minagawa, Y; Okada, M; Terakawa, N, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 9.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 9.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 9.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 9.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "Granisetron is a better prophylactic antiemetic than droperidol or metoclopramide in female patients with a history of motion sickness undergoing major gynaecological surgery." | 9.08 | Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness. ( Fujii, Y; Tanaka, H; Toyooka, H, 1997) |
| "To compare the efficacy of ondansetron, droperidol, or metoclopramide with placebo in preventing postoperative vomiting following strabismus surgery." | 9.08 | A randomized, double-blind, placebo controlled comparison of droperidol, ondansetron, and metoclopramide for the prevention of vomiting following outpatient strabismus surgery in children. ( Elliott, WG; James, RL; Mims, G; Scuderi, PE; Weaver, RG; Weeks, DB, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 9.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "Seminoma stage I patients on tropisetron experienced less nausea and vomiting during abdominal radiotherapy than patients receiving metoclopramide." | 9.08 | Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. ( Aass, N; Fosså, SD; Håtun, DE; Thoresen, M, 1997) |
| "Granisetron is more effective than droperidol or metoclopramide in preventing PONV in female patients with a history of postoperative emesis." | 9.08 | Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 9.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| "The antiemetic efficacy of droperidol, metoclopramide and granisetron was compared with placebo in the reduction of vomiting after paediatric surgery (the extremities; inguinal hernia; and phimosis) during general inhalational anaesthesia." | 9.08 | Prophylactic therapy with granisetron in the prevention of vomiting after paediatric surgery. A randomized, double-blind comparison with droperidol and metoclopramide. ( Fujii, Y; Tanaka, H, 1998) |
| "This study evaluates the prophylactic anti-emetic efficacy of granisetron, droperidol and metoclopramide, for the prevention of post-operative nausea and vomiting in female patients undergoing elective laparoscopic cholecystectomy." | 9.08 | Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "The incidence of postoperative emesis in the metoclopramide group was 60% versus 71% in a placebo group (p < 0." | 9.08 | Prophylactic metoclopramide administered immediately after the induction of anesthesia has no effect on the incidence of postoperative emesis after strabismus surgery. ( Haldar, M; Shende, D, 1998) |
| "A single institution, prospective, randomized trial was performed in terminal cancer patients to compare tropisetron (TRO), metoclopramide (MET), and chlorpromazine (CHL) in the management of nausea and emesis." | 9.08 | Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. ( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 9.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 9.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "Lignocaine has been shown to reduce the incidence of pain on injection of propofol." | 9.07 | Propofol injection pain: comparing the addition of lignocaine or metoclopramide. ( Mecklem, DW, 1994) |
| "Oral metoclopramide may be given as a premedicant to reduce post-operative nausea and vomiting, but there is little evidence that it is effective." | 9.07 | Sustained release metoclopramide for prophylaxis of post-operative nausea and vomiting. ( Curran, JP; Elliott, RH; Graham, SG, 1994) |
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 9.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "In a prospective, double-blind study, we have examined the effect of preoperative nabilone on postoperative nausea and vomiting (PONV)." | 9.07 | Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. ( Barrowcliffe, MP; Campbell, DN; Lewis, IH, 1994) |
| " Oral granisetron alone was as effective as met/dex in control of acute emesis in all parameters examined." | 9.07 | Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. ( Cedar, E; Cunningham, J; Goedhals, L; Heron, JF; Jordaan, JP, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 9.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 9.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "Metoclopramide is an active antiemetic against cisplatin-induced acute emesis." | 9.07 | Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis. ( Kajita, M; Niimi, T; Saito, H; Shimokata, K; Yamori, S, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 9.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 9.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 9.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "We investigated the usefulness of concurrent therapy of granisetron with methylprednisolone sodium for on nausea, vomiting and anorexia induced by chemotherapy, including cisplatin, in patients with oral cancer." | 9.07 | [Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin]. ( Kawashima, T; Miyata, K; Morita, N; Ohmata, T; Sakamoto, T; Wada, T, 1993) |
| " The purpose of this study was to compare the incidence of emesis after propofol anaesthesia with and without nitrous oxide, compared with thiopentone and halothane anaesthesia, in hospital and up to 24 hr postoperatively, in outpatient paediatric patients after strabismus surgery." | 9.07 | Propofol anaesthesia reduces early postoperative emesis after paediatric strabismus surgery. ( Bevan, JC; Blackstock, D; Merrick, PM; Montgomery, CJ; Popovic, V; Reimer, EJ, 1993) |
| ") was compared with a metoclopramide cocktail for the prevention of nausea and emesis." | 9.07 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994) |
| ", Basel, Switzerland), a new 5-HT3 receptor antagonist, was compared in a randomized multicenter trial with a high-dose metoclopramide-dexamethasone cocktail for the prevention of nausea and emesis during cisplatin-containing chemotherapy." | 9.07 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( de Bruijn, KM; Glimelius, B; Hansen, O; Högberg, T; Räisänen, I; Schmidt, M; Sorbe, BG; Sörensen, BT; van Oosterom, AT; Wernstedt, L, 1994) |
| "Vomiting was prevented in two thirds of patients treated with MDL plus ondansetron, a result similar to that observed in earlier trials of MDL alone." | 9.07 | The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. ( Baltzer, L; Kris, MG; Pisters, KM; Rigas, JR; Tyson, LB, 1994) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 9.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "The cost effectiveness of ondansetron was compared with that of metoclopramide in the prevention of acute emesis due to highly emetogenic chemotherapy in an open, randomised, parallel group pilot study." | 9.07 | The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. ( Cunningham, D; Davidson, N; Gore, M; Manchanda, M; Miocevich, M; Wells, N, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe." | 9.07 | A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. ( Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 9.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "The efficacy of intravenous metoclopramide in controlling vomiting in children after tonsillectomy was determined in a prospective randomized, double-blind investigation." | 9.07 | Metoclopramide reduces the incidence of vomiting after tonsillectomy in children. ( Donlon, JV; Ferrari, LR, 1992) |
| " One hundred ten pediatric patients, ages 8 months to 14 yr, admitted for outpatient strabismus surgery were enrolled in a randomized, double-blinded study to compare droperidol and metoclopramide to placebo for the prevention of postoperative emesis." | 9.07 | A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery. ( Furst, SR; Lin, DM; Rodarte, A, 1992) |
| "Sixty patients were studied in a randomized, double-blind manner to determine whether metoclopramide added to droperidol decreased further the incidence of emetic symptoms (nausea, retching, vomiting) in outpatients receiving alfentanil anaesthesia for nasal surgery." | 9.07 | Metoclopramide does not decrease the incidence of nausea and vomiting after alfentanil for outpatient anaesthesia. ( AlHaddad, S; Furgerson, C; Khalil, I; Maurer, W; Whalley, DG, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 9.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 9.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "This double-blind randomized cross-over study was conducted to compare the safety and efficacy of high-dose prochlorperazine infusion and dexamethasone (HDPD) with an effective and safe combination of high-dose metoclopramide and dexamethasone (HDMD) in controlling cisplatin-induced emesis." | 9.07 | A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis. ( Akhtar, SS; Bano, ZA; Bhat, GM; Bhat, MA, 1991) |
| "To prevent delayed emesis induced by cisplatin (mean dose 90 mg/m2), 120 consecutive patients were randomized to receive, in a 7-day crossover design, oral metoclopramide (20 mg q." | 9.07 | Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. ( Ballatori, E; Basurto, C; Boschetti, E; Bracarda, S; Patoia, L; Penza, O; Picciafuoco, M; Roila, F; Santi, E; Tonato, M, 1991) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 9.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 9.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "The efficacy of ondansetron was compared with metoclopramide in the prophylaxis of nausea and vomiting induced by cyclophosphamide greater than or equal to 500 mg/m2 in combination with doxorubicin greater than or equal to 40 mg/m2 or epirubicin greater than or equal to 40 mg/m2." | 9.06 | A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. ( Carruthers, L; Dicato, MA; Huys, JV; Kaasa, S; Kvaløy, S; Ries, F; Royer, E, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 9.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| "This randomized, double-blind study evaluated the efficacy of metoclopramide administered at the completion of surgery as an antiemetic agent in pediatric patients undergoing ambulatory strabismus surgery; 126 unpremedicated ASA Physical Status 1 and 2 children ranging in age from 2 to 18 yr served as subjects." | 9.06 | Metoclopramide reduces the incidence of vomiting following strabismus surgery in children. ( Broadman, LM; Ceruzzi, W; Friendly, D; Hannallah, RS; Patane, PS; Ruttimann, U, 1990) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 25 women with stage II breast cancer were entered into this study." | 9.06 | Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. ( Giannarelli, D; Marolla, P; Nardi, M; Pinnaró, P; Pollera, CF; Terzoli, E, 1989) |
| " All patients received intravenous (IV) metoclopramide, dexamethasone, and lorazepam for the control of acute emesis during the period from 0 to 24 hours after cisplatin." | 9.06 | Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. ( Cirrincione, C; Clark, RA; Gralla, RJ; Groshen, S; Kris, MG; Tyson, LB, 1989) |
| "In a randomized, double-blind study, we compared the efficacy of metoclopramide hydrochloride with that of low-dose droperidol for prevention of nausea and vomiting during and after elective cesarean section with epidural anesthesia." | 9.06 | Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section. ( Bates, JN; Chestnut, DH; Choi, WW; Geiger, M; Ostman, PL; Owen, CL, 1989) |
| " Lorazepam and dexamethasone are increasingly being used to alleviate chemotherapy induced emesis." | 9.06 | The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. ( Blackledge, GR; Burman, C; Cullen, MH; Kelly, K; O'Brien, ME; Palmer, K; Sharpe, J; Stuart, NS; Woodroffe, C, 1989) |
| "Sixty-four patients treated with cisplatin-containing regimens were entered into a randomized, double-blinded study examining the antiemetic efficacy of metoclopramide with and without lorazepam for control of cisplatin-induced emesis." | 9.06 | Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis. ( Al-Sarraf, M; Cummings, G; Gordon, CJ; Pazdur, R; Ziccarelli, A, 1989) |
| "Forty-two patients with advanced lung cancer undergoing chemotherapy containing cisplatin (80 mg/m2) were submitted to a randomized controlled trial to evaluate the effect of the combination of metoclopramide and dexamethasone for the treatment of delayed cisplatin-induced emesis occurring more than 24 hours after cisplatin administration." | 9.06 | Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. ( Eguchi, K; Fujiwara, Y; Fukuda, M; Mae, M; Ohe, Y; Saijo, N; Sasaki, S; Sasaki, Y; Shinkai, T; Tamura, T, 1989) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 9.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis." | 9.06 | [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. ( Eguchi, K; Inoue, I; Nino, S; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T; Umehara, H, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 9.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "Methylprednisolone sodium succinate and metoclopramide were compared for their efficacy, tolerance, and safety in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy in patients with cancer." | 9.06 | Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. ( Erlichman, C; Levitt, M; Osoba, D; Pater, JL; Willan, AR, 1986) |
| "A randomized cross-over study on the effects of methylprednisolone (MP), metoclopramide (MT) and droperidol (DP) on the control of nausea and vomiting associated with cis-platinum chemotherapy was performed." | 9.06 | [Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy]. ( Akaza, H; Aso, Y; Fujita, K; Isurugi, K; Kawabe, K; Kinoshita, K; Koiso, K; Kondo, Y; Niijima, T; Yokoyama, M, 1986) |
| "Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order." | 9.06 | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. ( Allan, SG; Cornbleet, MA; Leonard, RC; MacPherson, JS; Smyth, JF; Warrington, PS, 1986) |
| "One hundred and two patients with advanced solid tumors receiving chemotherapy were treated with metoclopramide (MCP; 100 mg) to prevent emesis." | 9.05 | Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. ( Bruera, ED; Cedaro, L; Chacón, R; Estévez, R; Roca, E, 1983) |
| " Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting." | 9.05 | [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy]. ( Budach, V; Krüger, K, 1983) |
| "In a double-blind comparison of domperidone 10 mg, domperidone 4 mg, metoclopramide 10 mg and a placebo, 176 adult patients were given an intravenous injection of one of these substances after postoperative vomiting had occurred." | 9.05 | Postoperative vomiting treated with domperidone. A double-blind comparison with metoclopramide and a placebo. ( Boghaert, A; Carron, D; Gallant, J; Stockman, A, 1980) |
| "The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial." | 9.05 | [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis]. ( Eguchi, K; Fujita, J; Funaki, Y; Futami, H; Sakurai, M; Sasaki, Y; Sawamura, N; Takahashi, S; Yokoyama, S; Yoshioka, S, 1985) |
| "In a double-blind trial in 60 children suffering from gastroenteritis complicated by vomiting, it was found that suppositories of domperidone (30 mg) were more effective than either metoclopramide (10 mg) or placebo in reducing the severity of vomiting, nausea and other symptomatic parameters." | 9.04 | A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. ( Ameryckx, L; Dhondt, F; Heck, E; Van Eygen, M; Van Ravensteyn, H, 1979) |
| "Forty-seven infants and children suffering from chronic vomiting or regurgitation, participated in a two-week double-blind trial comparing 1% drops of domperidone, 1% metoclopramide drops or placebo." | 9.04 | Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. ( Ameryckx, L; De Loore, I; Van Ravensteyn, H, 1979) |
| "One hundred and ninety-five female patients of child-bearing age were assessed for postoperative vomiting in a double-blind trial using domperidone, metoclopramide and placebo." | 9.04 | Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo. ( Ball, RW; Comyn, DJ; Cooke, RD, 1979) |
| "To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults." | 8.98 | Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. ( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 8.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "8 mg/kg was superior to metoclopramide in preventing emesis induced by high dose cisplatin or by moderately emetogenic chemotherapy in high risk subgroups." | 8.79 | Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. ( Balfour, JA; Goa, KL, 1997) |
| " Metoclopramide is generally acknowledged to be the single most effective conventional drug for the prevention of acute cisplatin-induced emesis and, therefore, was considered an appropriate agent for inclusion in comparative trials with ondansetron." | 8.78 | Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. ( Hesketh, PJ, 1992) |
| "Ondansetron is commonly used to treat nausea and vomiting in pregnancy despite inconclusive evidence of its safety." | 8.02 | Ondansetron use in early pregnancy and the risk of miscarriage. ( Boggess, K; Engel, SM; Jonsson Funk, M; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 7.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "Metoclopramide is commonly used to treat vomiting caused by seasickness and acute gastroenteritis on cruise ships and serious adverse effects have not been reported from use at sea." | 7.80 | Long-lasting adverse effects after short-term low-dose treatment with metoclopramide for vomiting. ( Dahl, E; Diskin, AL, 2014) |
| "Patients with cancer frequently report gastrointestinal symptoms such as anorexia, early satiety, nausea, vomiting, and bloating." | 7.80 | Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. ( Chow, W; Darke, A; Harsanyi, Z; Marshall, D; Pearen, S; Plourde, JY; Wilson, J; Yoshida, S, 2002) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 7.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The aim of study was, comparison of effects of Metoclopramide and Dropridol associated with Dexamethasone on prevalence of nausea and vomiting after operation was considered." | 7.76 | Comparison the effects of metoclopramide and dropridol associated with dexamethasone on post operative nausea and vomiting. ( Ebrahim, A; Ebrahim, N; Hosssain, B; Yousef, M, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "In various countries, metoclopramide is the antiemetic drug of choice in pregnant women, but insufficient information exists regarding its safety in pregnancy." | 7.75 | The safety of metoclopramide use in the first trimester of pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009) |
| "A patient who was given metoclopramide for vomiting and diarrhoea developed circulatory collapse with his blood pressure dropping to 50/20 mm Hg." | 7.75 | Circulatory collapse in a patient with gastrinoma after metoclopramide administration. ( Chan, AY; Chan, KW; Ching, CK; Lam, AW; Lau, KK; Lee, HH; Li, SM; Lo, J; Lok, CM; Luk, WF; Mak, CM, 2009) |
| " In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine." | 7.73 | Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 7.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| "A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of tropisetron (TRO), a 5-HT3 receptor antagonist, in 88 patients undergoing fractionated radiotherapy to the abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with metoclopramide (MET)." | 7.69 | Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. ( Behrouz, F; Blazek, N; Coucke, P; Gebhard, S; Melliger, M; Miralbell, R; Philipp, S; Rosset, A; Schwabb, T; Wickenhauser, R, 1995) |
| "Although buprenorphine sometimes causes severe emesis, its relation to the menstrual cycle has not been reported." | 7.69 | Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. ( Kamiyama, M; Kitamura, A; Kon, T; Ogawa, R, 1996) |
| "Fifty-one patients who received their first course of chemotherapy were studied to compare the respective efficacy and safety of granisetron and metoclopramide plus dexamethasone in the prevention of nausea and vomiting induced by emetogenic cytotoxic drugs." | 7.69 | Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. ( Chang, CS; Chen, LT; Chen, TP; Huang, SM; Lin, SF; Liu, TC; Wei, TC, 1997) |
| " Erythromycin administration is associated with gastrointestinal problems, disturbed gastrointestinal motility and emesis." | 7.68 | Effects of cholinoceptor and 5-hydroxytryptamine3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis. ( Pilot, MA; Qin, XY; Scott, M; Thompson, H, 1993) |
| " 5 min prior to morphine while each ferret was maintained under isoflurane-O2 anesthesia." | 7.68 | The effects of different antiemetic agents on morphine-induced emesis in ferrets. ( Essien, E; Thut, PD; Wynn, RL, 1993) |
| "A 4-year-old female blue and gold macaw (Ara ararauna) with a history of chronic vomiting was treated with metoclopramide hydrochloride." | 7.68 | Adverse drug reaction to metoclopramide hydrochloride in a macaw with proventricular dilatation syndrome. ( Massey, JG, 1993) |
| "Pancopride ((+-)N-(1-azabicyclo-[2,2,2]-oct-3-yl)-2-cyclopropylmethoxy-4-ami no-5-chlorobenzamide) is a new potent and selective 5-HT3 receptor antagonist, orally and parenterally effective against cytotoxic drug-induced emesis." | 7.68 | Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. ( Beleta, J; Berga, P; Bou, J; Doménech, T; Fernández, AG; Gristwood, RW; Puig, J; Roberts, DJ, 1992) |
| " The syndrome was associated with metoclopramide antiemetic therapy given for post-operative nausea and vomiting." | 7.68 | Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. ( Bakri, YN; Kawi, Z; Khan, R; Subhi, J, 1992) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 7.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "In prospective alternative crossover test, we confirmed significant superiority of a three-drug combination of clonazepam (C) lorazepam (L) and dexamethasone (D) to (L) and (D) to control vomiting induced by 50 mg/m CDDP containing chemotherapy for gynecological malignancies (p less than 0." | 7.68 | [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting]. ( Asano, H; Hatae, M; Hokanishi, H; Mitsuo, M; Nakamura, Y; Onishi, Y; Sakurai, K, 1990) |
| "Nabilone is a cannabinoid anti-emetic which has been extensively evaluated in control of chemotherapy-induced vomiting." | 7.67 | An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. ( Priestman, SG; Priestman, TJ, 1984) |
| "Using an original high-pressure liquid chromatographic assay, we measured serum levels of metoclopramide and defined a concentration-response relationship for metoclopramide control of cisplatin-induced emesis." | 7.67 | Optimizing metoclopramide control of cisplatin-induced emesis. ( Drayer, DE; Lewin, M; Lonski, L; Meyer, BR; Pasmantier, M; Reidenberg, MM, 1984) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 7.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "To investigate the effectiveness of high oral doses of the antiemetic agent 4-amino-5-chloro-N-(2-diethyl-aminoethyl)-2-methoxybenzamide (metoclopramide, MCP, Gastrosil) against nausea and vomiting induced by certain cyostatic drugs, blood was withdrawn repeatedly from 9 patients; MCP plasma levels were then determined." | 7.67 | [Metoclopramide plasma levels following oral administration of high doses for prophylaxis of emesis in cytostatic therapy]. ( Köhler, M; Senn, HJ; Vergin, H, 1984) |
| "The authors tested the safety and efficacy of intravenous metoclopramide in the prevention of chemotherapy-induced nausea and vomiting." | 7.67 | Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. ( McDermed, JE; Pileggi, J; Riech, LP; Strum, SB; Whitaker, H, 1984) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 7.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "The antiemetic activity, gastric motor activity, and dopamine receptor effects of metoclopramide, dazopride, and sulpiride were assessed to establish if enhancement of gastric motility or antagonism of central dopamine receptors is the predominant action for drug-induced suppression of cisplatin-induced emesis." | 7.67 | Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. ( Alphin, RS; Dannenburg, WN; Johnson, DN; Kinnier, WJ; Leonard, CA; Proakis, AG; Sancilio, LF; Smith, WL; Ward, JW, 1986) |
| " To prevent emesis, two high-dose metoclopramide regimens were started 2 hr before cytostatic therapy." | 7.67 | Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis. ( Achtert, G; Briemann, L; Brockmann, P; Hausleiter, HJ; Hellenbrecht, D; Hellstern, A; Hess, H; Hodgson, M; Mitrou, P; Saller, R, 1985) |
| "Intravenous metoclopramide and IM prochlorperazine and diazepam were compared in the management of vomiting occurring during treatment with cis-dichlorodiammineplatinum (cis-platinum)." | 7.67 | High-dose intravenous metoclopramide and intermittent intramuscular prochlorperazine and diazepam in the management of emesis induced by cis-dichlorodiammineplatinum. ( Chan, KK; Luesley, DM; Terry, PB, 1985) |
| "Having noticed psychotic traits in some patients showing incoercible vomiting due to antineoplastic drugs we have thought of establishing a therapy with lithium in the days preceding the therapeutic cycle in order to reduce the emetic events." | 7.67 | Sequential therapy with lithium in chemotherapy-induced vomiting. ( Alfano, G; Candido, A; Mango, G; Menichella, G; Rossi, P; Tartaglione, R, 1985) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 6.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 6.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "Metoclopramide was ineffective." | 6.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy." | 6.68 | Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. ( Ata, E; Butt, A; Khan, MA; Khan, WA; Malik, IA; Qazilbash, M, 1995) |
| " We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients." | 6.68 | Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. ( , 1997) |
| "Tropisetron+dexamethasone was significantly superior to tropisetron alone both for acute (P = 0." | 6.68 | Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. ( Bangerter, M; Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gallmeier, WM; Gosse, H; Grote-Kiehn, J; Imhoff, W; Mezger, J; Oehm, C; Ukena, D; Untch, M, 1997) |
| "The metoclopramide dosage was 20 mg i." | 6.68 | Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. ( Advani, SH; Cooverji, ND; Dhar, AK; Gopal, R; Lal, HM, 1996) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 6.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Tropisetron is an effective and well-tolerated agent in the prevention of chemotherapy-induced vomiting." | 6.67 | Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. ( Anderson, H; de Bruijn, KM; Howell, A; Logan, K; Sage, T; Thatcher, N, 1994) |
| "Droperidol was given just after induction and metoclopramide at the end of surgery, just before recovery." | 6.67 | Open placebo controlled comparison of the antiemetic effect of droperidol, metoclopramide or a combination of both in pediatric strabismus surgery. ( Pendeville, PE; Steinier, JR; Van Boven, MJ; Veyckemans, F, 1993) |
| " Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis." | 6.67 | Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. ( Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994) |
| "Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy." | 6.67 | Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. ( Balduck, N; Hachimi-Idrissi, S; Maurus, R; Otten, J, 1994) |
| "Acute nausea was prevented completely in 40% of patients in the tropisetron group and in 61% of the metoclopramide cocktail group during course 1 (P < ." | 6.67 | Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. ( Sorbe, BG, 1994) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 6.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Ondansetron was well tolerated in the dose and schedule used." | 6.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "Droperidol was more effective in reducing severe vomiting." | 6.67 | [Droperidol versus metoclopramide. Prevention of emesis following strabismus surgery in children]. ( Braun, U; Feldmann, M; Klockgether-Radke, A; Mühlendyck, H, 1992) |
| "Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight." | 6.67 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ( Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991) |
| "At the end of the treatment period, nausea, vomiting and reflux symptoms, adverse events and a global assessment of patients' symptom control were recorded by the investigator." | 6.67 | A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting. ( Miller, AJ; Patel, NH; Roy, P, 1991) |
| " Overall, the evidence suggests that this dosing schedule for batanopride may be too toxic for clinical use." | 6.67 | Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. ( Fleming, GF; Francher, D; Janisch, L; McEvilly, JM; Smaldone, L; Vokes, EE, 1991) |
| "Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0." | 6.67 | Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. ( Osterwalder, B; Schimke, J; Senn, HJ; Wilder-Smith, CH, 1991) |
| "Vomiting was not satisfactorily prevented by either treatment." | 6.67 | Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. ( Hallén, C; Sorbe, B, 1991) |
| " We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B)." | 6.66 | Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research ( Basurto, C; Bracarda, S; Di Costanzo, F; Donati, D; Malacarne, P; Monici, L; Patoia, L; Picciafuoco, M; Roila, F; Tonato, M, 1989) |
| "Clebopride was reasonably well tolerated at the used dosages, inducing sedation in 20% of cases (versus 24% with metoclopramide) and diarrhea in 37% (versus 20% with metoclopramide)." | 6.66 | [Comparative study on the tolerance and efficacy of high doses of metoclopramide and clebopride in vomiting induced by cisplatin]. ( Díaz-Rubio, E; Martín, M, 1989) |
| "19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters." | 6.66 | [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ( Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988) |
| "Droperidol was significantly more effective than domperidone, metoclopramide or placebo in reducing emetic sequelae." | 6.66 | Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery. ( Madej, TH; Simpson, KH, 1986) |
| "The metoclopramide regimen was either 2 mg/kg i." | 6.66 | A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis. ( Abdulhay, G; Dana, BW; Everts, E; McDermott, M, 1987) |
| " With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis." | 6.66 | A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. ( Carlini, P; Marolla, P; Nardi, M; Pollera, CF, 1987) |
| " It is concluded that there is a dose-response relationship for the antiemetic effect of metoclopramide." | 6.66 | High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. ( Grande, T; Moxnes, A; Onsrud, M; Solesvik, O; Sollien, A, 1988) |
| "Continuous infusion of metoclopramide was compared with bolus dosing in a randomized, double-blind study in 27 patients receiving cisplatin therapy." | 6.66 | Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis. ( Agostinucci, WA; Dinonno, EB; Gannon, RH; Golub, GR; Martin, RS; Schauer, PK, 1988) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 6.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "To better define the dose-response relationship of moderate-dose (MD) metoclopramide (MCP), 42 patients receiving their first course of cisplatin (50 mg/m2) were randomly allocated to receive a short-course regimen of MCP, either at 1 mg/kg X 1 dose, 30 min before cisplatin (regimen A) or 1 mg/kg X 2 doses, 30 min before and 1 h after cisplatin (regimen B)." | 6.66 | Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesis. ( Calabresi, F; Conti, EM; De Nigris, A; Pollera, CF, 1987) |
| "The metoclopramide-treated group demonstrated a statistically significant decrease in the incidence of nausea and vomiting." | 6.66 | Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. ( Brown, RE; Drew, SJ; Sabates, R, 1987) |
| "Metoclopramide was compared to a metoclopramide plus dexamethasone combination in patients receiving high-dose cisplatinum." | 6.66 | Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. ( Akerley, WL; Baker, CR; Cariffe, PA; Grunberg, SM; Johnson, KB; Krailo, MD, 1986) |
| "Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2." | 6.66 | [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]. ( Dozono, H; Ohmi, K, 1986) |
| "Metoclopramide (MCP) was given i." | 6.65 | Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. ( Carlini, P; Cognetti, F; Conti, EM; Cortese, M; Pinnarò, P; Pollera, CF, 1984) |
| "In a population of 51 ambulant cancer patients treated with doxorubicin-containing chemotherapy we conducted a double-blind cross-over randomized trial, comparing the anti-emetic efficacy of a combination of amitriptyline (25 mg p." | 6.65 | Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. ( Blijham, GH; Mellink, WA; van Deyk, WA, 1984) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 6.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| " The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized." | 6.65 | Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. ( Cox, R; Leyland, MJ; Newman, CE, 1982) |
| "Metoclopramide is a prokinetic agent reported to be safe in parturients." | 6.48 | Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. ( Habib, AS; Mishriky, BM, 2012) |
| " High-dose metoclopramide has demonstrated efficacy in small series of patients in the treatment of cisplatin-induced vomiting." | 6.15 | Advances in anti-emetic therapy. ( Bakowski, MT, 1984) |
| "Metoclopramide, 4-amino-5-chloro-2-methoxy-N-(2-diethyl-aminoethyl) benzamide, is advocated for use in gastro-intestinal diagnostics, and in treating various types of vomiting and a variety of functional and organic gastro-intestinal disorders." | 6.14 | Metoclopramide: a review of its pharmacological properties and clinical use. ( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1976) |
| "We considered akathisia and cancer-related anxiety/agitation as possible causes of restlessness and insomnia, and prescribed clonazepam." | 5.72 | Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report. ( Deguchi, Y; Inoue, K; Itoh, Y; Sakamoto, S; Uchida, S, 2022) |
| "To examine the clinical efficacy of prophylactic metoclopramide in reducing the incidence of nausea and vomiting in emergency department (ED) patients with acute pain who were treated with intravenous tramadol." | 5.69 | The efficacy of prophylactic metoclopramide in preventing nausea and vomiting in patients with acute pain treated with intravenous tramadol: a randomized double-blinded, placebo-controlled trial. ( Lokeskrawee, T; Patumanond, J; Phinyo, P; Sriwiset, H; Wongyikul, P, 2023) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 5.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 5.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| " Prior treatment with each dosage of metoclopramide significantly reduced the frequency of emetic episodes (P<0." | 5.36 | Effects of metoclopramide on emesis in cats sedated with xylazine hydrochloride. ( Jarolmasjed, S; Kolahian, S, 2010) |
| "Metoclopramide is a dopamine receptor blocking drug that is commonly used to treat nausea and vomiting." | 5.31 | Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. ( Addis, A; Arnon, J; Berkovitch, M; Elbirt, D; Greenberg, R; Magee, L; Mazzota, P; Merlob, P; Moretti, M; Ornoy, A; Schuler-Faccini, L; Stahl, B, 2002) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Despite treatment, emesis remains a major problem with cisplatin chemotherapy." | 5.28 | [Improved control of cisplatin-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam]. ( Hsu, KP; Li, YT; Mau, YK; Tsui, MS; Tu, FC, 1991) |
| "Both zacopride and BMY25801 were effective against emesis and related signs." | 5.28 | Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. ( King, GL; Landauer, MR, 1990) |
| "Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin." | 5.28 | Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. ( Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989) |
| " In these six patients plasma metoclopramide half-life was 5." | 5.27 | Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting. ( Bateman, DN; Proctor, SJ; Taylor, WB, 1984) |
| "Metoclopramide was orally administered (10 or 20 mg) to 22 subjects, 75 min before parabolic flight." | 5.27 | Hormonal responses of metoclopramide-treated subjects experiencing nausea or emesis during parabolic flight. ( Kohl, RL, 1987) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 5.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| " The quantitative dose-response curves of the four doses of the emetic agonist cisplatin were shifted to the right by increasing doses of MCL." | 5.27 | Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. ( Hellenbrecht, D; Saller, R, 1986) |
| "Metoclopramide was administered four times intravenously at a dose of 1." | 5.27 | [Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting]. ( Amano, H; Fujimoto, K; Saito, H; Shimokata, K; Tsunekawa, H; Yasuda, Y; Yoshii, S, 1985) |
| "Metoclopramide (Paspertin) was infused intravenously in the high doses of 1." | 5.27 | Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis. ( Hellenbrecht, D; Hellstern, A; Hess, H; Saller, R, 1985) |
| "Metoclopramide was used as an antiemetic." | 5.26 | [Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)]. ( Antz, H; Doepfmer, K; FEAUX DE Lacroix, W; Groth, W; Runne, U, 1980) |
| " Maropitant (MRP) and metoclopramide (MCP) prevent emesis attributable to the opioid agent apomorphine in dogs." | 5.24 | A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. ( Himelfarb, MA; Invaldi, SH; Litterio, NJ; Lorenzutti, AM; Martín-Flores, M; Zarazaga, MP, 2017) |
| "The aim of the study was to evaluate the efficiencies of selected anti-emetic drugs (metoclopramide, ondansetron and maropitant) in preventing vomiting in the treatment of canine parvoviral enteritis." | 5.24 | Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs. ( Keser, GO; Yalcin, E, 2017) |
| "There was no evidence that prophylactic metoclopramide affected the risk of vomiting, nausea, or the need for rescue medication when provided prior to intravenous opioids in the acute care setting." | 5.22 | Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting. ( Carlson, JN; Gottlieb, M; Peksa, GD, 2022) |
| "Eligible patients were those who were mechanically ventilated and over 20 years old, with delayed gastric emptying (DGE), defined as a gastric residual volume ≥250 ml or vomiting, and who failed to respond to first-line prokinetic treatment of 3 doses of 10 mg IV metoclopramide over 24 h." | 5.22 | A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastr ( Allan, K; Brown, J; Greenwood, R; Manara, A; McWilliam, H; Taylor, SJ; Toher, D, 2016) |
| " The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis." | 5.20 | Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. ( Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F, 2015) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 5.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| " The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0." | 5.17 | Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? ( Abdul Kassim, MS; Keat, CH; Phua, G; Poh, WK; Sriraman, M, 2013) |
| "To estimate whether the addition of metoclopramide or its combination with ondansetron to a prophylactic phenylephrine infusion provides improved intraoperative nausea and vomiting prophylaxis compared with phenylephrine infusion alone." | 5.17 | Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. ( Allen, TK; George, RB; Habib, AS; Ituk, US; McKeen, DM; Megalla, SA; White, WD, 2013) |
| "During the 72-h observation period, 39 out of 56 (70%) patients receiving olanzapine had no emesis compared to 16 out of 52 (31%) patients with no emesis for patients receiving metoclopramide (p < 0." | 5.17 | The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Gray, SE; Nagy, CK; Navari, RM, 2013) |
| " Parents or caregivers should be given more detailed discharge instructions about vomiting and diet considering the relatively long time to resuming a normal diet after ketamine sedation and the fact that KAV often occurred after ED discharge." | 5.16 | Adjunctive atropine versus metoclopramide: can we reduce ketamine-associated vomiting in young children? a prospective, randomized, open, controlled study. ( Choi, SC; Jeon, WC; Jung, YS; Kim, GW; Lee, JS; Min, YG; Park, EJ, 2012) |
| "Several trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature." | 5.15 | Antiemetic activity of megestrol acetate in patients receiving chemotherapy. ( Bi, F; Cao, D; Gou, HF; Hou, M; Jiang, M; Luo, de Y; Qiu, M; Shen, Y; Wang, J; Xu, F; Yang, Y; Yi, C; Zang, J; Zhou, XJ, 2011) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 5.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "To compare the efficacy and safety of ondansetron versus less expensive metoclopramide in the treatment of children with persistent vomiting with acute gastroenteritis." | 5.15 | Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. ( Abdulateef, H; Al-Ansari, K; Alomary, S; Alshawagfa, M; Kamal, K, 2011) |
| "We aimed to compare the relative efficacy of tropisetron and metoclopramide in treating nausea/vomiting in undifferentiated ED patients." | 5.15 | Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial. ( Chae, J; Frauman, AG; Taylor, DM, 2011) |
| "This study assesses the effects of ginger on nausea and vomiting caused by pregnancy and compares it with metoclopramide medicine." | 5.15 | Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea. ( Farhadifar, F; Mohammadbeigi, R; Rezaiie, M; Shahgeibi, S; Soufizadeh, N, 2011) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 5.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "Metoclopramide use during first trimester of pregnancy was not associated with the risk of major congenital malformations." | 5.12 | Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. ( Sun, L; Wen, X; Xi, Y; Zou, W, 2021) |
| "First-line antiemetics for nausea and vomiting in advanced cancer are metoclopramide and haloperidol, and second-line medications are methotrimeprazine and olanzapine." | 5.12 | MASCC antiemetics in advanced cancer updated guideline. ( Bruera, E; Capela, A; Davies, A; Davis, M; DeFeo, G; Del Fabbro, E; Hui, D; Ripamonti, C, 2021) |
| "The aim of this study was to compare the incidence of nausea and vomiting in patients with acute pain treated with morphine along with prophylactic metoclopramide or placebo." | 5.12 | Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial. ( Bradshaw, M; Sen, A, 2006) |
| "This study demonstrates that betamethasone does not prevent nausea, vomiting and increase of vasopressin induced by apomorphine, whereas metoclopramide prevents apomorphine-induced emesis." | 5.12 | Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine. ( Axelsson, P; Lövqvist, A; Thörn, SE; Wattwil, L; Wattwil, M, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 5.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "In children and adolescents with osteosarcoma, granisetron was safe and more efficient than metoclopramide plus dimenhydrinate for controlling chemotherapy-induced emesis and nausea." | 5.12 | Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. ( Caran, EM; Luisi, FA; Petrilli, AS; Tanaka, C, 2006) |
| "To determine whether intermediate dose metoclopramide is more effective than standard dose metoclopramide for patients who present to the ED with nausea and vomiting." | 5.11 | Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study. ( Basire, M; Cham, S; Kelly, AM, 2004) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 5.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "Aim of this study was to demonstrate that intravenous metoclopramide can reduce pain, nausea and discomfort during nasogastric tube (NGT) insertion in ED." | 5.11 | Effectiveness of pre-emptive metoclopramide infusion in alleviating pain, discomfort and nausea associated with nasogastric tube insertion: a randomised, double-blind, placebo-controlled trial. ( Karaca, MA; Ozucelik, DN; Sivri, B, 2005) |
| "In daily practice, a combination of oral dexamethasone and oral granisetron achieves an extremely high control of acute emesis (86% protection)." | 5.10 | A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. ( Aapro, MS; Bernhard, J; De Pree, C; Maibach, R; Sessa, C; Thuerlimann, B, 2003) |
| " The number of patients who were emesis free (no nausea, retching, or vomiting) was significantly higher in patients who received granisetron (88% [2225]) than in those who received droperidol (64% [1625]; P = 0." | 5.10 | A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial. ( Fujii, Y; Kawasaki, T; Tanaka, H, 2003) |
| "This study compares pyridoxine-metoclopramide combination therapy to prochlorperazine and promethazine monotherapies in the outpatient treatment of nausea and vomiting in pregnancy." | 5.10 | Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy. ( Bsat, FA; Hoffman, DE; Seubert, DE, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 5.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 5.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "Although combination antiemetics prevent vomiting during the initial 24 h after high-dose (> or =100 mg/m2) cisplatin, many patients experience delayed emesis 24-120 h afterwards despite receiving prophylactic dexamethasone and metoclopramide during this time." | 5.09 | Oral cisapride for the control of delayed vomiting following high-dose cisplatin. ( Baltzer, L; Grant, SC; Hinckley, L; Kris, MG; Miller, VA; Pisters, KM; Pizzo, BA, 1999) |
| "Several studies have confirmed the efficacy of high-dose metoclopramide and, more recently, serotonin antagonists, with and without dexamethasone, in the prophylaxis of cisplatin-induced nausea and vomiting." | 5.09 | Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. ( Hussain, M; Khan, Z; Malik, I; Moid, I, 1999) |
| "The purpose of the present study was to examine whether its is possible to successfully replace ondansetron (OND) with metoclopramide (MCP) in patients exposed to moderately emetogenic chemotherapy who did not experience severe nausea and vomiting while undergoing OND treatment during their first chemotherapy cycle." | 5.09 | Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy. ( Athanasiou, E; Dimitrakopoulos, A; Katsikas, M; Koufos, C; Linardaki, G; Tsavaris, NB, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 5.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "Complete control of established postoperative nausea and vomiting, defined as no emesis and no need for another rescue antiemetic medication, was more frequent among the patients who had received granisetron (88%) than among those who had received droperidol (55%) or metoclopramide (50%) (P <." | 5.09 | Granisetron, droperidol, and metoclopramide for the treatment of established postoperative nausea and vomiting in women undergoing gynecologic surgery. ( Fujii, Y; Somekawa, Y; Tanaka, H, 2000) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 5.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 5.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "A single 5-minute infusion of 3 mg granisetron was more effective and produced a less adverse effect than multiple doses of metoclopramide in controlling chemotherapy-induced emesis, both in the first 24 hours and over a 6-day period." | 5.08 | Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Wei, CH, 1995) |
| " Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combination of metoclopramide, dexamethasone phosphate and lorazepam to assess the comparative efficacy of the two regimens in the control of irradiation-induced nausea and vomiting." | 5.08 | Granisetron in the prevention of irradiation-induced emesis. ( Collis, C; Cunningham, J; Cunningham, S; Gandhi, L; Hamon, MD; Prentice, HG, 1995) |
| "Metoclopramide was significantly more effective at preventing both nausea and vomiting (20/44 (45%) compared with 32/47 (68%), p < 0." | 5.08 | Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. ( Appelgren, L; Haglind, E; Thune, A, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "To compare the efficacy of oral droperidol versus oral metoclopramide, or both oral droperidol and metoclopramide, on postoperative vomiting when used as a premedicant for strabismus surgery." | 5.08 | The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery. ( Brown, RE; Jones, E; Kymer, PJ; Lawhorn, CD; Pearce, L, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 5.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 5.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy." | 5.08 | Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996) |
| "Of the patients treated with metoclopramide plus methylprednisolone (n = 92), 53% had complete protection from delayed emesis, 16% a major response, 15% a minor response, and 15% no response." | 5.08 | Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A; Tirrito, ML; Valenza, R, 1995) |
| "Intravenous antiemetic combinations containing a 5-HT3 receptor antagonist (like metoclopramide, ondansetron, or granisetron) with dexamethasone have become the standard therapy for the treatment of acute chemotherapy-induced vomiting." | 5.08 | Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. ( Clark, RA; Cleri, LB; Gralla, RJ; Kris, MG; Pisters, KM; Tyson, LB, 1995) |
| "Both metoclopramide and prochlorperazine in combination with lorazepam and diphenhydramine offer good control of nausea and vomiting although the sedation and low risk for cardiac toxicity limit the regimen to an inpatient setting with close monitoring." | 5.08 | Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. ( Gilbert, CJ; Ohly, KV; Peters, WP; Rosner, G, 1995) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 5.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "We conducted a prospective randomized study to compare granisetron, a 5-hydroxytryptamine-3 receptor antagonist with standard anti-emetics (control group) consisting mainly of metoclopramide, in the prophylaxis of emesis induced by conditioning prior to stem cell transplantation." | 5.08 | Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. ( Asano, S; Ikeda, Y; Kimura, Y; Miyawaki, S; Oh, H; Okamoto, S; Onozawa, Y; Sakamaki, H; Takahashi, S; Tanosaki, R; Toyama, K, 1996) |
| " We report a single-blind randomized crossover trial comparing the efficacy of tropisetron plus dexamethasone (TROPDEX) vs conventional combination of metoclopramide, dexamethasone and diphenhydramine (METDEX) in prevention of acute and delayed vomiting in Chinese patients receiving high dose cisplatin." | 5.08 | The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. ( Au, GK; Cheng, AC; Choy, D; Chua, DT; Kwong, DL; Sham, JS; Yau, CC, 1996) |
| " The recurrence of retching or vomiting was higher with propofol (58%) than with droperidol (4%) or metoclopramide (24%) (P < 0." | 5.08 | Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide. ( Lacroix, G; Lessard, MR; Trépanier, CA, 1996) |
| "The purpose of this retrospective study is to assess the frequency and intensity of chronic nausea in patients admitted to the Palliative Care Unit and the results of a metoclopramide-based treatment regimen." | 5.08 | Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. ( Babul, N; Bruera, E; Darke, A; Harsanyi, Z; Seifert, L; Suarez-Almazor, M; Watanabe, S, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 5.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "This study determined the overall incidence of postoperative nausea and vomiting (PONV) in 38 patients undergoing laparoscopic gynaecological procedures who received a standardized propofol/isoflurane anaesthetic but no preoperative antiemetic." | 5.08 | A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy. ( Watts, SA, 1996) |
| "To compare the antimetic efficacy of prophylactic ondansetron, metoclopramide, and placebo for prevention of postoperative vomiting in pediatric tonsillectomy or adenotonsillectomy patients." | 5.08 | Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. ( Bohnsack, LE; Bostrom, BC; Seay, RE; Stene, FN; Young, LA, 1996) |
| "The purpose of this study was to compare the effectiveness of granisetron, metoclopramide and placebo in reducting the frequencies of retching and vomiting in children who had undergone strabismus repair and tonsillectomy with or without adenoidectomy." | 5.08 | Antiemetic efficacy of granisetron and metoclopramide in children undergoing ophthalmic or ENT surgery. ( Fujii, Y; Tanaka, H; Toyooka, H, 1996) |
| "The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens." | 5.08 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. ( Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL, 1997) |
| "In a prospective, randomised, double-blind trial, we assessed the relative efficacy of prophylactic ondansetron and metoclopramide administration in the reduction of postoperative nausea and vomiting in 60 patients undergoing routine major neurosurgical procedures." | 5.08 | A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures. ( Barsoum, LZ; Jones, NC; Pugh, SC, 1996) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 5.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "To evaluate the combined effect of granisetron and methylprednisolone against acute emesis induced by cytotoxic agents, we investigated the clinical response and the urinary excretion of 5-HIAA in 85 patients with ovarian cancer who received the same anticancer chemotherapeutic regimen in a prospective randomized trial." | 5.08 | Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents. ( Cheng, X; Itamochi, H; Kigawa, J; Minagawa, Y; Okada, M; Terakawa, N, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 5.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 5.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 5.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 5.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "Granisetron is a better prophylactic antiemetic than droperidol or metoclopramide in female patients with a history of motion sickness undergoing major gynaecological surgery." | 5.08 | Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness. ( Fujii, Y; Tanaka, H; Toyooka, H, 1997) |
| " The purpose of this study was to compare the efficacy of ondansetron, a highly selective 5-hydroxytryptamine subtype-3 receptor antagonist, with that of metoclopramide for the prevention of postoperative emesis in patients undergoing cataract surgery." | 5.08 | Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia. ( Ascaso, FJ; Ayala, I; Carbonell, P; Castro, FJ; Palomar, A, 1997) |
| "To compare the efficacy of ondansetron, droperidol, or metoclopramide with placebo in preventing postoperative vomiting following strabismus surgery." | 5.08 | A randomized, double-blind, placebo controlled comparison of droperidol, ondansetron, and metoclopramide for the prevention of vomiting following outpatient strabismus surgery in children. ( Elliott, WG; James, RL; Mims, G; Scuderi, PE; Weaver, RG; Weeks, DB, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 5.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "Seminoma stage I patients on tropisetron experienced less nausea and vomiting during abdominal radiotherapy than patients receiving metoclopramide." | 5.08 | Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. ( Aass, N; Fosså, SD; Håtun, DE; Thoresen, M, 1997) |
| "To establish a dose-response relationship for ondansetron, and to evaluate any effects of oral premedication with metoclopramide in pediatric patients undergoing tonsillectomy and adenoidectomy and strabismus surgery." | 5.08 | Ondansetron dose response curve in high-risk pediatric patients. ( Kymer, PJ; Lawhorn, CD; Shirey, R; Stewart, FC; Stoner, JM; Volpe, P, 1997) |
| "Granisetron is more effective than droperidol or metoclopramide in preventing PONV in female patients with a history of postoperative emesis." | 5.08 | Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 5.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| "The antiemetic efficacy of droperidol, metoclopramide and granisetron was compared with placebo in the reduction of vomiting after paediatric surgery (the extremities; inguinal hernia; and phimosis) during general inhalational anaesthesia." | 5.08 | Prophylactic therapy with granisetron in the prevention of vomiting after paediatric surgery. A randomized, double-blind comparison with droperidol and metoclopramide. ( Fujii, Y; Tanaka, H, 1998) |
| "This study evaluates the prophylactic anti-emetic efficacy of granisetron, droperidol and metoclopramide, for the prevention of post-operative nausea and vomiting in female patients undergoing elective laparoscopic cholecystectomy." | 5.08 | Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "The incidence of postoperative emesis in the metoclopramide group was 60% versus 71% in a placebo group (p < 0." | 5.08 | Prophylactic metoclopramide administered immediately after the induction of anesthesia has no effect on the incidence of postoperative emesis after strabismus surgery. ( Haldar, M; Shende, D, 1998) |
| "A single institution, prospective, randomized trial was performed in terminal cancer patients to compare tropisetron (TRO), metoclopramide (MET), and chlorpromazine (CHL) in the management of nausea and emesis." | 5.08 | Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. ( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998) |
| "To compare the prophylactic administration of ondansetron plus droperidol, droperidol plus metoclopramide, and perphenazine to determine effects on postoperative nausea, vomiting, and sedation after laparoscopic cholecystectomy." | 5.08 | Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide. ( Freiberger, D; Gosnell, JL; Steinbrook, RA, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 5.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "The aim of this study was to determine the mechanism of action of radiation-induced emesis by determining the incidence of radiation-induced emesis following hemibody irradiation; the effects of specific antiemetics especially ondansetron, a 5-hydroxytryptamine receptor antagonist, and to determine the relationship between radiation-induced emesis and serotonin (5-hydroxytryptamine) through its active metabolite, 5-hydroxyindoleacetic acid (5-HIAA)." | 5.07 | On the mechanism of radiation-induced emesis: the role of serotonin. ( Anderson, RF; Hoffman, LG; Ornitz, RD; Scarantino, CW, 1994) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 5.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "Lignocaine has been shown to reduce the incidence of pain on injection of propofol." | 5.07 | Propofol injection pain: comparing the addition of lignocaine or metoclopramide. ( Mecklem, DW, 1994) |
| "We carried out a randomized, single-blind, cross-over trial to compare the antiemetic effect, for both acute and delayed emesis, of granisetron plus dexamethasone (GRN+Dx) with that of high-dose metoclopramide plus dexamethasone (HDMP+Dx)." | 5.07 | A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. ( Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nakashima, H; Nisio, M; Ohe, Y; Ohmatsu, H; Shinkai, T; Tamura, T, 1994) |
| "Oral metoclopramide may be given as a premedicant to reduce post-operative nausea and vomiting, but there is little evidence that it is effective." | 5.07 | Sustained release metoclopramide for prophylaxis of post-operative nausea and vomiting. ( Curran, JP; Elliott, RH; Graham, SG, 1994) |
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 5.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "In a prospective, double-blind study, we have examined the effect of preoperative nabilone on postoperative nausea and vomiting (PONV)." | 5.07 | Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. ( Barrowcliffe, MP; Campbell, DN; Lewis, IH, 1994) |
| " Acetaminophen and meperidine were given for postoperative pain." | 5.07 | Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. ( Furst, SR; Rodarte, A, 1994) |
| " dexamethasone and oral metoclopramide) for delayed emesis, while they had received either i." | 5.07 | Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research. ( , 1994) |
| " Oral granisetron alone was as effective as met/dex in control of acute emesis in all parameters examined." | 5.07 | Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. ( Cedar, E; Cunningham, J; Goedhals, L; Heron, JF; Jordaan, JP, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 5.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 5.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "Metoclopramide is an active antiemetic against cisplatin-induced acute emesis." | 5.07 | Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis. ( Kajita, M; Niimi, T; Saito, H; Shimokata, K; Yamori, S, 1994) |
| "To improve the treatment of cisplatin-induced acute emesis and vomiting, the adjuvant effect of two different doses of metoclopramide and metoclopramide plus droperidol was compared to a defined standard antiemetic regiment." | 5.07 | Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting. ( Hernádi, Z; Juhász, B; Lampé, L; Póka, R, 1993) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 5.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 5.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "This placebo-controlled, randomized, double-blind trial was designed to evaluate the efficacy of three prophylactic antiemetic regimens on postoperative nausea and vomiting (PONV) during patient-controlled analgesia (PCA) with morphine." | 5.07 | Prophylactic antiemetic therapy with patient-controlled analgesia: a double-blind, placebo-controlled comparison of droperidol, metoclopramide, and tropisetron. ( Kaufmann, MA; Rosow, C; Schneider, M; Schnieper, P, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 5.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "We investigated the usefulness of concurrent therapy of granisetron with methylprednisolone sodium for on nausea, vomiting and anorexia induced by chemotherapy, including cisplatin, in patients with oral cancer." | 5.07 | [Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin]. ( Kawashima, T; Miyata, K; Morita, N; Ohmata, T; Sakamoto, T; Wada, T, 1993) |
| " The purpose of this study was to compare the incidence of emesis after propofol anaesthesia with and without nitrous oxide, compared with thiopentone and halothane anaesthesia, in hospital and up to 24 hr postoperatively, in outpatient paediatric patients after strabismus surgery." | 5.07 | Propofol anaesthesia reduces early postoperative emesis after paediatric strabismus surgery. ( Bevan, JC; Blackstock, D; Merrick, PM; Montgomery, CJ; Popovic, V; Reimer, EJ, 1993) |
| "Ondansetron plus dexamethasone was significantly more efficacious and better tolerated than metoclopramide plus dexamethasone and diphenhydramine during three cycles of chemotherapy and, in contrast to the metoclopramide regimen, the efficacy of ondansetron plus dexamethasone, at least for vomiting, is maintained in subsequent cycles." | 5.07 | Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research. ( , 1993) |
| ") was compared with a metoclopramide cocktail for the prevention of nausea and emesis." | 5.07 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994) |
| ", Basel, Switzerland), a new 5-HT3 receptor antagonist, was compared in a randomized multicenter trial with a high-dose metoclopramide-dexamethasone cocktail for the prevention of nausea and emesis during cisplatin-containing chemotherapy." | 5.07 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( de Bruijn, KM; Glimelius, B; Hansen, O; Högberg, T; Räisänen, I; Schmidt, M; Sorbe, BG; Sörensen, BT; van Oosterom, AT; Wernstedt, L, 1994) |
| "Vomiting was prevented in two thirds of patients treated with MDL plus ondansetron, a result similar to that observed in earlier trials of MDL alone." | 5.07 | The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. ( Baltzer, L; Kris, MG; Pisters, KM; Rigas, JR; Tyson, LB, 1994) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 5.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "The cost effectiveness of ondansetron was compared with that of metoclopramide in the prevention of acute emesis due to highly emetogenic chemotherapy in an open, randomised, parallel group pilot study." | 5.07 | The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. ( Cunningham, D; Davidson, N; Gore, M; Manchanda, M; Miocevich, M; Wells, N, 1993) |
| "This pilot randomized study compared MDL 72,222, a highly selective 5-HT3 receptor antagonist, with a high-dose metoclopramide regimen (HDM) for chemotherapy-induced nausea and vomiting." | 5.07 | Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen. ( Barrett, RJ; Hahne, WF; Heck, K; Homesley, HD; Lentz, SS; Lovelace, JV; McLees, B; Woodlief, L, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "Tiapride (Tiapridal, Delagrange), a dopaminergic D2 receptor blocking agent having anxiolytic, sedative, antiemetic and analgesic properties was compared with metoclopramide and placebo in a randomized double-blind trial to determine its effects on post-operative nausea, vomiting, and sedation." | 5.07 | Tiapride versus metoclopramide: comparison after minor gynaecological surgery. ( Joshi, R; Sivaganesanathan, A, 1993) |
| "This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe." | 5.07 | A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. ( Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 5.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| " Costs, effects and cost-effectiveness of ondansetron in the prophylaxis of acute nausea and vomiting induced by chemotherapy are assessed relative to antiemetic therapy with metoclopramide." | 5.07 | Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. ( Buxton, MJ; O'Brien, BJ, 1992) |
| "The efficacy of intravenous metoclopramide in controlling vomiting in children after tonsillectomy was determined in a prospective randomized, double-blind investigation." | 5.07 | Metoclopramide reduces the incidence of vomiting after tonsillectomy in children. ( Donlon, JV; Ferrari, LR, 1992) |
| " One hundred ten pediatric patients, ages 8 months to 14 yr, admitted for outpatient strabismus surgery were enrolled in a randomized, double-blinded study to compare droperidol and metoclopramide to placebo for the prevention of postoperative emesis." | 5.07 | A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery. ( Furst, SR; Lin, DM; Rodarte, A, 1992) |
| "Prevention and treatment of postoperative nausea and vomiting with ephedrine, droperidol and metoclopramide have been reported to be effective." | 5.07 | Comparison of antiemetic effect among ephedrine, droperidol and metoclopramide in pediatric inguinal hernioplasty. ( Kang, HM; Liou, CM; Liu, YC; Tso, HS, 1992) |
| "In order to decide the administration method of metoclopramide for prevention or control of chemotherapy-induced nausea and vomiting in multidrug chemotherapy, with cisplatin 5-day continuous intravenous infusion (25 mg/m2/day) for patients with advanced lung cancer, a randomised crossover study of intermittent bolus infusion (1 mg/kg, 30 min, every 8 h, day 1-5) and continuous infusion (3 mg/kg/24 h, 120 h) of metoclopramide was performed." | 5.07 | Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin. ( Miyazawa, N; Mori, K; Saitou, Y; Tominaga, K, 1991) |
| " One of these agents, batanopride, produced no severe toxicity at doses that prevented emesis due to chemotherapy in early Phase I trials." | 5.07 | A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. ( Findlay, B; Kaizer, L; Laberge, F; Latreille, J; Lofters, WS; Osoba, D; Pater, J; Rusthoven, J; Warr, D; Wilson, K, 1991) |
| "Sixty patients were studied in a randomized, double-blind manner to determine whether metoclopramide added to droperidol decreased further the incidence of emetic symptoms (nausea, retching, vomiting) in outpatients receiving alfentanil anaesthesia for nasal surgery." | 5.07 | Metoclopramide does not decrease the incidence of nausea and vomiting after alfentanil for outpatient anaesthesia. ( AlHaddad, S; Furgerson, C; Khalil, I; Maurer, W; Whalley, DG, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 5.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "Ondansetron, a new 5-HT3 receptor antagonist, has been compared with high-dose metoclopramide in the control of acute emesis (24 h) induced by cisplatin (greater than or equal to 100 mg/m2)." | 5.07 | Progress in the control of acute and delayed emesis induced by cisplatin. ( Gandara, DR, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 5.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "This double-blind randomized cross-over study was conducted to compare the safety and efficacy of high-dose prochlorperazine infusion and dexamethasone (HDPD) with an effective and safe combination of high-dose metoclopramide and dexamethasone (HDMD) in controlling cisplatin-induced emesis." | 5.07 | A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis. ( Akhtar, SS; Bano, ZA; Bhat, GM; Bhat, MA, 1991) |
| "To prevent delayed emesis induced by cisplatin (mean dose 90 mg/m2), 120 consecutive patients were randomized to receive, in a 7-day crossover design, oral metoclopramide (20 mg q." | 5.07 | Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. ( Ballatori, E; Basurto, C; Boschetti, E; Bracarda, S; Patoia, L; Penza, O; Picciafuoco, M; Roila, F; Santi, E; Tonato, M, 1991) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 5.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 5.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "40 patients with metastatic breast cancer, under treatment with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2), had an antiemetic therapy with Ondansetron 3 x 8 mg day, for a maximum of 10 cycles." | 5.06 | [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron]. ( Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 5.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| "This randomized, double-blind study evaluated the efficacy of metoclopramide administered at the completion of surgery as an antiemetic agent in pediatric patients undergoing ambulatory strabismus surgery; 126 unpremedicated ASA Physical Status 1 and 2 children ranging in age from 2 to 18 yr served as subjects." | 5.06 | Metoclopramide reduces the incidence of vomiting following strabismus surgery in children. ( Broadman, LM; Ceruzzi, W; Friendly, D; Hannallah, RS; Patane, PS; Ruttimann, U, 1990) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 25 women with stage II breast cancer were entered into this study." | 5.06 | Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. ( Giannarelli, D; Marolla, P; Nardi, M; Pinnaró, P; Pollera, CF; Terzoli, E, 1989) |
| " All patients received intravenous (IV) metoclopramide, dexamethasone, and lorazepam for the control of acute emesis during the period from 0 to 24 hours after cisplatin." | 5.06 | Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. ( Cirrincione, C; Clark, RA; Gralla, RJ; Groshen, S; Kris, MG; Tyson, LB, 1989) |
| "In a randomized, double-blind study, we compared the efficacy of metoclopramide hydrochloride with that of low-dose droperidol for prevention of nausea and vomiting during and after elective cesarean section with epidural anesthesia." | 5.06 | Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section. ( Bates, JN; Chestnut, DH; Choi, WW; Geiger, M; Ostman, PL; Owen, CL, 1989) |
| " Lorazepam and dexamethasone are increasingly being used to alleviate chemotherapy induced emesis." | 5.06 | The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. ( Blackledge, GR; Burman, C; Cullen, MH; Kelly, K; O'Brien, ME; Palmer, K; Sharpe, J; Stuart, NS; Woodroffe, C, 1989) |
| "Nineteen women receiving their first cycle of adjuvant chemotherapy for early breast cancer were randomized between two antiemetic drugs: methylprednisolone (MPN) 125mg and metoclopramide (MCP) 20mg, both given by intravenous push as a single dose." | 5.06 | Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study. ( Biran, S; Cass, Y; Gera, C; Gez, E; Nathan, S; Ochayon, L; Rubello, E; Sulkes, A, 1989) |
| "Sixty-four patients treated with cisplatin-containing regimens were entered into a randomized, double-blinded study examining the antiemetic efficacy of metoclopramide with and without lorazepam for control of cisplatin-induced emesis." | 5.06 | Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis. ( Al-Sarraf, M; Cummings, G; Gordon, CJ; Pazdur, R; Ziccarelli, A, 1989) |
| "Forty-two patients with advanced lung cancer undergoing chemotherapy containing cisplatin (80 mg/m2) were submitted to a randomized controlled trial to evaluate the effect of the combination of metoclopramide and dexamethasone for the treatment of delayed cisplatin-induced emesis occurring more than 24 hours after cisplatin administration." | 5.06 | Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. ( Eguchi, K; Fujiwara, Y; Fukuda, M; Mae, M; Ohe, Y; Saijo, N; Sasaki, S; Sasaki, Y; Shinkai, T; Tamura, T, 1989) |
| "A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of high-dose dexamethasone (Protocol D) with a combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD) in the management of chemotherapy-induced nausea and vomiting in cancer patients." | 5.06 | Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine. ( Ababtain, WA; Abdullah, KA; al-Idrissi, HY; Boukhary, HA; Ibrahim, EM; Macaulay, HM, 1988) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 5.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis." | 5.06 | [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. ( Eguchi, K; Inoue, I; Nino, S; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T; Umehara, H, 1987) |
| "Combinations of metoclopramide and dexamethasone given intravenously control vomiting caused by high doses of cisplatin." | 5.06 | Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. ( Clark, RA; Gralla, RJ; Groshen, S; Kris, MG; Tyson, LB, 1987) |
| "A randomized prospective clinical trial was conducted to evaluate the potential utility of adding transdermal scopolamine to a standard regimen of metoclopramide and dexamethasone for the prevention of cisplatin-induced emesis." | 5.06 | A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. ( Meyer, BR; O'Mara, V; Reidenberg, MM, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 5.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of high-dose dexamethasone and high-dose metoclopramide in the treatment of chemotherapy-induced nausea and vomiting." | 5.06 | Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. ( Absood, G; Al-Dossary, E; Al-Ethan, S; Al-Idrissi, HY; Al-Jammaa, A; Eliopoulos, A; Ibrahim, A; Ibrahim, EM, 1986) |
| "The efficacy of secobarbital sodium plus chlorpromazine (SC) in the prevention of cisplatin induced emesis was compared to the combination of metoclopramide, diphenhydramine, and dexamethasone (MDD)." | 5.06 | The antiemetic efficacy of secobarbital and chlorpromazine compared to metoclopramide, diphenhydramine, and dexamethasone. A randomized trial. ( Bateman, M; Flaum, MA; Kardinal, CG; Richards, PD, 1986) |
| "Methylprednisolone sodium succinate and metoclopramide were compared for their efficacy, tolerance, and safety in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy in patients with cancer." | 5.06 | Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. ( Erlichman, C; Levitt, M; Osoba, D; Pater, JL; Willan, AR, 1986) |
| "The existence of a threshold serum metoclopramide level above which total protection from cisplatin-induced vomiting is more likely to occur has been proposed." | 5.06 | Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin. ( Bernstein, L; Cohen, JL; Grunberg, SM; McDermed, JE, 1987) |
| "A randomized cross-over study on the effects of methylprednisolone (MP), metoclopramide (MT) and droperidol (DP) on the control of nausea and vomiting associated with cis-platinum chemotherapy was performed." | 5.06 | [Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy]. ( Akaza, H; Aso, Y; Fujita, K; Isurugi, K; Kawabe, K; Kinoshita, K; Koiso, K; Kondo, Y; Niijima, T; Yokoyama, M, 1986) |
| "25 mg droperidol, 20 mg metoclopramide or a saline placebo intravenously 5-10 min before the end of anaesthesia in a double-blind random fashion to prevent post-operative nausea and vomiting." | 5.06 | Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae. ( Gordin, A; Heikkinen, H; Kauste, A; Korttila, K; Tuominen, M, 1986) |
| "Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order." | 5.06 | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. ( Allan, SG; Cornbleet, MA; Leonard, RC; MacPherson, JS; Smyth, JF; Warrington, PS, 1986) |
| "The present trial was designed to compare the effect of metoclopramide(MCP) + dexamethasone(DM) (Method A) with that of MCP + DM + lorazepam(Lor) (Method B) in the treatment of CDDP (cis-diamminedichloroplatinum)-induced nausea and vomiting in a randomized fashion." | 5.06 | [Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy]. ( Arai, R; Furuse, K; Hayashi, S; Kawahara, M; Kiyota, T; Kodama, N; Tsuruta, S, 1987) |
| " Ondansetron revealed the largest effect in comparison to placebo for cessation of vomiting (odds ratio = 0." | 5.05 | Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. ( Acosta-Reyes, J; Florez, ID; Niño-Serna, LF; Veroniki, AA, 2020) |
| " A combination of Nabilone and metoclopramide was used in an unrandomized pilot study (prior to the withdrawal of Nabilone from clinical use); these patients recorded better scores for nausea and vomiting and patient acceptability than those in the randomized study." | 5.05 | Antiemetics for patients treated with antitumor chemotherapy. ( Bolton, A; de Pemberton, R; Whitehouse, JM; Williams, CJ, 1980) |
| "One hundred and two patients with advanced solid tumors receiving chemotherapy were treated with metoclopramide (MCP; 100 mg) to prevent emesis." | 5.05 | Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. ( Bruera, ED; Cedaro, L; Chacón, R; Estévez, R; Roca, E, 1983) |
| "Metoclopramide is an effective antiemetic for cisplatin-induced vomiting when given in parenteral high-dose regimens but not oral low-dose regimens." | 5.05 | Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. ( Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984) |
| " Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting." | 5.05 | [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy]. ( Budach, V; Krüger, K, 1983) |
| "In a double-blind comparison of domperidone 10 mg, domperidone 4 mg, metoclopramide 10 mg and a placebo, 176 adult patients were given an intravenous injection of one of these substances after postoperative vomiting had occurred." | 5.05 | Postoperative vomiting treated with domperidone. A double-blind comparison with metoclopramide and a placebo. ( Boghaert, A; Carron, D; Gallant, J; Stockman, A, 1980) |
| "An open-label clinical trial was conducted to test the safety and efficacy of intravenous metoclopramide monohydrochloride in preventing chemotherapy-induced nausea and vomiting." | 5.05 | Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. ( McDermed, JE; Opfell, RW; Riech, LP; Strum, SB, 1982) |
| "Fifty-five patients with delayed gastric emptying and the symptoms of nausea, vomiting, postprandial bloating and early satiety were treated with metoclopramide." | 5.05 | Metoclopramide therapy in fifty-five patients with delayed gastric emptying. ( Davidson, ED; Hersh, T; Moore, C; Perkel, MS, 1980) |
| "The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial." | 5.05 | [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis]. ( Eguchi, K; Fujita, J; Funaki, Y; Futami, H; Sakurai, M; Sasaki, Y; Sawamura, N; Takahashi, S; Yokoyama, S; Yoshioka, S, 1985) |
| "Using a sensitive and specific high-pressure liquid chromatographic (HPLC) assay, we measured serum levels of metoclopramide in 18 cancer patients receiving high-dose intravenous (IV) therapy to prevent cisplatin-induced emesis." | 5.05 | Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. ( Cohen, JL; Joseph, C; McDermed, JE; Strum, SB, 1985) |
| "The antinausea and antivomiting effects of delta-9-tetrahydrocannabinol (THC) in children receiving cancer chemotherapy were compared with those of metoclopramide syrup and prochlorperazine tablets in two double-blind studies." | 5.04 | Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. ( Ekert, H; Jurk, IH; Loughnan, P; Mobilia, J; Waters, KD, 1979) |
| "In a double-blind trial in 60 children suffering from gastroenteritis complicated by vomiting, it was found that suppositories of domperidone (30 mg) were more effective than either metoclopramide (10 mg) or placebo in reducing the severity of vomiting, nausea and other symptomatic parameters." | 5.04 | A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. ( Ameryckx, L; Dhondt, F; Heck, E; Van Eygen, M; Van Ravensteyn, H, 1979) |
| "Forty-seven infants and children suffering from chronic vomiting or regurgitation, participated in a two-week double-blind trial comparing 1% drops of domperidone, 1% metoclopramide drops or placebo." | 5.04 | Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. ( Ameryckx, L; De Loore, I; Van Ravensteyn, H, 1979) |
| "One hundred and ninety-five female patients of child-bearing age were assessed for postoperative vomiting in a double-blind trial using domperidone, metoclopramide and placebo." | 5.04 | Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo. ( Ball, RW; Comyn, DJ; Cooke, RD, 1979) |
| "A technique of premiedication using oral diazepam and metoclopramide with a drink is described and shown to provide better sedation and less vomiting than pethidine and atropine given intramuscularly without a drink to a group of similar patients." | 5.04 | Oral premedication: diazepam, metoclopramide and a drink. ( Deshpande, S; Fry, EN, 1977) |
| "Twelve patients with complete, or nearly complete, pyloric obstruction due to duodenal ulcer, were treated conservatively with metoclopramide." | 5.04 | The use of metoclopramide in acute pyloric obstruction. A clinical trial. ( Dintsman, M; Zer, M, 1975) |
| "To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults." | 4.98 | Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. ( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.89 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; Moore, RA, 2013) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 4.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "In patients with advanced cancer not being treated with chemotherapy or radiation therapy, metoclopramide can be used to reduce nausea and vomiting." | 4.88 | [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. ( Alt-Epping, B; Benze, G; Geyer, A; Nauck, F, 2012) |
| "The objective of the present study was to conduct a systematic review and meta-analysis of randomized controlled trials, comparing metoclopramide with placebo, for preventing vomiting in patients who have received i." | 4.87 | Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systematic review and meta-analysis of randomized controlled trials. ( Bendall, JC; Middleton, PM; Simpson, PM, 2011) |
| "Oral ondansetron increased the proportion of patients who had ceased vomiting and reduced the number needing intravenous rehydration and immediate hospital admission." | 4.87 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Carter, B; Fedorowicz, Z; Jagannath, VA, 2011) |
| "Based on the safety and efficacy of ondansetron, it may be used as a first-line agent for relief of nausea or vomiting for most patient populations in the ED." | 4.86 | Antiemetic therapy for nausea and vomiting in the emergency department. ( Amini, R; Hays, DP; Patanwala, AE; Rosen, P, 2010) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.86 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010) |
| "The small number of included trials provided some limited evidence favouring the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.85 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Al-Hashimi, H; Alhashimi, D; Fedorowicz, Z, 2009) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "A short cut review was carried out to establish whether metoclopramide reduced nausea and vomiting after the administration of morphine." | 4.82 | Best evidence topic reports. Metoclopramide versus placebo with opioid. ( Alsalim, W; Butler, J; Leung, WC, 2004) |
| " In the last decade the use of high-dose metoclopramide and, especially, the introduction of the 5-HT3 receptor antagonists, have been major leaps forward in the control of chemotherapy-induced emesis." | 4.79 | Optimal control of acute cisplatin-induced emesis. ( de Mulder, PH; de Wit, R; Verweij, J, 1996) |
| "In the past few years important progress in the prevention of chemotherapy-induced nausea and vomiting has been made mainly thanks to the introduction of the 5-HT3 receptor antagonists in clinical practice (ondansetron, granisetron, tropisetron)." | 4.79 | [Recent improvements in antiemetic therapy]. ( Basurto, C; Ciccarese, G; Palladino, MA; Roila, F, 1997) |
| "8 mg/kg was superior to metoclopramide in preventing emesis induced by high dose cisplatin or by moderately emetogenic chemotherapy in high risk subgroups." | 4.79 | Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. ( Balfour, JA; Goa, KL, 1997) |
| "This paper described an outline of clinically applications of 5-HT3 receptor antagonists, mainly on ondansetron, which control nausea and vomiting associated with cancer chemotherapy." | 4.78 | [An outline of 5-HT3 receptor antagonists (2)--In clinical applications]. ( Ohta, J; Taguchi, T; Tsukagoshi, S, 1993) |
| "Ondansetron is more effective than high-dose metoclopramide in the prevention of acute nausea and vomiting due to highly emetogenic chemotherapy, and, unlike metoclopramide, is rarely associated with extrapyramidal effects." | 4.78 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. ( Milne, RJ; Plosker, GL, 1992) |
| " Metoclopramide is generally acknowledged to be the single most effective conventional drug for the prevention of acute cisplatin-induced emesis and, therefore, was considered an appropriate agent for inclusion in comparative trials with ondansetron." | 4.78 | Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. ( Hesketh, PJ, 1992) |
| " 2), metoclopramide has been confirmed as an effective drug in treating and preventing various types of vomiting and as a useful agent in oesophageal reflux disease, gastroparesis, dyspepsia, and in a variety of functional gastrointestinal disorders." | 4.76 | Metoclopramide. An updated review of its pharmacological properties and clinical use. ( Brogden, RN; Hamilton, CW; Harrington, RA; Heel, RC; Linkewich, JA; Romankiewicz, JA, 1983) |
| " A third drug, lactulose (useful in treating hepatic encephalopathy), will soon be available." | 4.75 | Some aspects of medical management of gastrointestinal disease. I. ( Badley, BW, 1975) |
| "Following the administration of metoclopramide for vomiting associated with pertussis cough, the patient exhibited distressing symptoms, including torticollis, facial grimacing, and tongue protrusion." | 4.31 | Metoclopramide-induced acute dystonic reaction: A pediatric case report. ( Adebambo, S; Adenikinju, J; Egbunu, E; Elendu, C; Ogala, F; Ologunde, T, 2023) |
| "Ondansetron is commonly used to treat nausea and vomiting in pregnancy despite inconclusive evidence of its safety." | 4.02 | Ondansetron use in early pregnancy and the risk of miscarriage. ( Boggess, K; Engel, SM; Jonsson Funk, M; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| " Common etiologies included constipation, opioid use, and "other," and treatments associated with a statistically significant decrease in nausea/vomiting were olanzapine, laxatives, corticosteroids, domperidone, and metoclopramide." | 3.91 | The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. ( Frandsen, K; Groenvold, M; Harder, S; Herrstedt, J; Isaksen, J; Jespersen, BA; Mondrup, L; Neergaard, MA; Sigaard, J, 2019) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 3.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "Metoclopramide is commonly used to treat vomiting caused by seasickness and acute gastroenteritis on cruise ships and serious adverse effects have not been reported from use at sea." | 3.80 | Long-lasting adverse effects after short-term low-dose treatment with metoclopramide for vomiting. ( Dahl, E; Diskin, AL, 2014) |
| "Patients with cancer frequently report gastrointestinal symptoms such as anorexia, early satiety, nausea, vomiting, and bloating." | 3.80 | Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. ( Chow, W; Darke, A; Harsanyi, Z; Marshall, D; Pearen, S; Plourde, JY; Wilson, J; Yoshida, S, 2002) |
| "The purpose of this study was to formulate and characterize metoclopramide solid lipid nanoparticles (MCP-SLNs) and incorporating it into suppository bases for treatment of nausea and vomiting, produced with chemotherapeutic agents, using one dose per day." | 3.79 | Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository. ( Abass, HA; Attia, MA; Heikal, OA; Mohamed, RA, 2013) |
| "While providing a better efficacy in acute emesis control, the low incidence of acute emesis and high ICER makes use of granisetron as primary prophylaxis in LEC controversial." | 3.79 | Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. ( Ghani, NA; Keat, CH, 2013) |
| "We examined treatment outcomes in women with severe nausea and vomiting of pregnancy (NVP) receiving outpatient nursing support and either subcutaneous metoclopramide or subcutaneous ondansetron via a microinfusion pump." | 3.77 | Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. ( Desch, C; Fox, NS; Istwan, N; Klauser, CK; Palmer, B; Rebarber, A; Rhea, D; Saltzman, D, 2011) |
| " Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting." | 3.77 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. ( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 3.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "In total knee and hip arthroplasty, methylprednisolone is effective in preventing postoperative nausea; however, higher doses of methylprednisolone may be needed to prevent vomiting." | 3.76 | Methylprednisolone reduces postoperative nausea in total knee and hip arthroplasty. ( Ejiri, M; Ishiguro, N; Kuzuya, T; Miyagawa, Y; Osada, T; Yamada, K, 2010) |
| "The aim of study was, comparison of effects of Metoclopramide and Dropridol associated with Dexamethasone on prevalence of nausea and vomiting after operation was considered." | 3.76 | Comparison the effects of metoclopramide and dropridol associated with dexamethasone on post operative nausea and vomiting. ( Ebrahim, A; Ebrahim, N; Hosssain, B; Yousef, M, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "In various countries, metoclopramide is the antiemetic drug of choice in pregnant women, but insufficient information exists regarding its safety in pregnancy." | 3.75 | The safety of metoclopramide use in the first trimester of pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009) |
| "A patient who was given metoclopramide for vomiting and diarrhoea developed circulatory collapse with his blood pressure dropping to 50/20 mm Hg." | 3.75 | Circulatory collapse in a patient with gastrinoma after metoclopramide administration. ( Chan, AY; Chan, KW; Ching, CK; Lam, AW; Lau, KK; Lee, HH; Li, SM; Lo, J; Lok, CM; Luk, WF; Mak, CM, 2009) |
| " In the present studies, therefore, we used Suncus murinus, a species of insectivore capable of emesis, to investigate if the vanilloid receptor agonist resiniferatoxin is capable of modeling the emesis associated with migraine." | 3.73 | Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew). ( Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C, 2005) |
| " However, retching and vomiting were significantly inhibited by pretreatment with ondansetron and metoclopramide in cisplatin and copper sulfate groups (P=0." | 3.73 | Value of mink vomit model in study of anti-emetic drugs. ( Liu, ZT; Wang, L; Yang, ZH; Yue, W; Zhang, F, 2006) |
| " Cisplatin, apomorphine, copper sulfate and X-radiation were used to establish vomiting model." | 3.72 | [A new vomiting animal model--mink]. ( Fang, X; Liu, YX; Minami, M; Wang, L; Yue, W; Zhang, F, 2003) |
| "Two double-blind, placebo-controlled, prospective randomized trials in the emergency department (ED) setting have examined the use of metoclopramide for the prevention of opiate-induced nausea and vomiting." | 3.71 | Low incidence of nausea and vomiting with intravenous opiate analgesia in the ED. ( Paoloni, R; Talbot-Stern, J, 2002) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 3.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| " Two doses of oral metoclopramide 10 mg in solution were administered for nausea and vomiting." | 3.70 | Respiratory failure following oral administration of metoclopramide. ( MacLaren, R; Shields, CA, 1998) |
| "A two-stage retrospective audit of the efficacy of antiemetics used with intravenous cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and 5-fluorouracil 600 mg/m2 (CMF) chemotherapy for breast cancer has been performed in a single centre." | 3.70 | An audit of antiemetic use with CMF chemotherapy. ( Brown, RS; Brown, TK; Gaze, MN; Hoare, D, 1998) |
| " Intravenous ondansetron 8 mg and dexamethasone 20 mg served as an alternative regimen in patients <30 years old with a history of extrapyramidal manifestations or emesis in previous cycles." | 3.70 | Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy. ( Catalán Arlandis, JL; Jiménez Torres, NV, 2000) |
| "A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of tropisetron (TRO), a 5-HT3 receptor antagonist, in 88 patients undergoing fractionated radiotherapy to the abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with metoclopramide (MET)." | 3.69 | Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. ( Behrouz, F; Blazek, N; Coucke, P; Gebhard, S; Melliger, M; Miralbell, R; Philipp, S; Rosset, A; Schwabb, T; Wickenhauser, R, 1995) |
| "We evaluated the antiemetic efficacy of tropisetron, a 5-HT3 receptor antagonist, during its compassionate use in children with malignant disease who during previous chemotherapy cycles experienced emesis refractory to metoclopramide-based treatments." | 3.69 | Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments. ( Armiraglio, A; Cefalo, G; Pagan, MG; Rottoli, L, 1994) |
| "Although buprenorphine sometimes causes severe emesis, its relation to the menstrual cycle has not been reported." | 3.69 | Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. ( Kamiyama, M; Kitamura, A; Kon, T; Ogawa, R, 1996) |
| "Fifty-one patients who received their first course of chemotherapy were studied to compare the respective efficacy and safety of granisetron and metoclopramide plus dexamethasone in the prevention of nausea and vomiting induced by emetogenic cytotoxic drugs." | 3.69 | Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. ( Chang, CS; Chen, LT; Chen, TP; Huang, SM; Lin, SF; Liu, TC; Wei, TC, 1997) |
| " Erythromycin administration is associated with gastrointestinal problems, disturbed gastrointestinal motility and emesis." | 3.68 | Effects of cholinoceptor and 5-hydroxytryptamine3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis. ( Pilot, MA; Qin, XY; Scott, M; Thompson, H, 1993) |
| " 5 min prior to morphine while each ferret was maintained under isoflurane-O2 anesthesia." | 3.68 | The effects of different antiemetic agents on morphine-induced emesis in ferrets. ( Essien, E; Thut, PD; Wynn, RL, 1993) |
| "A 4-year-old female blue and gold macaw (Ara ararauna) with a history of chronic vomiting was treated with metoclopramide hydrochloride." | 3.68 | Adverse drug reaction to metoclopramide hydrochloride in a macaw with proventricular dilatation syndrome. ( Massey, JG, 1993) |
| "Pancopride ((+-)N-(1-azabicyclo-[2,2,2]-oct-3-yl)-2-cyclopropylmethoxy-4-ami no-5-chlorobenzamide) is a new potent and selective 5-HT3 receptor antagonist, orally and parenterally effective against cytotoxic drug-induced emesis." | 3.68 | Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. ( Beleta, J; Berga, P; Bou, J; Doménech, T; Fernández, AG; Gristwood, RW; Puig, J; Roberts, DJ, 1992) |
| " The syndrome was associated with metoclopramide antiemetic therapy given for post-operative nausea and vomiting." | 3.68 | Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. ( Bakri, YN; Kawi, Z; Khan, R; Subhi, J, 1992) |
| "Lorazepam, dexamethasone and high-dose metoclopramide were given to 54 patients to prevent emesis induced by cisplatin (50-120 mg/m2) on day 1, while prochlorperazine and dexamethasone were administered on days 2 and 3 for control of delayed emesis." | 3.68 | Acute and delayed emesis after cisplatin-based regimen: description and prevention. ( Beaulieu, R; Courchesne, Y; Latreille, J; Letendre, F; Lorange, A; Louvet, C; Monte, M; Neemeh, JA; Pretty, HM, 1991) |
| "The antiemetic activity of DAU 6215, a novel antagonist of 5-HT3 receptors, was investigated in animal models of cytotoxic treatment-evoked emesis and compared with the antiemetic activity of ondansetron and metoclopramide." | 3.68 | Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. ( Algate, DR; Bonali, P; Donetti, A; Micheletti, R; Montagna, E; Nicola, M; Rimoldi, EM; Sagrada, A; Schiantarelli, P; Turconi, M, 1991) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 3.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "In prospective alternative crossover test, we confirmed significant superiority of a three-drug combination of clonazepam (C) lorazepam (L) and dexamethasone (D) to (L) and (D) to control vomiting induced by 50 mg/m CDDP containing chemotherapy for gynecological malignancies (p less than 0." | 3.68 | [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting]. ( Asano, H; Hatae, M; Hokanishi, H; Mitsuo, M; Nakamura, Y; Onishi, Y; Sakurai, K, 1990) |
| "Nabilone is a cannabinoid anti-emetic which has been extensively evaluated in control of chemotherapy-induced vomiting." | 3.67 | An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. ( Priestman, SG; Priestman, TJ, 1984) |
| "Using an original high-pressure liquid chromatographic assay, we measured serum levels of metoclopramide and defined a concentration-response relationship for metoclopramide control of cisplatin-induced emesis." | 3.67 | Optimizing metoclopramide control of cisplatin-induced emesis. ( Drayer, DE; Lewin, M; Lonski, L; Meyer, BR; Pasmantier, M; Reidenberg, MM, 1984) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 3.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "To investigate the effectiveness of high oral doses of the antiemetic agent 4-amino-5-chloro-N-(2-diethyl-aminoethyl)-2-methoxybenzamide (metoclopramide, MCP, Gastrosil) against nausea and vomiting induced by certain cyostatic drugs, blood was withdrawn repeatedly from 9 patients; MCP plasma levels were then determined." | 3.67 | [Metoclopramide plasma levels following oral administration of high doses for prophylaxis of emesis in cytostatic therapy]. ( Köhler, M; Senn, HJ; Vergin, H, 1984) |
| "The authors tested the safety and efficacy of intravenous metoclopramide in the prevention of chemotherapy-induced nausea and vomiting." | 3.67 | Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. ( McDermed, JE; Pileggi, J; Riech, LP; Strum, SB; Whitaker, H, 1984) |
| "We evaluated whether chronic nausea and vomiting in diabetic patients correlate with abnormal gastric emptying of liquid or solid, or both liquid and solid, radiolabeled meals and recorded the acute effects of metoclopramide." | 3.67 | Gastric emptying in patients with diabetes mellitus. ( Kalbfleisch, JH; Loo, FD; Palmer, DW; Soergel, KH; Wood, CM, 1984) |
| "Because of vomiting, a 15 years old girl inserted one metoclopramide suppository." | 3.67 | [Effect of metoclopramide in a subject at risk for Huntington's chorea]. ( Escousse, A; Fabre, JL; Giroud, M; Nivelon-Chevallier, A; Putelat, R, 1985) |
| "The effect of metoclopramide premedication on the incidence of gastric regurgitation and postoperative nausea and vomiting was studied in 101 women during gynaecological procedures performed under mask anaesthesia." | 3.67 | Silent regurgitation in day case gynaecological patients. ( Anderson, WG; Miller, CD, 1988) |
| " Vomiting was a frequent side effect (about 20 per cent of cases) and was treated successfully with metoclopramide at a dosage of 0." | 3.67 | Treatment of pseudopregnancy with bromocriptin, an ergot alkaloid. ( Janssens, LA, 1986) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 3.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "The antiemetic activity, gastric motor activity, and dopamine receptor effects of metoclopramide, dazopride, and sulpiride were assessed to establish if enhancement of gastric motility or antagonism of central dopamine receptors is the predominant action for drug-induced suppression of cisplatin-induced emesis." | 3.67 | Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. ( Alphin, RS; Dannenburg, WN; Johnson, DN; Kinnier, WJ; Leonard, CA; Proakis, AG; Sancilio, LF; Smith, WL; Ward, JW, 1986) |
| "In two previous consecutive studies on antiemetic combination of metoclopramide and dexamethasone was found to be very active against nausea and vomiting induced by cisplatin (DDP; 50 mg/m2) alone or in combination with other cytotoxic emetogenic drugs." | 3.67 | Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses. ( Caporali, C; Carlini, P; Cognetti, F; Pinnarò, P; Ruggeri, EM, 1986) |
| " To prevent emesis, two high-dose metoclopramide regimens were started 2 hr before cytostatic therapy." | 3.67 | Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis. ( Achtert, G; Briemann, L; Brockmann, P; Hausleiter, HJ; Hellenbrecht, D; Hellstern, A; Hess, H; Hodgson, M; Mitrou, P; Saller, R, 1985) |
| "Intravenous metoclopramide and IM prochlorperazine and diazepam were compared in the management of vomiting occurring during treatment with cis-dichlorodiammineplatinum (cis-platinum)." | 3.67 | High-dose intravenous metoclopramide and intermittent intramuscular prochlorperazine and diazepam in the management of emesis induced by cis-dichlorodiammineplatinum. ( Chan, KK; Luesley, DM; Terry, PB, 1985) |
| "Sixteen of 26 patients given 51 courses of treatment of the doxorubicin and cisplatin combination with no antiemetic therapy suffered the same number of vomiting episodes and had the same duration of vomiting as did the remaining ten patients given 20 cycles of this chemotherapy plus the standard high-dose metoclopramide regimen." | 3.67 | Lack of antiemetic effect of high-dose metoclopramide. ( Christiansen, NP; Hrushesky, WJ; Roemeling, RV, 1985) |
| "Having noticed psychotic traits in some patients showing incoercible vomiting due to antineoplastic drugs we have thought of establishing a therapy with lithium in the days preceding the therapeutic cycle in order to reduce the emetic events." | 3.67 | Sequential therapy with lithium in chemotherapy-induced vomiting. ( Alfano, G; Candido, A; Mango, G; Menichella, G; Rossi, P; Tartaglione, R, 1985) |
| "Metoclopramide hydrochloride was administered to nine children for the treatment of gastric stasis (N=6) and unexplained vomiting (N=3)." | 3.66 | Enhanced gastroduodenal motility in children. ( Hitch, DC; Torres-Pinedo, RB; Vanhoutte, JJ, 1982) |
| " Antagonism with metoclopramide provided complete protection from cisplatin-induced emesis." | 3.66 | Cisplatin-induced emesis in the Ferret: a new animal model. ( Bradner, WT; Florczyk, AP; Schurig, JE, 1982) |
| "When given with pethidine 100 mg or morphine 10 mg as preanaesthetic medication, 10 and 20 mg of metoclopramide cause a reduction in postoperative nausea and vomiting in women undergoing a standard operation with a standard anaesthetic technique." | 3.65 | Studies of drugs given before anaesthesia. XXIV: Metocloramide with morphine and pethidine. ( Assaf, RA; Clarke, RS; Dundee, JW; Samuel, IO, 1974) |
| "Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone." | 2.77 | Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. ( Akewanlop, C; Ithimakin, S; Keerativitayanan, N; Laocharoenkeat, A; Nimmannit, A; Runglodvatana, K; Soparattanapaisarn, N; Srimuninnimit, V, 2012) |
| "Pretreatment with ondansetron or metoclopramide does not reduce oral contrast solution ingestion time." | 2.74 | Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy. ( Bamber, D; Chohan, J; Garra, G; Singer, AJ; Thode, HC; Troxell, R, 2009) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 2.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 2.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "None of these differences reached statistical significance." | 2.69 | Prophylactic metoclopramide is unnecessary with intravenous analgesia in the ED. ( Paoloni, R; Talbot-Stern, J, 2000) |
| "Metoclopramide was ineffective." | 2.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "An intermittent intake of low-dose droperidol with morphine given via a PCA delivery system in two treatment groups gave evidence for a dose-response relation between the amount of droperidol added and the proportion of patients needing a rescue antiemetic." | 2.68 | Antiemetic efficacy of a droperidol-morphine combination in patient-controlled analgesia. ( Bach, T; Jackson, D; McKenzie, R; Riley, T; Tantisira, B, 1995) |
| "Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy." | 2.68 | Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. ( Ata, E; Butt, A; Khan, MA; Khan, WA; Malik, IA; Qazilbash, M, 1995) |
| "Metoclopramide was ineffective." | 2.68 | Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. ( Attia, M; Channa, AB; el Bakry, AK; el Gammal, K; el Gammal, M; Elhattab, YS; Jaroudi, R; Khoshim, MH; Naguib, M; Saddique, A, 1996) |
| " We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients." | 2.68 | Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. ( , 1997) |
| "Tropisetron+dexamethasone was significantly superior to tropisetron alone both for acute (P = 0." | 2.68 | Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. ( Bangerter, M; Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gallmeier, WM; Gosse, H; Grote-Kiehn, J; Imhoff, W; Mezger, J; Oehm, C; Ukena, D; Untch, M, 1997) |
| "The metoclopramide dosage was 20 mg i." | 2.68 | Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. ( Advani, SH; Cooverji, ND; Dhar, AK; Gopal, R; Lal, HM, 1996) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 2.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| "Tropisetron is an effective and well-tolerated agent in the prevention of chemotherapy-induced vomiting." | 2.67 | Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. ( Anderson, H; de Bruijn, KM; Howell, A; Logan, K; Sage, T; Thatcher, N, 1994) |
| "ondansetron was superior to metoclopramide in preventing nausea and vomiting after general anaesthesia for day-case gynaecological laparoscopic surgery." | 2.67 | Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide. ( Norton, AC; Raphael, JH, 1993) |
| "Droperidol was given just after induction and metoclopramide at the end of surgery, just before recovery." | 2.67 | Open placebo controlled comparison of the antiemetic effect of droperidol, metoclopramide or a combination of both in pediatric strabismus surgery. ( Pendeville, PE; Steinier, JR; Van Boven, MJ; Veyckemans, F, 1993) |
| " The overall incidence of adverse experiences was significantly lower in the granisetron group (60." | 2.67 | The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. ( , 1993) |
| " Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis." | 2.67 | Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. ( Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994) |
| "Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy." | 2.67 | Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. ( Balduck, N; Hachimi-Idrissi, S; Maurus, R; Otten, J, 1994) |
| "Acute nausea was prevented completely in 40% of patients in the tropisetron group and in 61% of the metoclopramide cocktail group during course 1 (P < ." | 2.67 | Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. ( Sorbe, BG, 1994) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 2.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Ondansetron was well tolerated in the dose and schedule used." | 2.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "The metoclopramide regimen was five times as expensive as prochlorperazine." | 2.67 | A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. ( Bishop, JF; Buchanan, L; Cooper, IA; Laidlaw, C; Matthews, J; Olver, IN; Smith, R; Wolf, M, 1992) |
| "Ondansetron hydrochloride is a selective serotonin subtype 3 (5HT3) receptor antagonist that has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy." | 2.67 | Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. ( Einhorn, L; House, K; Nagy, C; Sledge, GW, 1992) |
| "Vomiting was decreased in the DXM groups compared to groups A and C (p < 0." | 2.67 | Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy: a randomized trial. ( Bacoyannis, C; Droufakou, S; Kosmidis, P; Kozatsani-Halividi, D; Mylonakis, N; Tsaroucha-Noutsou, E; Tsavaris, N; Tsoutsos, H; Valilis, P, 1992) |
| " Regimen B, employing a lower dosage of metoclopramide and steroids and using a more simple schedule of administration should be the preferred treatment." | 2.67 | Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. ( Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M, 1992) |
| "Droperidol was more effective in reducing severe vomiting." | 2.67 | [Droperidol versus metoclopramide. Prevention of emesis following strabismus surgery in children]. ( Braun, U; Feldmann, M; Klockgether-Radke, A; Mühlendyck, H, 1992) |
| "Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight." | 2.67 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ( Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991) |
| "Metoclopramide-treated patients did not demonstrate a lower incidence of nausea or emesis but did tolerate oral liquids earlier after surgery than the placebo group (P less than 0." | 2.67 | Outpatient cholecystectomy simulated in an inpatient population. ( Downes, TW; Hayes, DH; McKinnon, WM; Treen, DC, 1991) |
| "At the end of the treatment period, nausea, vomiting and reflux symptoms, adverse events and a global assessment of patients' symptom control were recorded by the investigator." | 2.67 | A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting. ( Miller, AJ; Patel, NH; Roy, P, 1991) |
| " Overall, the evidence suggests that this dosing schedule for batanopride may be too toxic for clinical use." | 2.67 | Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. ( Fleming, GF; Francher, D; Janisch, L; McEvilly, JM; Smaldone, L; Vokes, EE, 1991) |
| " It is concluded that oral lorazepam is an effective and safe adjuvant to MCP for the control of vomiting during cancer chemotherapy." | 2.67 | Low dose, oral lorazepam: a safe and effective adjuvant to antiemetic therapy. ( Advani, SH; Banavali, SD; Charak, BS; Gopal, R; Iyer, RS; Saikia, TK, 1991) |
| "Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0." | 2.67 | Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. ( Osterwalder, B; Schimke, J; Senn, HJ; Wilder-Smith, CH, 1991) |
| "Vomiting was not satisfactorily prevented by either treatment." | 2.67 | Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. ( Hallén, C; Sorbe, B, 1991) |
| "56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours." | 2.67 | [Antiemetic treatments associated with antineoplastic chemotherapy]. ( Guillén Lloveria, G; Mayordomo Cámara, JJ; Sáenz Cusi, A; Sáez Martínez, MJ; Tres Sánchez, A, 1990) |
| " Only one adverse event, headache, occurred in more than five patients in the granisetron group." | 2.67 | Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. ( Chevallier, B, 1990) |
| "Sixty-nine patients with malignant tumors receiving cancer chemotherapy, 90% including cis-platinum, were evaluated in a randomized crossover study for the antiemetic efficacy and the side effects of two antiemetic regimens: chlorpromazine (CPM) 2." | 2.66 | Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study. ( Ben-Yosef, R; Biran, S; Brufman, G; Catane, R; Gez, E, 1989) |
| "The metoclopramide dosage was escalated in six steps from 0." | 2.66 | Dose-ranging antiemetic trial of high-dose oral metoclopramide. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB; Young, CW, 1989) |
| " We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B)." | 2.66 | Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research ( Basurto, C; Bracarda, S; Di Costanzo, F; Donati, D; Malacarne, P; Monici, L; Patoia, L; Picciafuoco, M; Roila, F; Tonato, M, 1989) |
| "Clebopride was reasonably well tolerated at the used dosages, inducing sedation in 20% of cases (versus 24% with metoclopramide) and diarrhea in 37% (versus 20% with metoclopramide)." | 2.66 | [Comparative study on the tolerance and efficacy of high doses of metoclopramide and clebopride in vomiting induced by cisplatin]. ( Díaz-Rubio, E; Martín, M, 1989) |
| "19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters." | 2.66 | [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ( Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988) |
| "Droperidol was significantly more effective than domperidone, metoclopramide or placebo in reducing emetic sequelae." | 2.66 | Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery. ( Madej, TH; Simpson, KH, 1986) |
| "The metoclopramide regimen was either 2 mg/kg i." | 2.66 | A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis. ( Abdulhay, G; Dana, BW; Everts, E; McDermott, M, 1987) |
| " With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis." | 2.66 | A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. ( Carlini, P; Marolla, P; Nardi, M; Pollera, CF, 1987) |
| "Thirty-two patients with primary lung cancer receiving combination chemotherapy including cisplatin at a dosage of 80-120 mg/m2 were entered into an antiemetic randomized crossover trial." | 2.66 | [Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial]. ( Fujii, M; Kamei, H; Kiura, K; Okabe, K; Toki, H, 1987) |
| " It is concluded that there is a dose-response relationship for the antiemetic effect of metoclopramide." | 2.66 | High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. ( Grande, T; Moxnes, A; Onsrud, M; Solesvik, O; Sollien, A, 1988) |
| "Continuous infusion of metoclopramide was compared with bolus dosing in a randomized, double-blind study in 27 patients receiving cisplatin therapy." | 2.66 | Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis. ( Agostinucci, WA; Dinonno, EB; Gannon, RH; Golub, GR; Martin, RS; Schauer, PK, 1988) |
| "Metoclopramide serum levels were measured by high-performance liquid chromatography." | 2.66 | Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial. ( Anthony, LB; Brenner, DE; Burish, TG; Greco, FA; Hainsworth, JD; Hande, KR; Krozely, MG; Woodward, NJ, 1986) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 2.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "Metoclopramide was more effective in decreasing the volume of emesis than was alizapride (median of 100 ml vs." | 2.66 | The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. ( Bischoff, AK; Brunner, KW; Galeazzi, RL; Joss, RA; Pirovino, M; Ryssel, HJ, 1986) |
| " A further trial is necessary to determine the optimal dosage and scheduling of the available agents." | 2.66 | [Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy]. ( Fujii, M; Kiura, K; Okabe, K; Tamai, M; Toki, H, 1986) |
| "We designed a multicenter, double-blind randomized study to determine the safety and antiemetic effectiveness of intravenous (IV) methylprednisolone (P) combined with high-dose IV metoclopramide (MTC) v MTC alone in 200 untreated cancer patients receiving cisplatin chemotherapy." | 2.66 | Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. ( Ballatori, E; Basurto, C; Bella, M; DiCostanzo, F; Donati, D; Morsia, D; Passalacqua, R; Roila, F; Tognoni, G; Tonato, M, 1987) |
| "To better define the dose-response relationship of moderate-dose (MD) metoclopramide (MCP), 42 patients receiving their first course of cisplatin (50 mg/m2) were randomly allocated to receive a short-course regimen of MCP, either at 1 mg/kg X 1 dose, 30 min before cisplatin (regimen A) or 1 mg/kg X 2 doses, 30 min before and 1 h after cisplatin (regimen B)." | 2.66 | Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesis. ( Calabresi, F; Conti, EM; De Nigris, A; Pollera, CF, 1987) |
| "The metoclopramide-treated group demonstrated a statistically significant decrease in the incidence of nausea and vomiting." | 2.66 | Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. ( Brown, RE; Drew, SJ; Sabates, R, 1987) |
| " The biological half-life of metoclopramide was 9." | 2.66 | Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens. ( Havsteen, H; Kjaer, M; Nielsen, H, 1986) |
| "The oral bioavailability of high-dose metoclopramide was studied in 12 patients, who received oral or intravenous (i." | 2.66 | Oral bioavailability of high-dose metoclopramide. ( Bateman, DN; Taylor, WB, 1986) |
| "Metoclopramide was compared to a metoclopramide plus dexamethasone combination in patients receiving high-dose cisplatinum." | 2.66 | Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. ( Akerley, WL; Baker, CR; Cariffe, PA; Grunberg, SM; Johnson, KB; Krailo, MD, 1986) |
| " Its optimal dosage schedule, however, has not yet been completely defined." | 2.66 | Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. ( Ballatori, E; Basurto, C; Canaletti, R; Colombo, N; DiCostanzo, F; Donati, D; Morsia, D; Passalacqua, R; Roila, F; Tonato, M, 1985) |
| "Four consecutive trials were undertaken to study lorazepam at each of three dosage levels and diphenhydramine when used in combination with iv metoclopramide and dexamethasone in patients receiving cisplatin at 120 mg/m2." | 2.66 | Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. ( Clark, RA; Fiore, JJ; Gralla, RJ; Groshen, S; Kelsen, DP; Kris, MG; Tyson, LB, 1985) |
| " The results demonstrate that the dosage regimen originally suggested by Gralla for cytostatic drugs, with forced diuresis for high-dose metoclopramide therapy, may also be applied, with no dosage reduction, with to other cytostatic drugs which do not require forced diuresis." | 2.66 | Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis. ( Braun, J; Domschke, S; Domschke, W; Ell, C; König, HJ, 1985) |
| "Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2." | 2.66 | [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]. ( Dozono, H; Ohmi, K, 1986) |
| "Metoclopramide (MCP) was given i." | 2.65 | Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. ( Carlini, P; Cognetti, F; Conti, EM; Cortese, M; Pinnarò, P; Pollera, CF, 1984) |
| "In a population of 51 ambulant cancer patients treated with doxorubicin-containing chemotherapy we conducted a double-blind cross-over randomized trial, comparing the anti-emetic efficacy of a combination of amitriptyline (25 mg p." | 2.65 | Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. ( Blijham, GH; Mellink, WA; van Deyk, WA, 1984) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 2.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| " The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized." | 2.65 | Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. ( Cox, R; Leyland, MJ; Newman, CE, 1982) |
| "5." | 2.64 | Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. ( Debono, A; Marsden, CD; Parkes, JD; Price, P; Rosenthaler, J, 1978) |
| "Nausea is a common symptom in advanced cancer, with a prevalence of up to 70%." | 2.55 | Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). ( Good, P; Hardy, JR; Haywood, A; Khan, S; Rickett, K; Vayne-Bossert, P, 2017) |
| "Nausea and vomiting is a common and distressing presenting complaint in emergency departments (ED)." | 2.52 | Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. ( Egerton-Warburton, D; Furyk, JS; Meek, RA, 2015) |
| "Metoclopramide is a prokinetic agent reported to be safe in parturients." | 2.48 | Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. ( Habib, AS; Mishriky, BM, 2012) |
| "Nausea and vomiting are common symptoms of migraine, which can be controlled with a variety of anti-emetics including phenothiazines and antihistamines." | 2.41 | Anti-emetics. ( MacGregor, EA, 2001) |
| "Nausea and vomiting are debilitating side effects that often accompany the administration of chemotherapy and may lead to adverse physiological and psychological effects." | 2.39 | Antiemetics in children receiving cancer chemotherapy. ( Billett, AL; Sallan, SE, 1994) |
| "Ondansetron (GR 38032F) is a highly selective 5-HT3 receptor antagonist, one of a new class of compounds which may have several therapeutic applications." | 2.38 | Ondansetron. Therapeutic use as an antiemetic. ( Heel, RC; Milne, RJ, 1991) |
| "Nausea and vomiting are a serious side effect of chemotherapy, frequently leading to failure of treatment compliance." | 2.38 | [Nausea and vomiting induced by chemotherapy: bases to a rational treatment]. ( Fodor, M; Gallardo, J, 1989) |
| "Nausea and vomiting are the most feared toxicities of chemotherapy." | 2.38 | Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. ( Grunberg, SM, 1989) |
| " Pyridoxine is considered safe for use during pregnancy, but its efficacy in treating nausea and vomiting has not been determined." | 2.37 | Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. ( Leathem, AM, 1986) |
| "Metoclopramide also has an important place in the investigation of the role of dopamine in physiological and pathological processes." | 2.37 | Metoclopramide--a review. ( Desmond, PV; Watson, KJ, 1986) |
| "Metoclopramide appears to be an effective drug in stimulating the mobility of the upper gastrointestinal tract without increasing gastric secretions." | 2.36 | Review of a new gastrointestinal drug--metoclopramide. ( Nappi, JM; Ponte, CD, 1981) |
| "We considered akathisia and cancer-related anxiety/agitation as possible causes of restlessness and insomnia, and prescribed clonazepam." | 1.72 | Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report. ( Deguchi, Y; Inoue, K; Itoh, Y; Sakamoto, S; Uchida, S, 2022) |
| "Nausea is a common symptom in patients taken care of by the ambulance service." | 1.43 | Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study. ( Hjelte Judell, O; Lindström, V; Vicente, V; Westerlund, A, 2016) |
| "Nausea and vomiting are common, but prevalence of antiemetic use in ED patients is unknown." | 1.43 | Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective. ( Garra, G; Singer, AJ; Thode, HC, 2016) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| "Metoclopramide has the greatest evidence for efficacy followed by phenothiazines and tropisetron." | 1.36 | Nausea and vomiting in advanced cancer. ( Ang, SK; Davis, MP; Shoemaker, LK, 2010) |
| " Prior treatment with each dosage of metoclopramide significantly reduced the frequency of emetic episodes (P<0." | 1.36 | Effects of metoclopramide on emesis in cats sedated with xylazine hydrochloride. ( Jarolmasjed, S; Kolahian, S, 2010) |
| "For moderate dehydration, eight CPGs advocated nasogastric (NG) rehydration in preference to intravenous (IV) rehydration." | 1.35 | Emergency department management of gastro-enteritis in Australia and New Zealand. ( Babl, FE; Borland, M; Schutz, J; Sheriff, N, 2008) |
| "Metoclopramide probably has a mechanism of action to prevent U46619-induced emesis via 5-HT(4) receptor activation and NK(1) tachykinin receptor antagonists could be useful to prevent emesis induced by TP receptor activation in man." | 1.35 | Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret. ( Kan, KK; Ngan, MP; Rudd, JA; Wai, MK, 2008) |
| " Clinicians should attempt to treat patients with the lowest effective dosage of medication for the briefest therapeutic period to minimize the risks of adverse reactions." | 1.31 | Metoclopramide-induced supersensitivity psychosis. ( Lu, ML; Pan, JJ; Shen, WW; Su, KP; Teng, HW, 2002) |
| "Metoclopramide is a dopamine receptor blocking drug that is commonly used to treat nausea and vomiting." | 1.31 | Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. ( Addis, A; Arnon, J; Berkovitch, M; Elbirt, D; Greenberg, R; Magee, L; Mazzota, P; Merlob, P; Moretti, M; Ornoy, A; Schuler-Faccini, L; Stahl, B, 2002) |
| "Emesis was characterized by expulsion of solid or liquid material." | 1.29 | Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. ( Göthert, M; Herold, H; Szelenyi, I, 1994) |
| "Domperidone did not inhibit these cytotoxic agents-induced emeses." | 1.29 | The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. ( Fukuda, T; Haga, K; Inaba, K; Morimoto, Y; Setoguchi, M; Shoji, H, 1993) |
| "Vomiting was the first cause of admission in diabetics." | 1.29 | Gastroparesis: an important cause of hospitalization in continuous ambulatory peritoneal dialysis patients and the role of erythromycin. ( Gallar, P; Guijo, G; Oliet, A; Ortega, O; Vigil, A, 1993) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Severe vomiting was present in 34 (89%) and proved to be a serious obstacle to the administration of enteral charcoal." | 1.28 | Management of theophylline overdose patients in the intensive care unit. ( Henderson, A; Pond, SM; Wright, DM, 1992) |
| "Despite treatment, emesis remains a major problem with cisplatin chemotherapy." | 1.28 | [Improved control of cisplatin-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam]. ( Hsu, KP; Li, YT; Mau, YK; Tsui, MS; Tu, FC, 1991) |
| "Cisapride was a potent stimulant of gastric emptying in rats, 7 times more potent than metoclopramide." | 1.28 | General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride. ( Awouters, FH; Megens, AA; Niemegeers, CJ, 1991) |
| "Despite this preventative treatment, nausea and/or vomiting occurred in over one-third of all the courses." | 1.28 | [Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin]. ( Aoki, Y; Horiuchi, Y; Kamikawa, R; Kyokane, K; Miwa, Y; Nagai, H; Ninomiya, E; Noro, T; Suga, S; Yasue, K, 1990) |
| "The neuroleptic malignant syndrome is a serious and potentially fatal complication of neuroleptic and other dopamine antagonist drugs that are commonly used in symptom control in advanced cancer." | 1.28 | The neuroleptic malignant syndrome. ( O'Neill, WM, 1990) |
| "Nausea and emesis during cancer chemotherapy are very common, but can often be controlled with repetitive boli of antiemetic drugs." | 1.28 | Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting. ( Naji, P; Osterwalder, B; Schuler, L; Senn, HJ; Wilder-Smith, CH, 1990) |
| "Both zacopride and BMY25801 were effective against emesis and related signs." | 1.28 | Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. ( King, GL; Landauer, MR, 1990) |
| "Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin." | 1.28 | Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. ( Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989) |
| "Metoclopramide was given in 4 doses of 1mg/kg on the same schedule." | 1.28 | [Antiemetic efficacy of betamethasone versus betamethasone combined with metoclopramide in cisplatin-treated cancer patients]. ( Kagami, Y; Narimatsu, N; Nishio, M; Sakurai, T; Tomita, M, 1989) |
| "Sixty patients with Hodgkin's disease were treated with a polychemotherapy regimen including very emetic dacarbazine and adriamycin in addition to bleomycin and vincristine on 622 treatment days during the last 10 years." | 1.28 | [Management of vomiting induced by polychemotherapy in Hodgkin's disease]. ( Berényi, E; Kiss, E, 1989) |
| "In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle." | 1.27 | Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. ( Altenburg, HP; Heim, ME; Queisser, W, 1984) |
| "Metoclopramide was given intravenously (IV) at a dose of 0." | 1.27 | Combination metoclopramide and dexamethasone: an effective antiemetic regimen in outpatients receiving non-cisplatin chemotherapy. ( McDermed, JE; McDermott, NM; Streng, BR; Strum, SB, 1984) |
| "With increasingly effective cancer chemotherapy, the control of chemotherapy-induced nausea and vomiting has become more important." | 1.27 | Control of cancer chemotherapy-induced nausea and vomiting. ( Eyre, HJ; Ward, JH, 1984) |
| " In these six patients plasma metoclopramide half-life was 5." | 1.27 | Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting. ( Bateman, DN; Proctor, SJ; Taylor, WB, 1984) |
| "Nausea and vomiting are often severe and prolonged, rendering a patient unfit for further treatment." | 1.27 | [New aspects in the antiemetic therapy of cytostatic drug-induced vomiting]. ( Gerhartz, H; Hiller, E, 1984) |
| "Metoclopramide was orally administered (10 or 20 mg) to 22 subjects, 75 min before parabolic flight." | 1.27 | Hormonal responses of metoclopramide-treated subjects experiencing nausea or emesis during parabolic flight. ( Kohl, RL, 1987) |
| "Metoclopramide was nonselectively active against emesis induced by cytostatic agents, radiation and D2-dopamine receptor agonists, whereas domperidone was selectively effective against emesis induced by apomorphine and hydergine only." | 1.27 | BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. ( Buyniski, JP; Crenshaw, RR; Gylys, JA; Nicolosi, WD; Wright, RN, 1988) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 1.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| " The quantitative dose-response curves of the four doses of the emetic agonist cisplatin were shifted to the right by increasing doses of MCL." | 1.27 | Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. ( Hellenbrecht, D; Saller, R, 1986) |
| "Vomiting was observed more frequently after non intra-ocular surgery than after intra-ocular surgery (37% cf." | 1.27 | Vomiting after ophthalmic surgery. Effects of intra-operative antiemetics and postoperative oral fluid restriction. ( Laghari, NA; Lambourne, A; Van den Berg, AA; Yazji, NS, 1987) |
| "Nausea and vomiting are common complications of cisplatin chemotherapy." | 1.27 | Evaluation of ethanol as an antiemetic in patients receiving cisplatin. ( Adelstein, DJ; Hines, JD; Spiess, JL, 1987) |
| "Metoclopramide hydrochloride is an antiemetic and gastric motility stimulant with a wide variety of extrapyramidal side effects, including parkinsonism." | 1.27 | Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. ( Diamond, BF; Kimmel, PL; Sirota, RA; Stein, HD; Trichtinger, MD; Yudis, M, 1986) |
| "Emesis was observed from 0." | 1.27 | [Experimental study on the control of cisplatin-induced emesis in dogs]. ( Abo, T; Ito, J; Okada, M; Okamoto, Y; Takahashi, K; Yamashita, T, 1987) |
| "Metoclopramide (MCP) was used as an antiemetic agent in 11 pediatric oncology patients during 22 courses of cancer therapy including cisplatin, doxorubicin, and other agents." | 1.27 | Metoclopramide as an antiemetic agent in pediatric oncology patients. ( Blatt, J; Felix, C; Howrie, DL; Juhl, RP; Wollman, M, 1986) |
| "Metoclopramide was administered four times intravenously at a dose of 1." | 1.27 | [Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting]. ( Amano, H; Fujimoto, K; Saito, H; Shimokata, K; Tsunekawa, H; Yasuda, Y; Yoshii, S, 1985) |
| "Metoclopramide (Paspertin) was infused intravenously in the high doses of 1." | 1.27 | Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis. ( Hellenbrecht, D; Hellstern, A; Hess, H; Saller, R, 1985) |
| "Magnesium deficiency was present in seven patients and its correction resulted in amelioration of the symptom complex." | 1.26 | Chronic intestinal pseudo-obstruction. ( Brandenburg, D; Brooks, WS; Hersh, T; Hirsh, EH, 1981) |
| "Metoclopramide was used as an antiemetic." | 1.26 | [Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)]. ( Antz, H; Doepfmer, K; FEAUX DE Lacroix, W; Groth, W; Runne, U, 1980) |
| " The toxicity of high dose metoclopramide was of concern mainly in patients younger than 30, and/or when dosage escalation have been attempted." | 1.26 | [High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients]. ( Albin, H; Bui, NB; Durand, M; Hoerni, B; Marit, G; Mauriac, L, 1982) |
| "Although vomiting was not inhibited by chlorpromazine or atropine, a strong inhibition was evident when metoclopramide was administered subcutaneously at such doses as inhibit vomiting induced by oral administration of CuSO4." | 1.25 | Pharmacological studies of caerulein. II. The possibility of mediation through the central nervous system. ( Kojima, T; Koyama, Y; Marumo, H; Nakamura, N; Shiozaki, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 294 (39.57) | 18.7374 |
| 1990's | 301 (40.51) | 18.2507 |
| 2000's | 58 (7.81) | 29.6817 |
| 2010's | 69 (9.29) | 24.3611 |
| 2020's | 21 (2.83) | 2.80 |
| Authors | Studies |
|---|---|
| Youssefyeh, RD | 2 |
| Campbell, HF | 2 |
| Klein, S | 2 |
| Airey, JE | 2 |
| Darkes, P | 1 |
| Powers, M | 2 |
| Schnapper, M | 2 |
| Neuenschwander, K | 1 |
| Fitzpatrick, LR | 1 |
| Pendley, CE | 1 |
| Woodward, R | 1 |
| Rodriguez, W | 1 |
| Golec, S | 1 |
| Studt, W | 1 |
| Piana, F | 1 |
| Minghella, E | 1 |
| Sun, L | 1 |
| Xi, Y | 1 |
| Wen, X | 1 |
| Zou, W | 1 |
| Robson, S | 1 |
| McParlin, C | 1 |
| Mossop, H | 1 |
| Lie, M | 1 |
| Fernandez-Garcia, C | 1 |
| Howel, D | 1 |
| Graham, R | 1 |
| Ternent, L | 1 |
| Steel, A | 1 |
| Goudie, N | 1 |
| Nadeem, A | 1 |
| Phillipson, J | 1 |
| Shehmar, M | 1 |
| Simpson, N | 1 |
| Tuffnell, D | 1 |
| Campbell, I | 1 |
| Williams, R | 1 |
| O'Hara, ME | 1 |
| McColl, E | 1 |
| Nelson-Piercy, C | 1 |
| Gottlieb, M | 1 |
| Carlson, JN | 1 |
| Peksa, GD | 1 |
| Sher, AA | 1 |
| Iqbal, A | 1 |
| Adil, M | 1 |
| Ullah, S | 1 |
| Bawazeer, S | 1 |
| Binmahri, MK | 1 |
| Zamil, LZ | 1 |
| Irfan, M | 1 |
| Sakamoto, S | 1 |
| Deguchi, Y | 1 |
| Uchida, S | 1 |
| Itoh, Y | 1 |
| Inoue, K | 1 |
| Henze, L | 1 |
| Foth, S | 1 |
| Meller, S | 1 |
| Twele, F | 1 |
| Charalambous, M | 1 |
| Kenward, H | 1 |
| Elliott, J | 1 |
| Pelligand, L | 1 |
| Volk, HA | 1 |
| Na, S | 1 |
| Jung, DE | 1 |
| Hwang, E | 1 |
| Kim, T | 1 |
| Sriwiset, H | 1 |
| Lokeskrawee, T | 1 |
| Patumanond, J | 1 |
| Wongyikul, P | 1 |
| Phinyo, P | 1 |
| Elendu, C | 1 |
| Adenikinju, J | 1 |
| Ogala, F | 1 |
| Ologunde, T | 1 |
| Adebambo, S | 1 |
| Egbunu, E | 1 |
| Barney, EZ | 1 |
| Fuller, ME | 1 |
| Habib, AS | 4 |
| Harder, S | 2 |
| Groenvold, M | 2 |
| Herrstedt, J | 3 |
| Niño-Serna, LF | 1 |
| Acosta-Reyes, J | 1 |
| Veroniki, AA | 1 |
| Florez, ID | 1 |
| Rowland, KD | 1 |
| Fuehrer, J | 1 |
| Motov, SM | 1 |
| Vilke, G | 1 |
| Rosenbaum, SB | 1 |
| Quenzer, F | 1 |
| Radhakrishnan, V | 1 |
| Pai, V | 1 |
| Rajaraman, S | 1 |
| Mehra, N | 1 |
| Ganesan, T | 1 |
| Dhanushkodi, M | 1 |
| Perumal Kalaiyarasi, J | 1 |
| Rajan, AK | 1 |
| Selvarajan, G | 1 |
| Ranganathan, R | 1 |
| Karunakaran, P | 1 |
| Sagar, TG | 1 |
| Kaneishi, K | 1 |
| Imai, K | 1 |
| Nishimura, K | 1 |
| Sakurai, N | 1 |
| Kohara, H | 1 |
| Ishiki, H | 1 |
| Kanai, Y | 1 |
| Oyamada, S | 1 |
| Yamaguchi, T | 1 |
| Morita, T | 1 |
| Iwase, S | 1 |
| van der Vorst, MJDL | 1 |
| Toffoli, EC | 1 |
| Beusink, M | 1 |
| van Linde, ME | 1 |
| van Voorthuizen, T | 1 |
| Brouwer, S | 1 |
| van Zweeden, AA | 1 |
| Vrijaldenhoven, S | 1 |
| Berends, JC | 1 |
| Berkhof, J | 1 |
| Verheul, HMW | 1 |
| Suarez, EA | 1 |
| Boggess, K | 1 |
| Engel, SM | 1 |
| Stürmer, T | 1 |
| Lund, JL | 1 |
| Jonsson Funk, M | 1 |
| Sakran, R | 1 |
| Shechtman, S | 1 |
| Arnon, J | 2 |
| Diav-Citrin, O | 1 |
| Lacy, BE | 1 |
| Cangemi, DJ | 1 |
| Davis, M | 1 |
| Hui, D | 1 |
| Davies, A | 1 |
| Ripamonti, C | 1 |
| Capela, A | 1 |
| DeFeo, G | 1 |
| Del Fabbro, E | 1 |
| Bruera, E | 3 |
| Taylor, SJ | 1 |
| Allan, K | 1 |
| McWilliam, H | 1 |
| Manara, A | 1 |
| Brown, J | 1 |
| Greenwood, R | 1 |
| Toher, D | 1 |
| Vayne-Bossert, P | 1 |
| Haywood, A | 1 |
| Good, P | 1 |
| Khan, S | 1 |
| Rickett, K | 1 |
| Hardy, JR | 1 |
| Kim, GH | 1 |
| Jung, KW | 1 |
| Brioschi, FA | 1 |
| Gioeni, D | 1 |
| Jacchetti, A | 1 |
| Carotenuto, AM | 1 |
| Sutherland, A | 1 |
| Naessens, K | 1 |
| Plugge, E | 1 |
| Ware, L | 1 |
| Head, K | 1 |
| Burton, MJ | 1 |
| Wee, B | 1 |
| Isaksen, J | 1 |
| Neergaard, MA | 1 |
| Frandsen, K | 1 |
| Sigaard, J | 1 |
| Mondrup, L | 1 |
| Jespersen, BA | 1 |
| Giusti, R | 1 |
| Mazzotta, M | 1 |
| Filetti, M | 1 |
| Daniele, G | 1 |
| Tsukuura, H | 2 |
| Ficorella, C | 1 |
| Porzio, G | 1 |
| Marchetti, P | 1 |
| Verna, L | 1 |
| Lee, CS | 1 |
| Chen, KC | 1 |
| Yu, CH | 1 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Keat, CH | 2 |
| Phua, G | 1 |
| Abdul Kassim, MS | 1 |
| Poh, WK | 1 |
| Sriraman, M | 1 |
| Kirthi, V | 2 |
| Derry, S | 2 |
| Moore, RA | 2 |
| George, RB | 1 |
| McKeen, DM | 1 |
| White, WD | 1 |
| Ituk, US | 1 |
| Megalla, SA | 1 |
| Allen, TK | 1 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Mohamed, RA | 1 |
| Abass, HA | 1 |
| Attia, MA | 1 |
| Heikal, OA | 1 |
| Ghani, NA | 1 |
| Dahl, E | 1 |
| Diskin, AL | 1 |
| Li, HQ | 1 |
| Chan, IS | 1 |
| Tang, ML | 1 |
| Tian, GL | 1 |
| Tang, NS | 1 |
| Egerton-Warburton, D | 3 |
| Meek, R | 3 |
| Mee, MJ | 2 |
| Braitberg, G | 1 |
| Heiberger, A | 1 |
| Zhang, XF | 1 |
| Yin, GZ | 1 |
| Liu, QG | 1 |
| Liu, XM | 1 |
| Wang, B | 1 |
| Yu, L | 1 |
| Liu, SN | 1 |
| Cui, HY | 1 |
| Lv, Y | 1 |
| Furyk, JS | 2 |
| McKenzie, S | 1 |
| Pitts, SR | 1 |
| Roila, F | 19 |
| Ruggeri, B | 1 |
| Ballatori, E | 14 |
| Fatigoni, S | 1 |
| Caserta, C | 1 |
| Licitra, L | 1 |
| Mirabile, A | 1 |
| Ionta, MT | 1 |
| Massidda, B | 1 |
| Cavanna, L | 1 |
| Palladino, MA | 2 |
| Tocci, A | 1 |
| Fava, S | 1 |
| Colantonio, I | 1 |
| Angelelli, L | 1 |
| Ciuffreda, L | 1 |
| Fasola, G | 1 |
| Zerilli, F | 1 |
| Meek, RA | 1 |
| Ando, Y | 1 |
| Gyawali, B | 1 |
| Matsumoto, M | 1 |
| Sugishita, M | 1 |
| Honda, K | 1 |
| Urakawa, H | 1 |
| Maeda, O | 1 |
| Hasegawa, Y | 1 |
| Smith, LA | 1 |
| Azariah, F | 1 |
| Lavender, VT | 1 |
| Stoner, NS | 1 |
| Bettiol, S | 1 |
| Bajgoric, S | 1 |
| Samra, K | 1 |
| Chandrapalan, S | 1 |
| Gautam, N | 1 |
| Beer, AM | 1 |
| Westerlund, A | 1 |
| Vicente, V | 1 |
| Hjelte Judell, O | 1 |
| Lindström, V | 1 |
| Waqar, SN | 1 |
| Mann, J | 1 |
| Baggstrom, MQ | 1 |
| Waqar, MA | 1 |
| Chitneni, P | 1 |
| Williams, K | 1 |
| Gao, F | 1 |
| Morgensztern, D | 1 |
| Govindan, R | 1 |
| Singer, AJ | 2 |
| Garra, G | 2 |
| Thode, HC | 2 |
| Lewis, K | 1 |
| Alqahtani, Z | 1 |
| Mcintyre, L | 1 |
| Almenawer, S | 1 |
| Alshamsi, F | 1 |
| Rhodes, A | 1 |
| Evans, L | 1 |
| Angus, DC | 1 |
| Alhazzani, W | 1 |
| Lorenzutti, AM | 1 |
| Martín-Flores, M | 1 |
| Litterio, NJ | 1 |
| Himelfarb, MA | 1 |
| Invaldi, SH | 1 |
| Zarazaga, MP | 1 |
| Malekolkottab, M | 1 |
| Khalili, H | 1 |
| Mohammadi, M | 1 |
| Ramezani, M | 1 |
| Nourian, A | 1 |
| Yalcin, E | 1 |
| Keser, GO | 1 |
| Schutz, J | 1 |
| Babl, FE | 1 |
| Sheriff, N | 1 |
| Borland, M | 1 |
| Kan, KK | 1 |
| Ngan, MP | 2 |
| Wai, MK | 2 |
| Rudd, JA | 3 |
| Bamber, D | 1 |
| Chohan, J | 1 |
| Troxell, R | 1 |
| Krobbuaban, B | 1 |
| Pitakpol, S | 1 |
| Diregpoke, S | 1 |
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 2 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Hawkins, R | 1 |
| Grunberg, S | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Alhashimi, D | 3 |
| Al-Hashimi, H | 1 |
| Fedorowicz, Z | 4 |
| Du Bois, A | 2 |
| Matok, I | 1 |
| Gorodischer, R | 1 |
| Koren, G | 1 |
| Sheiner, E | 1 |
| Wiznitzer, A | 1 |
| Levy, A | 1 |
| Lau, KK | 1 |
| Chan, KW | 1 |
| Lok, CM | 1 |
| Lam, AW | 1 |
| Lee, HH | 1 |
| Luk, WF | 1 |
| Mak, CM | 1 |
| Ching, CK | 1 |
| Lo, J | 1 |
| Li, SM | 1 |
| Chan, AY | 1 |
| Patanwala, AE | 1 |
| Amini, R | 1 |
| Hays, DP | 1 |
| Rosen, P | 1 |
| Trepanier, L | 1 |
| Ang, SK | 1 |
| Shoemaker, LK | 1 |
| Davis, MP | 1 |
| McQuay, HJ | 1 |
| Zang, J | 1 |
| Hou, M | 1 |
| Gou, HF | 1 |
| Qiu, M | 1 |
| Wang, J | 1 |
| Zhou, XJ | 1 |
| Luo, de Y | 1 |
| Yang, Y | 1 |
| Jiang, M | 1 |
| Cao, D | 1 |
| Bi, F | 1 |
| Xu, F | 1 |
| Shen, Y | 1 |
| Yi, C | 1 |
| Molassiotis, A | 3 |
| Brearley, SG | 1 |
| Stamataki, Z | 1 |
| Kolahian, S | 1 |
| Jarolmasjed, S | 1 |
| Miyagawa, Y | 1 |
| Ejiri, M | 1 |
| Kuzuya, T | 1 |
| Osada, T | 1 |
| Ishiguro, N | 1 |
| Yamada, K | 1 |
| Salvo, N | 1 |
| Doble, B | 1 |
| Khan, L | 1 |
| Amirthevasar, G | 1 |
| Dennis, K | 1 |
| Pasetka, M | 1 |
| Deangelis, C | 1 |
| Tsao, M | 1 |
| Chow, E | 1 |
| Yousef, M | 1 |
| Ebrahim, N | 1 |
| Ebrahim, A | 1 |
| Hosssain, B | 1 |
| Ithimakin, S | 1 |
| Runglodvatana, K | 1 |
| Nimmannit, A | 1 |
| Akewanlop, C | 1 |
| Srimuninnimit, V | 1 |
| Keerativitayanan, N | 1 |
| Soparattanapaisarn, N | 1 |
| Laocharoenkeat, A | 1 |
| Bonilla-Palomas, JL | 1 |
| López-López, JM | 1 |
| Moreno-Conde, M | 1 |
| Gallego de la Sacristana, A | 1 |
| Gámez-López, AL | 1 |
| Villar-Ráez, A | 1 |
| Klauser, CK | 1 |
| Fox, NS | 1 |
| Istwan, N | 1 |
| Rhea, D | 1 |
| Rebarber, A | 1 |
| Desch, C | 1 |
| Palmer, B | 1 |
| Saltzman, D | 1 |
| Ebrahim Soltani, AR | 1 |
| Mohammadinasab, H | 1 |
| Goudarzi, M | 1 |
| Arbabi, S | 1 |
| Mohammadinasab, A | 1 |
| Mohammadinasab, F | 1 |
| Samimi, M | 1 |
| Festin, M | 1 |
| Al-Ansari, K | 1 |
| Alomary, S | 1 |
| Abdulateef, H | 1 |
| Alshawagfa, M | 1 |
| Kamal, K | 1 |
| Simpson, PM | 1 |
| Bendall, JC | 1 |
| Middleton, PM | 1 |
| Perwitasari, DA | 1 |
| Wessels, JA | 1 |
| van der Straaten, RJ | 1 |
| Baak-Pablo, RF | 1 |
| Mustofa, M | 1 |
| Hakimi, M | 1 |
| Nortier, JW | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Jagannath, VA | 1 |
| Carter, B | 1 |
| Chae, J | 1 |
| Taylor, DM | 1 |
| Frauman, AG | 1 |
| Mishriky, BM | 2 |
| Wickham, R | 1 |
| Mohammadbeigi, R | 1 |
| Shahgeibi, S | 1 |
| Soufizadeh, N | 1 |
| Rezaiie, M | 1 |
| Farhadifar, F | 1 |
| Pinto, TF | 1 |
| Rocha, R | 1 |
| Paula, CA | 1 |
| de Jesus, RP | 1 |
| Stich, O | 1 |
| Nagy, S | 1 |
| Reinhard, M | 1 |
| Hetzel, A | 1 |
| Winkler, C | 1 |
| Taschner, C | 1 |
| Leschka, SC | 1 |
| Weiller, C | 1 |
| Rijntjes, M | 1 |
| Reichmann, JP | 1 |
| Kirkbride, MS | 1 |
| Lalla, R | 1 |
| Malhotra, HS | 1 |
| Garg, RK | 1 |
| Verma, R | 1 |
| Cayley, WE | 1 |
| Gelfand, AA | 1 |
| Goadsby, PJ | 1 |
| Benze, G | 1 |
| Alt-Epping, B | 1 |
| Geyer, A | 1 |
| Nauck, F | 1 |
| Lee, JS | 3 |
| Jeon, WC | 1 |
| Park, EJ | 1 |
| Min, YG | 1 |
| Jung, YS | 1 |
| Kim, GW | 1 |
| Choi, SC | 1 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 1 |
| Navari, RM | 3 |
| Nagy, CK | 1 |
| Gray, SE | 1 |
| Wilson, J | 1 |
| Plourde, JY | 1 |
| Marshall, D | 1 |
| Yoshida, S | 1 |
| Chow, W | 1 |
| Harsanyi, Z | 2 |
| Pearen, S | 1 |
| Darke, A | 2 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Kim, TW | 1 |
| Bahng, H | 1 |
| Chang, HM | 1 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Park, JS | 1 |
| Lu, ML | 1 |
| Pan, JJ | 1 |
| Teng, HW | 1 |
| Su, KP | 1 |
| Shen, WW | 1 |
| Berkovitch, M | 1 |
| Mazzota, P | 1 |
| Greenberg, R | 1 |
| Elbirt, D | 1 |
| Addis, A | 1 |
| Schuler-Faccini, L | 1 |
| Merlob, P | 1 |
| Stahl, B | 1 |
| Magee, L | 1 |
| Moretti, M | 1 |
| Ornoy, A | 1 |
| Paoloni, R | 2 |
| Talbot-Stern, J | 2 |
| MacGregor, EA | 1 |
| Numbenjapon, T | 1 |
| Sriswasdi, C | 1 |
| Mongkonsritragoon, W | 1 |
| Leelasiri, A | 1 |
| Prayoonwiwat, W | 1 |
| Aapro, MS | 3 |
| Thuerlimann, B | 1 |
| Sessa, C | 1 |
| De Pree, C | 1 |
| Bernhard, J | 1 |
| Maibach, R | 1 |
| Yue, W | 2 |
| Zhang, F | 2 |
| Wang, L | 2 |
| Fang, X | 1 |
| Liu, YX | 1 |
| Minami, M | 1 |
| Fujii, Y | 10 |
| Tanaka, H | 10 |
| Kawasaki, T | 1 |
| Bsat, FA | 1 |
| Hoffman, DE | 1 |
| Seubert, DE | 1 |
| Bhatia, A | 2 |
| Tripathi, KD | 2 |
| Sharma, M | 2 |
| Kubota, Y | 2 |
| Mihara, K | 1 |
| Ishii, F | 1 |
| Ohno, K | 1 |
| Ogata, H | 1 |
| Makimura, M | 1 |
| Kikuchi, N | 1 |
| Kitano, T | 1 |
| Alsalim, W | 1 |
| Leung, WC | 1 |
| Butler, J | 1 |
| Cham, S | 1 |
| Basire, M | 1 |
| Kelly, AM | 1 |
| Cheng, FH | 1 |
| Andrews, PL | 3 |
| Moreaux, B | 1 |
| Sam, TS | 1 |
| Wan, C | 1 |
| Basurto, C | 14 |
| Bracarda, S | 7 |
| Del Favero, A | 13 |
| Tonato, M | 16 |
| Weschules, DJ | 1 |
| Ozucelik, DN | 1 |
| Karaca, MA | 1 |
| Sivri, B | 1 |
| Bradshaw, M | 1 |
| Sen, A | 1 |
| Yang, ZH | 1 |
| Liu, ZT | 1 |
| Axelsson, P | 1 |
| Thörn, SE | 1 |
| Lövqvist, A | 1 |
| Wattwil, L | 1 |
| Wattwil, M | 1 |
| Leksowski, K | 1 |
| Peryga, P | 1 |
| Szyca, R | 1 |
| Alhashimi, H | 2 |
| Luisi, FA | 1 |
| Petrilli, AS | 1 |
| Tanaka, C | 1 |
| Caran, EM | 1 |
| Kerstan, A | 1 |
| Seitz, CS | 1 |
| Bröcker, EB | 1 |
| Trautmann, A | 1 |
| Lajolo, PP | 1 |
| del Giglio, A | 1 |
| Lou, E | 1 |
| Abou-Zeid, N | 1 |
| Moutzouris, DA | 1 |
| Manetas, S | 1 |
| Mountantonakis, SE | 1 |
| Falagas, ME | 1 |
| Fiore, JJ | 2 |
| Gralla, RJ | 12 |
| Bakowski, MT | 1 |
| Giroud, M | 2 |
| Fabre, JL | 2 |
| Putelat, R | 2 |
| Caillot, X | 1 |
| Escousse, A | 2 |
| Nivelon-Chevalier, A | 1 |
| Dumas, R | 1 |
| Maule, WF | 1 |
| Perry, MC | 1 |
| Palazzo, MG | 1 |
| Strunin, L | 1 |
| Kotlarek-Haus, S | 1 |
| Orzechowska-Juzwenko, K | 1 |
| Gabryś, K | 1 |
| Williams, CJ | 1 |
| Bolton, A | 1 |
| de Pemberton, R | 1 |
| Whitehouse, JM | 1 |
| Baggerman, C | 1 |
| Laszlo, J | 1 |
| Bachmann-Mettler, I | 3 |
| Priestman, TJ | 3 |
| Priestman, SG | 1 |
| Jensen, NH | 1 |
| Termansen, K | 1 |
| Bruera, ED | 2 |
| Roca, E | 2 |
| Cedaro, L | 1 |
| Chacón, R | 1 |
| Estévez, R | 1 |
| Harrington, RA | 1 |
| Hamilton, CW | 1 |
| Brogden, RN | 2 |
| Linkewich, JA | 1 |
| Romankiewicz, JA | 1 |
| Heel, RC | 2 |
| Guldager, H | 1 |
| Jensen, FM | 1 |
| Andersen, KH | 1 |
| Arnfred, I | 1 |
| Ell, C | 4 |
| König, HJ | 4 |
| Gutmann, W | 1 |
| Domschke, S | 3 |
| Domschke, W | 3 |
| Clarke, RS | 4 |
| Spelina, KR | 1 |
| Gerber, HR | 1 |
| Pagels, IL | 1 |
| Cognetti, F | 2 |
| Pinnarò, P | 3 |
| Carlini, P | 3 |
| Conti, EM | 2 |
| Cortese, M | 1 |
| Pollera, CF | 6 |
| Gagen, M | 1 |
| Gochnour, D | 1 |
| Young, D | 1 |
| Gaginella, T | 1 |
| Neidhart, J | 1 |
| Domenici, R | 1 |
| Saponati, G | 1 |
| Castelli, S | 1 |
| Manchikanti, L | 1 |
| Marrero, TC | 1 |
| Roush, JR | 1 |
| Valenzuela, JE | 1 |
| Dooley, CP | 1 |
| Mellink, WA | 1 |
| Blijham, GH | 1 |
| van Deyk, WA | 1 |
| Allan, SG | 5 |
| Cornbleet, MA | 4 |
| Lockhart, SP | 1 |
| Warrington, PS | 5 |
| Leonard, RC | 4 |
| Smyth, JF | 2 |
| Chiara, S | 1 |
| Scarsi, P | 1 |
| Campora, E | 1 |
| Bruzzi, P | 1 |
| Tatarek, R | 1 |
| Rosso, R | 1 |
| Barlow, AM | 1 |
| Jalihal, SS | 1 |
| Feldman, M | 1 |
| Schiller, LR | 1 |
| Fielding, JW | 1 |
| Priestman, T | 1 |
| Kris, MG | 10 |
| Tyson, LB | 9 |
| Clark, RA | 8 |
| Bowcock, SJ | 1 |
| Stockdale, AD | 1 |
| Bolton, JA | 1 |
| Kang, AA | 1 |
| Retsas, S | 1 |
| Golland, IM | 1 |
| Smyth, JN | 1 |
| Heim, ME | 1 |
| Queisser, W | 1 |
| Altenburg, HP | 1 |
| Strum, SB | 4 |
| McDermed, JE | 6 |
| Streng, BR | 1 |
| McDermott, NM | 1 |
| Perego, P | 1 |
| Brivio, F | 1 |
| Pulinetti, B | 1 |
| Bugatti, A | 1 |
| Baldoni, A | 1 |
| Eyre, HJ | 1 |
| Ward, JH | 1 |
| Taylor, WB | 3 |
| Proctor, SJ | 1 |
| Bateman, DN | 3 |
| Meyer, BR | 2 |
| Lewin, M | 1 |
| Drayer, DE | 1 |
| Pasmantier, M | 1 |
| Lonski, L | 1 |
| Reidenberg, MM | 2 |
| Senn, HJ | 6 |
| Glaus, A | 2 |
| Grunberg, SM | 6 |
| Gala, KV | 1 |
| Lampenfeld, M | 1 |
| Jamin, D | 1 |
| Johnson, K | 1 |
| Cariffe, P | 1 |
| Strych, D | 1 |
| Krailo, M | 1 |
| Donovitz, GS | 1 |
| O'Quinn, AG | 1 |
| Smith, ML | 1 |
| Plezia, PM | 2 |
| Alberts, DS | 2 |
| Kessler, J | 1 |
| Graham, V | 1 |
| Surwit, EA | 1 |
| Vergin, H | 2 |
| Köhler, M | 2 |
| Reich, SD | 1 |
| Paice, JA | 1 |
| Gever, LN | 1 |
| Niddam, R | 1 |
| Perrot-Marsault, M | 1 |
| Budach, V | 1 |
| Krüger, K | 1 |
| Burrows, CF | 1 |
| Chacón, RD | 1 |
| Chan, SC | 1 |
| Lo, JR | 1 |
| Wong, KC | 1 |
| Grau, JJ | 1 |
| Millá, A | 1 |
| Cirera, L | 1 |
| Estapé, J | 1 |
| Terrin, BN | 1 |
| McWilliams, NB | 1 |
| Maurer, HM | 1 |
| Pileggi, J | 1 |
| Riech, LP | 2 |
| Whitaker, H | 1 |
| Loo, FD | 1 |
| Palmer, DW | 1 |
| Soergel, KH | 1 |
| Kalbfleisch, JH | 1 |
| Wood, CM | 1 |
| Hiller, E | 1 |
| Gerhartz, H | 1 |
| Ise, T | 1 |
| Ohira, M | 1 |
| Omiya, A | 1 |
| Hirose, M | 1 |
| Shibata, T | 1 |
| Hirsh, EH | 1 |
| Brandenburg, D | 1 |
| Hersh, T | 2 |
| Brooks, WS | 1 |
| Daniels, M | 1 |
| Belt, RJ | 1 |
| Runne, U | 1 |
| Doepfmer, K | 1 |
| Antz, H | 1 |
| Groth, W | 1 |
| FEAUX DE Lacroix, W | 1 |
| Boghaert, A | 1 |
| Carron, D | 1 |
| Gallant, J | 1 |
| Stockman, A | 1 |
| Schulze-Delrieu, K | 2 |
| Ponte, CD | 1 |
| Nappi, JM | 1 |
| Caruso, U | 1 |
| D'Iddio, S | 1 |
| Cravotto, E | 1 |
| Pesce, S | 1 |
| Betti, I | 1 |
| Ruscitto, G | 1 |
| Ecari, U | 1 |
| Sabrie, AM | 1 |
| Itri, LM | 1 |
| Pisko, SE | 1 |
| Squillante, AE | 1 |
| Kelsen, DP | 2 |
| Braun, DW | 1 |
| Bordin, LA | 1 |
| Braun, TJ | 1 |
| Young, CW | 2 |
| Mosca, S | 1 |
| D'Amato, L | 1 |
| Gargiulo, PL | 1 |
| Cautela, G | 1 |
| Cristau, P | 1 |
| Laverdant, C | 1 |
| Coquelin, JP | 1 |
| Narbonne, G | 1 |
| Padrón, F | 1 |
| Sanz, J | 1 |
| Flórez, J | 1 |
| Opfell, RW | 1 |
| Cox, R | 1 |
| Newman, CE | 1 |
| Leyland, MJ | 1 |
| Hitch, DC | 1 |
| Vanhoutte, JJ | 1 |
| Torres-Pinedo, RB | 1 |
| Cowan, AN | 1 |
| Bui, NB | 2 |
| Marit, G | 2 |
| Hoerni, B | 2 |
| Albin, H | 1 |
| Durand, M | 1 |
| Mauriac, L | 1 |
| Florczyk, AP | 1 |
| Schurig, JE | 1 |
| Bradner, WT | 1 |
| Bolis, PF | 1 |
| Guaschino, S | 1 |
| Paganelli, AM | 1 |
| Sampaolo, P | 1 |
| Giordano, L | 1 |
| Visone, C | 1 |
| Rosatti, R | 1 |
| Di Mezza, G | 1 |
| Montanino, C | 1 |
| Turtur, A | 1 |
| Losanna Cannavacciuolo, G | 1 |
| Green, L | 1 |
| Brown, MD | 1 |
| Diamond, MJ | 2 |
| Keeri-Szanto, M | 1 |
| Reuss, D | 1 |
| Perkel, MS | 1 |
| Moore, C | 1 |
| Davidson, ED | 1 |
| Rose, JB | 3 |
| McCloskey, JJ | 1 |
| Dick, GS | 1 |
| Meller, ST | 1 |
| Pinkerton, CR | 1 |
| Scarantino, CW | 1 |
| Ornitz, RD | 1 |
| Hoffman, LG | 1 |
| Anderson, RF | 1 |
| Chiou, TJ | 1 |
| Wei, CH | 1 |
| Hsieh, RK | 1 |
| Fan, FS | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Heron, JF | 2 |
| Parasuraman, TV | 1 |
| Osterhaus, JT | 1 |
| Miralbell, R | 1 |
| Coucke, P | 1 |
| Behrouz, F | 1 |
| Blazek, N | 1 |
| Melliger, M | 1 |
| Philipp, S | 1 |
| Wickenhauser, R | 1 |
| Gebhard, S | 1 |
| Schwabb, T | 1 |
| Rosset, A | 1 |
| Desilva, PH | 1 |
| Darvish, AH | 1 |
| McDonald, SM | 1 |
| Cronin, MK | 1 |
| Clark, K | 1 |
| McKenzie, R | 1 |
| Tantisira, B | 1 |
| Jackson, D | 1 |
| Bach, T | 1 |
| Riley, T | 1 |
| Prentice, HG | 1 |
| Cunningham, S | 1 |
| Gandhi, L | 1 |
| Cunningham, J | 2 |
| Collis, C | 1 |
| Hamon, MD | 1 |
| Thune, A | 1 |
| Appelgren, L | 1 |
| Haglind, E | 1 |
| Framarino dei Malatesta, M | 1 |
| Veneziano, M | 1 |
| Fiorelli, C | 1 |
| Bandiera, AF | 1 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Cubeddu, LX | 3 |
| Hoffmann, IS | 1 |
| Lee, CW | 1 |
| Suh, CW | 1 |
| Lee, KH | 1 |
| Cho, GY | 1 |
| Kim, SH | 1 |
| Martin, TM | 2 |
| Kymer, PJ | 2 |
| Brown, RE | 2 |
| Lawhorn, CD | 2 |
| Jones, E | 1 |
| Pearce, L | 1 |
| Rust, M | 2 |
| Paxton, LD | 1 |
| McKay, AC | 1 |
| Mirakhur, RK | 1 |
| Mecklem, DW | 1 |
| Seng, KT | 1 |
| Tiong, CE | 1 |
| Hiang, TC | 1 |
| Ohmatsu, H | 3 |
| Eguchi, K | 4 |
| Shinkai, T | 4 |
| Tamura, T | 3 |
| Ohe, Y | 2 |
| Nisio, M | 1 |
| Kunikane, H | 1 |
| Arioka, H | 1 |
| Karato, A | 1 |
| Nakashima, H | 1 |
| Elliott, RH | 1 |
| Graham, SG | 1 |
| Curran, JP | 1 |
| Tomirotti, M | 1 |
| Dimaiuta, M | 1 |
| Confalonieri, M | 1 |
| Scanni, A | 1 |
| Szelenyi, I | 1 |
| Herold, H | 1 |
| Göthert, M | 1 |
| Rubenstein, EB | 2 |
| Elting, LS | 2 |
| Malik, IA | 1 |
| Khan, WA | 1 |
| Qazilbash, M | 1 |
| Ata, E | 1 |
| Butt, A | 1 |
| Khan, MA | 1 |
| Lewis, IH | 2 |
| Campbell, DN | 1 |
| Barrowcliffe, MP | 1 |
| Furst, SR | 2 |
| Rodarte, A | 2 |
| Czeglédi, F | 1 |
| Baki, M | 1 |
| Walder, AD | 1 |
| Aitkenhead, AR | 1 |
| Goedhals, L | 1 |
| Jordaan, JP | 1 |
| Cedar, E | 1 |
| Yaddanapudi, LN | 1 |
| Olver, IN | 2 |
| Matthews, JP | 2 |
| Bishop, JF | 3 |
| Smith, RA | 1 |
| Billett, AL | 1 |
| Sallan, SE | 1 |
| Hesketh, PJ | 5 |
| Bleiberg, H | 2 |
| Autier, P | 1 |
| Michaux, D | 1 |
| Pater, J | 3 |
| Slamet, L | 1 |
| Zee, B | 1 |
| Osoba, D | 4 |
| Warr, D | 4 |
| Rusthoven, J | 2 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Khoo, KS | 1 |
| Cefalo, G | 1 |
| Rottoli, L | 1 |
| Armiraglio, A | 1 |
| Pagan, MG | 1 |
| Goldspiel, BR | 1 |
| Kohler, DR | 1 |
| Misra, R | 1 |
| Agarwal, N | 1 |
| Calamandrei, M | 1 |
| Andreuccetti, T | 1 |
| Crescioli, M | 1 |
| Messeri, A | 1 |
| Sarti, A | 1 |
| Sestini, G | 1 |
| Busoni, P | 1 |
| Anderson, H | 1 |
| Thatcher, N | 1 |
| Howell, A | 1 |
| Logan, K | 1 |
| Sage, T | 1 |
| de Bruijn, KM | 2 |
| Sims, C | 1 |
| Johnson, CM | 1 |
| Bergesio, R | 1 |
| Delfos, SJ | 1 |
| Avraamides, EA | 1 |
| Saito, H | 3 |
| Shimokata, K | 3 |
| Yamori, S | 1 |
| Kajita, M | 1 |
| Niimi, T | 1 |
| Zbrozek, AS | 2 |
| Cantor, SB | 1 |
| Cardenas, MP | 1 |
| Hill, DP | 1 |
| Qin, XY | 1 |
| Pilot, MA | 1 |
| Thompson, H | 2 |
| Scott, M | 1 |
| Póka, R | 1 |
| Hernádi, Z | 1 |
| Juhász, B | 1 |
| Lampé, L | 1 |
| Haga, K | 1 |
| Inaba, K | 1 |
| Shoji, H | 1 |
| Morimoto, Y | 1 |
| Fukuda, T | 1 |
| Setoguchi, M | 1 |
| Malins, AF | 1 |
| Field, JM | 1 |
| Nesling, PM | 1 |
| Cooper, GM | 1 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Kaufmann, MA | 1 |
| Rosow, C | 1 |
| Schnieper, P | 1 |
| Schneider, M | 1 |
| Fleishman, SB | 1 |
| Lavin, MR | 1 |
| Sattler, M | 1 |
| Szarka, H | 1 |
| Gan, TJ | 1 |
| Collis, R | 1 |
| Hetreed, M | 1 |
| Phillips, S | 1 |
| Ruggier, R | 1 |
| Hutchinson, SE | 1 |
| Kawashima, T | 1 |
| Wada, T | 1 |
| Morita, N | 1 |
| Ohmata, T | 1 |
| Miyata, K | 1 |
| Sakamoto, T | 1 |
| Reimer, EJ | 1 |
| Montgomery, CJ | 1 |
| Bevan, JC | 1 |
| Merrick, PM | 1 |
| Blackstock, D | 1 |
| Popovic, V | 1 |
| Carella, G | 1 |
| Marra, L | 1 |
| Wynn, RL | 2 |
| Essien, E | 1 |
| Thut, PD | 1 |
| Hindle, A | 1 |
| Tsukagoshi, S | 1 |
| Ohta, J | 1 |
| Taguchi, T | 1 |
| Raphael, JH | 1 |
| Norton, AC | 1 |
| Sorbe, B | 4 |
| Hallén, C | 4 |
| Frankendal, B | 1 |
| Sorbe, BG | 2 |
| Högberg, T | 1 |
| Glimelius, B | 1 |
| Schmidt, M | 1 |
| Wernstedt, L | 1 |
| Hansen, O | 2 |
| Sörensen, BT | 1 |
| Räisänen, I | 1 |
| van Oosterom, AT | 1 |
| Baltzer, L | 2 |
| Rigas, JR | 1 |
| Pisters, KM | 3 |
| Pendeville, PE | 1 |
| Veyckemans, F | 1 |
| Van Boven, MJ | 1 |
| Steinier, JR | 1 |
| Clerico, M | 1 |
| Bertetto, O | 1 |
| Morandini, MP | 1 |
| Cardinali, C | 1 |
| Giaccone, G | 1 |
| Cullen, MH | 2 |
| Mori, K | 2 |
| Saito, Y | 1 |
| Tominaga, K | 2 |
| Cunningham, D | 4 |
| Gore, M | 1 |
| Davidson, N | 1 |
| Miocevich, M | 1 |
| Manchanda, M | 1 |
| Wells, N | 1 |
| Gallar, P | 1 |
| Oliet, A | 1 |
| Vigil, A | 1 |
| Ortega, O | 1 |
| Guijo, G | 1 |
| Massey, JG | 1 |
| Bhandari, P | 1 |
| Homesley, HD | 2 |
| Hahne, WF | 1 |
| McLees, B | 1 |
| Heck, K | 1 |
| Barrett, RJ | 1 |
| Lentz, SS | 1 |
| Woodlief, L | 1 |
| Lovelace, JV | 1 |
| Levitt, M | 2 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 2 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Latreille, J | 4 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Michaloudis, D | 1 |
| O'Keeffe, N | 1 |
| O'Sullivan, K | 1 |
| Healy, TE | 1 |
| Joshi, R | 1 |
| Sivaganesanathan, A | 1 |
| Chang, TC | 1 |
| Hsieh, F | 1 |
| Lai, CH | 1 |
| Tseng, CJ | 1 |
| Cheng, HH | 1 |
| Li, CL | 1 |
| Michael, BJ | 1 |
| Soong, YK | 1 |
| Naylor, RJ | 4 |
| Pfeiffer, P | 1 |
| Madsen, B | 1 |
| Andersen, I | 1 |
| Hansen, B | 1 |
| Mathiesen, B | 1 |
| Gebbia, V | 2 |
| Testa, A | 2 |
| Valenza, R | 1 |
| Cannata, G | 2 |
| Tirrito, ML | 1 |
| Gebbia, N | 2 |
| Cleri, LB | 1 |
| Gilbert, CJ | 1 |
| Ohly, KV | 1 |
| Rosner, G | 1 |
| Peters, WP | 1 |
| Jørgensen, M | 1 |
| Victor, MA | 1 |
| Sekine, I | 2 |
| Nishiwaki, Y | 2 |
| Kakinuma, R | 2 |
| Kubota, K | 2 |
| Hojo, F | 2 |
| Matsumoto, T | 2 |
| Yokozaki, M | 2 |
| Kodama, T | 2 |
| Soukop, M | 3 |
| Verweij, J | 2 |
| de Wit, R | 2 |
| de Mulder, PH | 2 |
| Rittenberg, C | 1 |
| Peralta, M | 1 |
| Lettow, L | 1 |
| Cronin, M | 1 |
| Hall, JE | 2 |
| Harmer, M | 2 |
| Torrance, C | 1 |
| Jordan, S | 1 |
| Masters, JC | 1 |
| O'Grady, M | 1 |
| Ali-Melkkilä, T | 1 |
| Kanto, J | 1 |
| Katevuo, R | 1 |
| Kitamura, A | 1 |
| Kon, T | 1 |
| Kamiyama, M | 1 |
| Ogawa, R | 1 |
| Okamoto, S | 1 |
| Takahashi, S | 5 |
| Tanosaki, R | 1 |
| Sakamaki, H | 1 |
| Onozawa, Y | 1 |
| Oh, H | 1 |
| Miyawaki, S | 1 |
| Kimura, Y | 1 |
| Toyama, K | 1 |
| Ikeda, Y | 1 |
| Asano, S | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Choy, D | 1 |
| Kwong, DL | 1 |
| Yau, CC | 1 |
| Cheng, AC | 1 |
| Güller, R | 1 |
| Reichlin, B | 1 |
| Jost, G | 1 |
| Barrenetxea, G | 1 |
| Schneider, J | 1 |
| Centeno, MM | 1 |
| Romero, H | 1 |
| de la Rica, M | 1 |
| Rodríguez-Escudero, FJ | 1 |
| Page, B | 1 |
| Dallara, J | 1 |
| Basade, M | 1 |
| Kulkarni, SS | 1 |
| Dhar, AK | 2 |
| Sastry, PS | 1 |
| Saikia, B | 1 |
| Advani, SH | 4 |
| Lacroix, G | 1 |
| Lessard, MR | 1 |
| Trépanier, CA | 1 |
| Naguib, M | 1 |
| el Bakry, AK | 1 |
| Khoshim, MH | 1 |
| Channa, AB | 1 |
| el Gammal, M | 1 |
| el Gammal, K | 1 |
| Elhattab, YS | 1 |
| Attia, M | 1 |
| Jaroudi, R | 1 |
| Saddique, A | 1 |
| Iwanaga, Y | 1 |
| Miyashita, N | 1 |
| Saito, T | 1 |
| Morikawa, K | 1 |
| Itoh, Z | 1 |
| Baines, D | 1 |
| Seifert, L | 1 |
| Watanabe, S | 1 |
| Babul, N | 1 |
| Suarez-Almazor, M | 1 |
| Chen, PP | 1 |
| Chui, PT | 1 |
| Gin, T | 1 |
| Steinbrook, RA | 2 |
| Freiberger, D | 2 |
| Gosnell, JL | 2 |
| Brooks, DC | 1 |
| Watts, SA | 1 |
| Stene, FN | 1 |
| Seay, RE | 1 |
| Young, LA | 1 |
| Bohnsack, LE | 1 |
| Bostrom, BC | 1 |
| Cupissol, D | 1 |
| Venkatraman, E | 1 |
| Toyooka, H | 7 |
| Harrington, ML | 1 |
| Moore, MP | 1 |
| Talcott, PA | 1 |
| Bagley, RS | 1 |
| Sandmeier, P | 1 |
| Chevallier, B | 3 |
| Cappelaere, P | 1 |
| Splinter, T | 1 |
| Fabbro, M | 1 |
| Wendling, JL | 1 |
| Cals, L | 1 |
| Catimel, G | 1 |
| Giovannini, M | 1 |
| Khayat, D | 1 |
| Bastit, P | 1 |
| Claverie, N | 1 |
| Stein, DJ | 1 |
| Birnbach, DJ | 1 |
| Danzer, BI | 1 |
| Kuroda, MM | 1 |
| Grunebaum, A | 1 |
| Thys, DM | 1 |
| Suga, S | 2 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Nishio, Y | 1 |
| Ichihara, T | 1 |
| Ichihara, S | 1 |
| Kusugami, K | 1 |
| Pugh, SC | 1 |
| Jones, NC | 1 |
| Barsoum, LZ | 1 |
| Trujillo, LM | 1 |
| Talmaciu, I | 1 |
| Gonzalez, V | 1 |
| Guariguata, J | 1 |
| Seijas, J | 1 |
| Miller, IA | 1 |
| Paska, W | 1 |
| Fry, RA | 1 |
| Walker, MA | 1 |
| Bliss, A | 1 |
| Pitkänen, MT | 1 |
| Numminen, MK | 1 |
| Tuominen, MK | 1 |
| Rosenberg, PH | 1 |
| Chang, CS | 1 |
| Chen, LT | 1 |
| Huang, SM | 1 |
| Liu, TC | 1 |
| Lin, SF | 1 |
| Chen, TP | 1 |
| Wei, TC | 1 |
| Madej, G | 1 |
| Krzakowski, M | 2 |
| Pawinski, A | 1 |
| Lasota, W | 1 |
| Rogowski, W | 1 |
| Skoneczna, I | 1 |
| Bruntsch, U | 2 |
| Drechsler, S | 2 |
| Eggert, J | 2 |
| Gosse, H | 2 |
| Ukena, D | 2 |
| Imhoff, W | 2 |
| Faerber, L | 2 |
| Otten, J | 1 |
| Hachimi-Idrissi, S | 1 |
| Balduck, N | 1 |
| Maurus, R | 1 |
| Tavorath, R | 1 |
| Kigawa, J | 1 |
| Minagawa, Y | 1 |
| Itamochi, H | 1 |
| Cheng, X | 1 |
| Okada, M | 2 |
| Terakawa, N | 1 |
| Shende, D | 2 |
| Mandal, NG | 1 |
| Mjahed, K | 1 |
| el Harrar, N | 1 |
| Idali, B | 1 |
| Laouissi, F | 1 |
| Benaguida, M | 1 |
| Amraoui, A | 1 |
| Goto, K | 1 |
| Miyamoto, T | 1 |
| Takafuji, J | 1 |
| Ciccarese, G | 1 |
| Alexander, R | 1 |
| Fennelly, M | 1 |
| Polati, E | 1 |
| Verlato, G | 1 |
| Finco, G | 1 |
| Mosaner, W | 1 |
| Grosso, S | 1 |
| Gottin, L | 1 |
| Pinaroli, AM | 1 |
| Ischia, S | 1 |
| Balfour, JA | 1 |
| Goa, KL | 1 |
| Wong, RH | 1 |
| Lao, L | 1 |
| Berman, BM | 1 |
| Carter, AK | 1 |
| Ascaso, FJ | 1 |
| Ayala, I | 1 |
| Carbonell, P | 1 |
| Castro, FJ | 1 |
| Palomar, A | 1 |
| Khoo, VS | 1 |
| Rainford, K | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Grote-Kiehn, J | 1 |
| Bangerter, M | 1 |
| Oehm, C | 1 |
| Mezger, J | 1 |
| Untch, M | 1 |
| Gallmeier, WM | 1 |
| Scuderi, PE | 1 |
| Weaver, RG | 1 |
| James, RL | 1 |
| Mims, G | 1 |
| Elliott, WG | 1 |
| Weeks, DB | 1 |
| Diemunsch, P | 1 |
| Conseiller, C | 1 |
| Clyti, N | 1 |
| Mamet, JP | 1 |
| Moyle, JT | 1 |
| Aass, N | 1 |
| Håtun, DE | 1 |
| Thoresen, M | 1 |
| Fosså, SD | 1 |
| Saunders, MI | 1 |
| Hoskin, PJ | 1 |
| Pigott, K | 1 |
| Powell, ME | 1 |
| Goodchild, K | 1 |
| Dische, S | 1 |
| Denekamp, J | 1 |
| Stratford, MR | 1 |
| Dennis, MF | 1 |
| Rojas, AM | 1 |
| Bach-Styles, T | 1 |
| Martin-Sheridan, D | 1 |
| Hughes, C | 1 |
| Kaufman, S | 1 |
| Stewart, FC | 1 |
| Stoner, JM | 1 |
| Shirey, R | 1 |
| Volpe, P | 1 |
| Monagle, J | 1 |
| Barnes, R | 1 |
| Goodchild, C | 1 |
| Hewitt, M | 1 |
| Brüggenjürgen, B | 1 |
| Saitoh, Y | 2 |
| Morris, RW | 1 |
| Aune, H | 1 |
| Feiss, P | 1 |
| Hanson, A | 1 |
| Hasselstrøm, L | 1 |
| Maltby, JR | 1 |
| Rocke, DA | 1 |
| Rozenberg, B | 1 |
| Cohen, LA | 1 |
| Harper, CM | 1 |
| Barker, JP | 1 |
| Haldar, M | 1 |
| Mystakidou, K | 1 |
| Befon, S | 1 |
| Liossi, C | 1 |
| Vlachos, L | 1 |
| MacLaren, R | 1 |
| Shields, CA | 1 |
| Köseoglu, V | 1 |
| Kürekçi, AE | 1 |
| Sarici, U | 1 |
| Atay, AA | 1 |
| Ozcan, O | 1 |
| Sorici, U | 1 |
| Brown, RS | 1 |
| Brown, TK | 1 |
| Hoare, D | 1 |
| Gaze, MN | 1 |
| Pizzo, BA | 1 |
| Miller, VA | 1 |
| Grant, SC | 1 |
| Hinckley, L | 1 |
| Berto, P | 1 |
| De Angelis, V | 1 |
| Neri, C | 1 |
| Olivieri, A | 1 |
| Plosker, GL | 1 |
| Milne, RJ | 2 |
| Malik, I | 1 |
| Moid, I | 1 |
| Khan, Z | 1 |
| Hussain, M | 1 |
| Kobayashi, N | 1 |
| Mabro, M | 1 |
| Granisétron, PK | 1 |
| Gorchein, A | 1 |
| Mukhopadhyay, K | 1 |
| Narang, A | 1 |
| Kumar, P | 1 |
| Chakraborty, S | 1 |
| Mittal, BR | 1 |
| Cohen, N | 1 |
| Alon, I | 1 |
| Almoznino-Sarfian, D | 1 |
| Gorelik, O | 1 |
| Chachasvili, S | 1 |
| Litvinjuk, V | 1 |
| Modai, D | 1 |
| Weissgarten, J | 1 |
| Bouaggad, A | 1 |
| Bouderka, MA | 1 |
| Semkaoui, A | 1 |
| Haida, F | 1 |
| Abassi, O | 1 |
| Tsavaris, NB | 3 |
| Koufos, C | 1 |
| Katsikas, M | 1 |
| Dimitrakopoulos, A | 1 |
| Athanasiou, E | 1 |
| Linardaki, G | 1 |
| Chung, F | 1 |
| Lane, R | 1 |
| Spraggs, C | 1 |
| McQuade, B | 2 |
| Jacka, M | 1 |
| Luttropp, HH | 1 |
| Alahuta, S | 1 |
| Rocherieux, S | 1 |
| Roy, M | 1 |
| Duvaldestin, P | 1 |
| Curtis, P | 2 |
| Lachaine, J | 1 |
| Laurier, C | 1 |
| Langleben, A | 1 |
| Vaillant, L | 1 |
| Somekawa, Y | 1 |
| Catalán Arlandis, JL | 1 |
| Jiménez Torres, NV | 1 |
| Gopal, R | 3 |
| Lal, HM | 1 |
| Cooverji, ND | 1 |
| Bosnjak, SM | 1 |
| Nesković-Konstantinović, ZB | 1 |
| Radulović, SS | 1 |
| Susnjar, S | 1 |
| Mitrovi, LB | 1 |
| Suga, A | 1 |
| Tanaka, M | 1 |
| Roome, C | 1 |
| Thompson, J | 1 |
| Yoshida, K | 1 |
| Tatsukawa, H | 1 |
| Ashida, K | 1 |
| Matsubara, K | 1 |
| Uwatoko, H | 1 |
| Ogasawara, H | 1 |
| Katsuma, Y | 1 |
| Kitamura, K | 1 |
| Zatman, TF | 1 |
| Manusirivithaya, S | 1 |
| Chareoniam, V | 1 |
| Isariyodom, P | 1 |
| Sungsab, D | 1 |
| Ljutić, D | 1 |
| Perković, D | 1 |
| Rumboldt, Z | 1 |
| Bagatin, J | 1 |
| Hozo, I | 1 |
| Pivac, N | 1 |
| Hardy, J | 1 |
| Daly, S | 1 |
| Albertsson, M | 1 |
| Chimontsi-Kypriou, V | 1 |
| Stathopoulos, P | 1 |
| Mok, TS | 1 |
| Yam, BM | 1 |
| Yung, H | 1 |
| Gibbs, D | 1 |
| Tarsy, D | 1 |
| Parkes, JD | 2 |
| Marsden, CD | 2 |
| Caralps, A | 1 |
| Rosser, R | 1 |
| Herxheimer, A | 1 |
| Ekert, H | 1 |
| Waters, KD | 1 |
| Jurk, IH | 1 |
| Mobilia, J | 1 |
| Loughnan, P | 1 |
| Badley, BW | 1 |
| Price, P | 1 |
| Debono, A | 1 |
| Rosenthaler, J | 1 |
| Edelstyn, GA | 1 |
| MacRae, KD | 1 |
| MacDonald, FM | 1 |
| Van Eygen, M | 1 |
| Dhondt, F | 1 |
| Heck, E | 1 |
| Ameryckx, L | 2 |
| Van Ravensteyn, H | 2 |
| De Loore, I | 1 |
| Cooke, RD | 1 |
| Comyn, DJ | 1 |
| Ball, RW | 1 |
| Gylys, JA | 2 |
| Doran, KM | 1 |
| Buyniski, JP | 2 |
| Swann, IL | 1 |
| Thompson, EN | 1 |
| Qureshi, K | 1 |
| Kahn, T | 1 |
| Elias, EG | 1 |
| Mason, GR | 1 |
| Reynolds, GJ | 1 |
| Pinder, RM | 1 |
| Sawyer, PR | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Fry, EN | 1 |
| Deshpande, S | 1 |
| Borgne, D | 1 |
| Grillet, Y | 1 |
| Lucas, F | 1 |
| Zer, M | 1 |
| Dintsman, M | 1 |
| Kocián, J | 1 |
| Kociánová, J | 1 |
| Nakamura, N | 1 |
| Shiozaki, S | 1 |
| Koyama, Y | 1 |
| Kojima, T | 1 |
| Marumo, H | 1 |
| Nuss, D | 1 |
| Winship, WS | 1 |
| Angrist, B | 1 |
| Shopsin, B | 1 |
| Gershon, S | 1 |
| Holmsen, R | 1 |
| Corsini, GU | 1 |
| Zompo, MD | 1 |
| Cianchetti, C | 1 |
| Mangoni, A | 1 |
| Diehl, V | 1 |
| Wilan, A | 1 |
| Venner, P | 1 |
| Kaizer, L | 2 |
| Laberge, F | 2 |
| Stewart, D | 1 |
| O'Connell, G | 1 |
| Houghton, LA | 1 |
| Fowler, P | 1 |
| Keene, ON | 1 |
| Read, NW | 1 |
| Fürst, CJ | 2 |
| Johansson, S | 2 |
| Fredrikson, M | 2 |
| Hursti, T | 2 |
| Steineck, G | 2 |
| Peterson, C | 2 |
| Dogliotti, L | 1 |
| Antonacci, RA | 1 |
| Pazè, E | 1 |
| Ortega, C | 1 |
| Berruti, A | 1 |
| Faggiuolo, R | 1 |
| Gandara, DR | 3 |
| Harvey, WH | 1 |
| Monaghan, GG | 1 |
| Perez, EA | 1 |
| Stokes, C | 1 |
| Bryson, JC | 1 |
| Finn, AL | 1 |
| Alon, E | 1 |
| Himmelseher, S | 1 |
| Wolf, M | 2 |
| Laidlaw, C | 1 |
| Cooper, IA | 2 |
| Matthews, J | 1 |
| Smith, R | 1 |
| Buchanan, L | 1 |
| Sledge, GW | 1 |
| Einhorn, L | 1 |
| Nagy, C | 1 |
| House, K | 1 |
| Fukui, H | 1 |
| Yamamoto, M | 1 |
| Sato, S | 1 |
| Roberts, RH | 1 |
| Tan, ST | 1 |
| Sinclair, SW | 1 |
| Putnam, PE | 1 |
| Orenstein, SR | 1 |
| Wessel, HB | 1 |
| Stowe, RM | 1 |
| Fernández, AG | 1 |
| Puig, J | 1 |
| Beleta, J | 1 |
| Doménech, T | 1 |
| Bou, J | 1 |
| Berga, P | 1 |
| Gristwood, RW | 1 |
| Roberts, DJ | 1 |
| Tsavaris, N | 3 |
| Tsaroucha-Noutsou, E | 2 |
| Bacoyannis, C | 3 |
| Mylonakis, N | 4 |
| Valilis, P | 2 |
| Kozatsani-Halividi, D | 2 |
| Tsoutsos, H | 2 |
| Droufakou, S | 1 |
| Kosmidis, P | 3 |
| Buxton, MJ | 1 |
| O'Brien, BJ | 1 |
| Wetchler, BV | 1 |
| Russell, D | 1 |
| Kenny, GN | 1 |
| Ferrari, LR | 1 |
| Donlon, JV | 1 |
| Moreno, I | 4 |
| Rosell, R | 5 |
| Abad, A | 2 |
| Barnadas, A | 2 |
| Carles, J | 2 |
| Ribelles, N | 2 |
| Solano, V | 1 |
| Font, A | 1 |
| Sands, R | 1 |
| Roberts, JT | 2 |
| Marsh, M | 1 |
| Gill, A | 1 |
| Lin, DM | 1 |
| Bakri, YN | 1 |
| Khan, R | 1 |
| Subhi, J | 1 |
| Kawi, Z | 1 |
| Sassi, M | 2 |
| Lupattelli, M | 2 |
| Picciafuoco, M | 6 |
| Boschetti, E | 3 |
| Liu, YC | 1 |
| Kang, HM | 1 |
| Liou, CM | 1 |
| Tso, HS | 1 |
| Henderson, A | 1 |
| Wright, DM | 1 |
| Pond, SM | 1 |
| Klockgether-Radke, A | 1 |
| Feldmann, M | 1 |
| Braun, U | 1 |
| Mühlendyck, H | 1 |
| Brechot, JM | 2 |
| Dupeyron, JP | 2 |
| Delattre, C | 2 |
| Chastang, C | 1 |
| Laaban, JP | 1 |
| Rochemaure, J | 2 |
| Saitou, Y | 1 |
| Miyazawa, N | 1 |
| Li, YT | 2 |
| Mau, YK | 2 |
| Hsu, KP | 2 |
| Treen, DC | 1 |
| Downes, TW | 1 |
| Hayes, DH | 1 |
| McKinnon, WM | 1 |
| Lucraft, H | 1 |
| Collis, CH | 1 |
| Adams, M | 1 |
| Upadhyaya, BK | 1 |
| Priestman, S | 1 |
| Wilson, K | 1 |
| Findlay, B | 1 |
| Louvet, C | 1 |
| Lorange, A | 1 |
| Letendre, F | 1 |
| Beaulieu, R | 1 |
| Pretty, HM | 1 |
| Courchesne, Y | 1 |
| Neemeh, JA | 1 |
| Monte, M | 1 |
| Abad-Esteve, A | 3 |
| Whalley, DG | 1 |
| AlHaddad, S | 1 |
| Khalil, I | 1 |
| Maurer, W | 1 |
| Furgerson, C | 1 |
| Lim, KS | 1 |
| Lim, BL | 1 |
| Tee, CS | 1 |
| Vengadasalam, D | 1 |
| Karvounis, N | 2 |
| Klinaki, A | 1 |
| Marr, HE | 1 |
| Davey, PT | 1 |
| Bartlett, AJ | 1 |
| Roy, P | 1 |
| Patel, NH | 1 |
| Miller, AJ | 1 |
| Hainsworth, J | 1 |
| Harvey, W | 1 |
| Pendergrass, K | 1 |
| Kasimis, B | 1 |
| Oblon, D | 1 |
| Monaghan, G | 1 |
| Gandara, D | 1 |
| Hesketh, P | 1 |
| Khojasteh, A | 1 |
| Harker, G | 1 |
| Marschner, N | 1 |
| Sagrada, A | 1 |
| Turconi, M | 1 |
| Bonali, P | 1 |
| Schiantarelli, P | 1 |
| Micheletti, R | 1 |
| Montagna, E | 1 |
| Nicola, M | 1 |
| Algate, DR | 1 |
| Rimoldi, EM | 1 |
| Donetti, A | 1 |
| Marschner, NW | 2 |
| Adler, M | 2 |
| Nagel, GA | 2 |
| Christmann, D | 1 |
| Fenzl, E | 1 |
| Upadhyaya, B | 1 |
| Campbell, NN | 1 |
| Thomas, AD | 1 |
| Tsui, MS | 1 |
| Tu, FC | 1 |
| Fleming, GF | 1 |
| Vokes, EE | 1 |
| McEvilly, JM | 1 |
| Janisch, L | 1 |
| Francher, D | 1 |
| Smaldone, L | 2 |
| González Barón, M | 1 |
| Chacón, JI | 1 |
| García Girón, C | 1 |
| Ordóñez Gallego, A | 1 |
| García de Paredes, ML | 1 |
| Feliu, J | 1 |
| Zamora, P | 1 |
| Herranz, C | 1 |
| Garrido, P | 1 |
| Artal, A | 1 |
| Megens, AA | 1 |
| Awouters, FH | 1 |
| Niemegeers, CJ | 1 |
| Charak, BS | 2 |
| Banavali, SD | 2 |
| Iyer, RS | 1 |
| Saikia, TK | 2 |
| Francom, M | 1 |
| Zamanis, N | 1 |
| Zinelis, A | 1 |
| Tsoutsos, E | 1 |
| Sarafidou, M | 1 |
| Wilder-Smith, CH | 2 |
| Schimke, J | 2 |
| Osterwalder, B | 2 |
| Costall, B | 3 |
| Tattersall, FD | 2 |
| Dieras, V | 1 |
| Extra, JM | 1 |
| Le Bonniec, M | 1 |
| Madelaine, I | 1 |
| Espie, M | 1 |
| Marty, M | 2 |
| Molino, A | 1 |
| Guglielmo, L | 1 |
| Azzolini, ME | 1 |
| Biondani, P | 1 |
| Capelli, MC | 1 |
| Grandinetti, A | 1 |
| Griso, C | 1 |
| Martinelli, G | 1 |
| Martini, N | 1 |
| Zanotti, R | 1 |
| Froidevaux, P | 1 |
| Roth, A | 1 |
| Alberto, P | 1 |
| Akhtar, SS | 1 |
| Bano, ZA | 1 |
| Bhat, GM | 1 |
| Bhat, MA | 1 |
| Patoia, L | 2 |
| Santi, E | 1 |
| Penza, O | 1 |
| Salles, G | 1 |
| Archimbaud, E | 1 |
| Thomas, X | 1 |
| Fiere, D | 1 |
| Kaasa, S | 2 |
| Mella, O | 1 |
| Kvikstad, A | 1 |
| Hannibal, J | 1 |
| Hallas, J | 1 |
| Andersen, E | 1 |
| Laursen, LC | 1 |
| Hansen, M | 1 |
| Tongia, SK | 1 |
| Bhagwat, AW | 1 |
| Tres Sánchez, A | 1 |
| Sáez Martínez, MJ | 1 |
| Mayordomo Cámara, JJ | 1 |
| Guillén Lloveria, G | 1 |
| Sáenz Cusi, A | 1 |
| Nagai, H | 1 |
| Horiuchi, Y | 1 |
| Kyokane, K | 1 |
| Miwa, Y | 1 |
| Aoki, Y | 1 |
| Yasue, K | 1 |
| Noro, T | 1 |
| Kamikawa, R | 1 |
| Ninomiya, E | 1 |
| Pouillart, P | 1 |
| Scholl, S | 1 |
| Droz, JP | 2 |
| Azab, M | 2 |
| Brion, N | 1 |
| Pujade-Lauraine, E | 2 |
| Paule, B | 1 |
| Paes, D | 2 |
| Bons, J | 2 |
| Bonneterre, J | 1 |
| Metz, R | 1 |
| Fargeot, P | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Kvaløy, S | 1 |
| Dicato, MA | 1 |
| Ries, F | 1 |
| Huys, JV | 1 |
| Royer, E | 1 |
| Carruthers, L | 1 |
| Jaenicke, F | 1 |
| Albrecht, U | 1 |
| Seynaeve, C | 1 |
| Vermorken, JB | 1 |
| van Liessum, PA | 1 |
| Mols-Jevdevic, S | 1 |
| Allman, EL | 1 |
| Beranek, P | 1 |
| King, GL | 2 |
| Watanabe, A | 1 |
| Horio, Y | 1 |
| Minami, H | 1 |
| Shibagaki, T | 1 |
| Iwahara, T | 1 |
| Sakai, S | 1 |
| Kessler, JF | 1 |
| Berens, PL | 1 |
| Chase, JL | 1 |
| Roe, DJ | 1 |
| Tortorice, PV | 1 |
| O'Connell, MB | 1 |
| Stephens, SH | 1 |
| Silvey, VL | 1 |
| Wheeler, RH | 1 |
| Bone, ME | 1 |
| Wilkinson, DJ | 1 |
| Young, JR | 1 |
| McNeil, J | 1 |
| Charlton, S | 1 |
| Gwynne, A | 1 |
| Malone, JM | 1 |
| Christensen, CW | 1 |
| Yashinsky, D | 1 |
| Malviya, VK | 1 |
| Deppe, G | 1 |
| Díaz-Rubio, E | 4 |
| González-Larriba, JL | 1 |
| Martín, M | 2 |
| Valerdi, JJ | 1 |
| Barriga, JJ | 1 |
| O'Neill, WM | 1 |
| Schuler, L | 1 |
| Naji, P | 1 |
| Midgaard, T | 1 |
| Plezia, P | 1 |
| Alberts, D | 1 |
| Aapro, M | 1 |
| Sartiano, G | 1 |
| Dorn, M | 1 |
| Brady, M | 1 |
| Comerski, C | 1 |
| Schwartz, SE | 1 |
| Fairchild, C | 1 |
| Papaioannou, D | 1 |
| Beldecos, D | 1 |
| Kakoliris, S | 1 |
| Komitsopoulou, P | 1 |
| Karagiaouris, P | 1 |
| Sarmas, J | 1 |
| Tzannou, I | 1 |
| Przepiorka, D | 1 |
| Katlubeck, A | 1 |
| Taylor, D | 1 |
| Aglietti, L | 1 |
| Landauer, MR | 1 |
| Federico, M | 1 |
| Sabbatini, R | 1 |
| Piccinini, P | 1 |
| Zironi, S | 1 |
| Piccinini, L | 1 |
| Silingardi, V | 1 |
| Hatae, M | 1 |
| Nakamura, Y | 1 |
| Mitsuo, M | 1 |
| Sakurai, K | 1 |
| Asano, H | 1 |
| Onishi, Y | 1 |
| Hokanishi, H | 1 |
| Kikuchi, K | 1 |
| Tsuyuki, A | 1 |
| Fujishiro, Y | 1 |
| Utsumi, T | 1 |
| Fujisaki, M | 1 |
| Kurihara, E | 1 |
| Uematsu, M | 1 |
| Broadman, LM | 1 |
| Ceruzzi, W | 1 |
| Patane, PS | 1 |
| Hannallah, RS | 1 |
| Ruttimann, U | 1 |
| Friendly, D | 1 |
| Gallardo, J | 1 |
| Fodor, M | 1 |
| Nardi, M | 2 |
| Marolla, P | 2 |
| Terzoli, E | 1 |
| Giannarelli, D | 2 |
| Dundee, JW | 4 |
| Ghaly, RG | 1 |
| Bill, KM | 1 |
| Chestnutt, WN | 1 |
| Fitzpatrick, KT | 1 |
| Lynas, AG | 1 |
| Wilder-Smith, C | 1 |
| Cirrincione, C | 1 |
| Groshen, S | 3 |
| Gez, E | 4 |
| Ben-Yosef, R | 2 |
| Catane, R | 2 |
| Brufman, G | 2 |
| Biran, S | 4 |
| Marshall, G | 1 |
| Kerr, S | 1 |
| Vowels, M | 1 |
| O'Gorman-Hughes, D | 1 |
| White, L | 1 |
| Culine, S | 1 |
| Pietri, F | 1 |
| Ghosn, M | 1 |
| Ben Amor, B | 1 |
| Lupera, H | 1 |
| Theodore, C | 1 |
| Renaux, J | 1 |
| Chestnut, DH | 2 |
| Owen, CL | 2 |
| Geiger, M | 1 |
| Bates, JN | 2 |
| Choi, WW | 2 |
| Ostman, PL | 1 |
| O'Brien, ME | 1 |
| Woodroffe, C | 1 |
| Kelly, K | 1 |
| Burman, C | 1 |
| Palmer, K | 1 |
| Stuart, NS | 1 |
| Blackledge, GR | 1 |
| Sharpe, J | 1 |
| Donati, D | 3 |
| Malacarne, P | 1 |
| Monici, L | 1 |
| Di Costanzo, F | 1 |
| Sulkes, A | 1 |
| Ochayon, L | 1 |
| Gera, C | 1 |
| Nathan, S | 1 |
| Cass, Y | 1 |
| Rubello, E | 1 |
| Kagami, Y | 1 |
| Nishio, M | 1 |
| Narimatsu, N | 1 |
| Tomita, M | 1 |
| Sakurai, T | 1 |
| Buzzi, F | 1 |
| Calabresi, F | 3 |
| Ballmer, PE | 1 |
| Reinhart, WH | 1 |
| Berényi, E | 1 |
| Kiss, E | 1 |
| Skåre, NG | 1 |
| Underskog, I | 1 |
| Hatae, Y | 1 |
| Takeda, T | 1 |
| Nakadate, H | 1 |
| Hatayama, Y | 1 |
| Kishino, T | 1 |
| Ogawa, Y | 1 |
| Kohl, RL | 1 |
| Sato, T | 1 |
| Igarashi, N | 1 |
| Minami, S | 1 |
| Okabe, T | 1 |
| Hashimoto, H | 1 |
| Hasui, M | 1 |
| Kato, E | 1 |
| Bradley, CJ | 1 |
| Forrest, GJ | 2 |
| Hutcheon, AW | 2 |
| Adams, L | 1 |
| Sneddon, M | 1 |
| Harding, M | 1 |
| Kerr, DJ | 2 |
| Kaye, SB | 3 |
| Guyon, F | 1 |
| Delfour, C | 1 |
| Lebeau, B | 1 |
| Dodds, LJ | 1 |
| Leathem, AM | 1 |
| Howden, CW | 1 |
| Gordon, CJ | 1 |
| Pazdur, R | 1 |
| Ziccarelli, A | 1 |
| Cummings, G | 1 |
| Al-Sarraf, M | 1 |
| Saijo, N | 4 |
| Sasaki, Y | 4 |
| Fujiwara, Y | 1 |
| Mae, M | 1 |
| Fukuda, M | 1 |
| Sasaki, S | 1 |
| Madej, TH | 2 |
| Simpson, KH | 2 |
| Huo, ML | 1 |
| Wang, YS | 1 |
| Wang, P | 1 |
| Xiang, YS | 1 |
| Wang, JG | 1 |
| Wright, RN | 1 |
| Nicolosi, WD | 1 |
| Crenshaw, RR | 1 |
| Murakami, M | 1 |
| Ota, K | 1 |
| Umehara, H | 2 |
| Sawamura, N | 3 |
| Kusano, H | 1 |
| Yokoyama, S | 4 |
| Suemasu, K | 3 |
| Parikh, PM | 1 |
| Koppikar, SB | 1 |
| Giri, N | 1 |
| Nadkarni, P | 1 |
| Minotti, V | 3 |
| Vollmer-Larsen, B | 1 |
| Sonne, N | 1 |
| Richtsmeier, WJ | 1 |
| Mazur, EM | 1 |
| Domeney, AM | 2 |
| Gunning, SJ | 1 |
| Kelly, ME | 1 |
| Nohria, V | 1 |
| Owera-Atepo, JB | 1 |
| Simpson, KM | 1 |
| Tan, CC | 1 |
| Tattersall, D | 1 |
| Parashos, PJ | 2 |
| Dugan, WM | 2 |
| Fry, MW | 2 |
| Nivelon-Chevallier, A | 1 |
| Chen, JT | 1 |
| Hirai, Y | 1 |
| Yagi, H | 1 |
| Katase, K | 1 |
| Shimizu, Y | 1 |
| Nakayama, K | 1 |
| Teshima, H | 1 |
| Hamada, T | 1 |
| Fujimoto, I | 1 |
| Yamuchi, K | 1 |
| Blumenberg, D | 1 |
| Sridhar, KS | 1 |
| Donnelly, E | 1 |
| al-Idrissi, HY | 2 |
| Ibrahim, EM | 2 |
| Abdullah, KA | 1 |
| Ababtain, WA | 1 |
| Boukhary, HA | 1 |
| Macaulay, HM | 1 |
| Dana, BW | 1 |
| McDermott, M | 1 |
| Everts, E | 1 |
| Abdulhay, G | 1 |
| Edge, SB | 1 |
| Funkhouser, WK | 1 |
| Berman, A | 1 |
| Seipp, C | 1 |
| Tanner, A | 1 |
| Wesley, R | 1 |
| Rosenberg, SA | 1 |
| Chang, AE | 1 |
| Palmer, MC | 1 |
| Colls, BM | 1 |
| Fujii, M | 2 |
| Kiura, K | 2 |
| Kamei, H | 1 |
| Okabe, K | 2 |
| Toki, H | 2 |
| Aasebø, U | 2 |
| Slørdal, L | 1 |
| Prytz, PS | 1 |
| Aarbakke, J | 1 |
| Nino, S | 1 |
| Inoue, I | 1 |
| Sakurai, M | 2 |
| Miner, WD | 1 |
| Sanger, GJ | 1 |
| Turner, DH | 1 |
| Scott, K | 1 |
| Ackland, S | 1 |
| Yuen, K | 1 |
| Morton, C | 1 |
| Hillcoat, BL | 1 |
| Shiu, W | 1 |
| Tsang, V | 1 |
| Lam, YM | 1 |
| Zacharia, A | 1 |
| Martin, WM | 1 |
| O'Mara, V | 1 |
| Simpson, JM | 1 |
| Hawthorn, J | 1 |
| Ostler, KJ | 1 |
| Michaud, M | 1 |
| Partington, J | 1 |
| Brenneis, C | 1 |
| Paterson, AH | 1 |
| MacDonald, RN | 1 |
| Kobayashi, H | 1 |
| Onsrud, M | 1 |
| Moxnes, A | 1 |
| Sollien, A | 1 |
| Grande, T | 1 |
| Solesvik, O | 1 |
| Miller, CD | 1 |
| Anderson, WG | 1 |
| Cheyne, AJ | 1 |
| Rosenblatt, E | 1 |
| Lev, LM | 1 |
| Robinson, E | 1 |
| Ehler, E | 1 |
| Akerley, WL | 2 |
| Bindi, M | 1 |
| Pepi, F | 1 |
| Sebaste, L | 1 |
| Tucci, E | 1 |
| Pirtoli, L | 1 |
| Agostinucci, WA | 2 |
| Gannon, RH | 2 |
| Golub, GR | 1 |
| Martin, RS | 2 |
| Schauer, PK | 3 |
| Dinonno, EB | 1 |
| Hayashi, Y | 1 |
| Iwasaka, T | 1 |
| Hachisuga, T | 1 |
| Fukuda, K | 1 |
| Tanaka, T | 1 |
| Matsuo, N | 1 |
| Sugimori, H | 1 |
| Mathia, WJ | 1 |
| Bell, SK | 1 |
| Leak, WD | 1 |
| Dozono, H | 2 |
| Yasuda, M | 1 |
| Ochiai, K | 1 |
| Tsuruoka, M | 1 |
| Morimoto, O | 1 |
| Sasaki, H | 1 |
| Arihiro, T | 1 |
| Terashima, Y | 1 |
| Joss, R | 1 |
| Rohrbach, D | 1 |
| Pirovino, M | 2 |
| Bischoff, A | 1 |
| Kiser, J | 1 |
| Brunner, K | 1 |
| Goldsmith, TL | 1 |
| Norton, JA | 1 |
| Young, AB | 1 |
| Tibbs, PA | 1 |
| Dempsey, RJ | 1 |
| Rapp, RP | 1 |
| Anthony, LB | 1 |
| Krozely, MG | 1 |
| Woodward, NJ | 1 |
| Hainsworth, JD | 1 |
| Hande, KR | 1 |
| Brenner, DE | 1 |
| Greco, FA | 1 |
| Burish, TG | 1 |
| Weigand, W | 1 |
| Saller, R | 6 |
| Hellenbrecht, D | 6 |
| Bühring, M | 1 |
| Hess, H | 3 |
| Desmond, PV | 1 |
| Watson, KJ | 1 |
| Joss, RA | 1 |
| Galeazzi, RL | 1 |
| Bischoff, AK | 1 |
| Ryssel, HJ | 1 |
| Brunner, KW | 1 |
| Ibrahim, A | 1 |
| Absood, G | 1 |
| Al-Dossary, E | 1 |
| Al-Jammaa, A | 1 |
| Al-Ethan, S | 1 |
| Eliopoulos, A | 1 |
| Richards, PD | 1 |
| Flaum, MA | 1 |
| Bateman, M | 1 |
| Kardinal, CG | 1 |
| Rhinehart, SN | 1 |
| Triplett, WC | 1 |
| Minnick, DJ | 1 |
| Tamai, M | 1 |
| Veenhof, CH | 1 |
| Janssens, LA | 1 |
| Erlichman, C | 1 |
| Willan, AR | 1 |
| Pater, JL | 1 |
| Bella, M | 1 |
| Passalacqua, R | 2 |
| Morsia, D | 2 |
| DiCostanzo, F | 2 |
| Tognoni, G | 1 |
| De Nigris, A | 1 |
| Craig, JB | 1 |
| Powell, BL | 1 |
| White, DR | 1 |
| Capizzi, RL | 1 |
| Gumbart, CH | 1 |
| Sorensen, SH | 1 |
| Bickers, JN | 1 |
| Vandewalker, GE | 1 |
| Ribas-Mundó, M | 1 |
| Fernández-Marcial, C | 1 |
| Van den Berg, AA | 2 |
| Lambourne, A | 2 |
| Yazji, NS | 1 |
| Laghari, NA | 1 |
| Bécouarn, Y | 1 |
| Nguyen, BB | 1 |
| David, M | 1 |
| Lakdja, F | 1 |
| Brunet, R | 1 |
| Chauvergne, J | 1 |
| Spiess, JL | 1 |
| Adelstein, DJ | 1 |
| Hines, JD | 1 |
| Warner-Efraty, E | 1 |
| Ben-Baruch, N | 1 |
| Yitzhaki, N | 1 |
| Uziely, B | 1 |
| Sabates, R | 1 |
| Drew, SJ | 1 |
| Friedman, LS | 1 |
| Weinrauch, LA | 1 |
| D'Elia, JA | 1 |
| Saab, GA | 1 |
| Ibrahim, N | 1 |
| Azouri, N | 1 |
| Presant, CA | 1 |
| Wiseman, C | 1 |
| Gala, K | 1 |
| Kennedy, P | 1 |
| Bouzaglou, A | 1 |
| Blayney, D | 1 |
| Schindler, J | 1 |
| Rigas, M | 1 |
| Melville, J | 1 |
| Dolan, J | 1 |
| Alba, E | 1 |
| Bastus, R | 1 |
| Castro, I | 1 |
| Ojeda, B | 1 |
| de Andrés, L | 1 |
| Bernstein, L | 1 |
| Cohen, JL | 2 |
| Alphin, RS | 2 |
| Proakis, AG | 1 |
| Leonard, CA | 1 |
| Smith, WL | 2 |
| Dannenburg, WN | 1 |
| Kinnier, WJ | 1 |
| Johnson, DN | 1 |
| Sancilio, LF | 2 |
| Ward, JW | 1 |
| Jackson, CB | 1 |
| Niijima, T | 1 |
| Isurugi, K | 1 |
| Akaza, H | 1 |
| Kondo, Y | 1 |
| Kawabe, K | 1 |
| Fujita, K | 1 |
| Koiso, K | 1 |
| Yokoyama, M | 1 |
| Kinoshita, K | 1 |
| Aso, Y | 1 |
| Martín Jiménez, M | 2 |
| González Larriba, JL | 1 |
| Sangro, B | 1 |
| Ruggeri, EM | 1 |
| Caporali, C | 1 |
| Sirota, RA | 1 |
| Kimmel, PL | 1 |
| Trichtinger, MD | 1 |
| Diamond, BF | 1 |
| Stein, HD | 1 |
| Yudis, M | 1 |
| Kauste, A | 1 |
| Tuominen, M | 1 |
| Heikkinen, H | 1 |
| Gordin, A | 1 |
| Korttila, K | 1 |
| Havsteen, H | 1 |
| Nielsen, H | 1 |
| Kjaer, M | 1 |
| MacPherson, JS | 1 |
| Bernstein, G | 1 |
| Rifkin, H | 1 |
| Kodama, N | 1 |
| Furuse, K | 1 |
| Kawahara, M | 1 |
| Arai, R | 1 |
| Tsuruta, S | 1 |
| Hayashi, S | 1 |
| Kiyota, T | 1 |
| Krailo, MD | 1 |
| Johnson, KB | 1 |
| Baker, CR | 1 |
| Cariffe, PA | 1 |
| Monrás, P | 1 |
| Fernández, C | 1 |
| Serichol, M | 1 |
| Clotet, M | 1 |
| Ribas Mundó, M | 1 |
| Ito, J | 1 |
| Abo, T | 1 |
| Okamoto, Y | 1 |
| Yamashita, T | 1 |
| Takahashi, K | 1 |
| Jordan, NS | 1 |
| Schauer, A | 1 |
| Nightingale, C | 1 |
| Golub, G | 1 |
| Williams, HM | 1 |
| Funaki, Y | 1 |
| Fujita, J | 3 |
| Futami, H | 2 |
| Yoshioka, S | 1 |
| Waldmann, CS | 1 |
| Verghese, C | 1 |
| Short, SM | 1 |
| Goldhill, DR | 1 |
| Evans, SJ | 1 |
| Krebs, HB | 1 |
| Myers, MB | 1 |
| Wheelock, JB | 1 |
| Goplerud, DR | 1 |
| Funaki, U | 1 |
| Shimizu, E | 1 |
| Pruitt, BT | 1 |
| Justice, RL | 1 |
| Periman, P | 1 |
| Joseph, C | 1 |
| Kearsley, JH | 1 |
| Tattersall, MH | 1 |
| Swierz, J | 1 |
| Szutkowski, Z | 1 |
| Nowakowski, W | 1 |
| Canaletti, R | 1 |
| Colombo, N | 1 |
| Gilchrist, NL | 1 |
| Hepplestone, A | 1 |
| Calder, IT | 1 |
| McArdle, CS | 1 |
| Vella, L | 1 |
| Francis, D | 1 |
| Houlton, P | 1 |
| Reynolds, F | 1 |
| Bayliss, EJ | 1 |
| Braun, J | 1 |
| Howrie, DL | 1 |
| Felix, C | 1 |
| Wollman, M | 1 |
| Juhl, RP | 1 |
| Blatt, J | 1 |
| Ohmi, K | 1 |
| Walters, JK | 1 |
| Frontenas, P | 1 |
| Saad Zoi, R | 1 |
| Daste, J | 1 |
| Briemann, L | 1 |
| Hellstern, A | 2 |
| Mitrou, P | 1 |
| Hodgson, M | 1 |
| Achtert, G | 1 |
| Brockmann, P | 2 |
| Hausleiter, HJ | 1 |
| Myhr, K | 1 |
| Markman, M | 1 |
| Newman, DR | 1 |
| Hawkins, RS | 1 |
| Pfau, L | 1 |
| Luesley, DM | 1 |
| Terry, PB | 1 |
| Chan, KK | 1 |
| Benrubi, GI | 1 |
| Norvell, M | 1 |
| Nuss, RC | 1 |
| Robinson, H | 1 |
| Roemeling, RV | 1 |
| Christiansen, NP | 1 |
| Hrushesky, WJ | 1 |
| Amano, H | 1 |
| Yasuda, Y | 1 |
| Tsunekawa, H | 1 |
| Fujimoto, K | 1 |
| Yoshii, S | 1 |
| McCallum, RW | 1 |
| Graham, J | 1 |
| Blackie, RG | 1 |
| McGovern, E | 1 |
| Kelman, AW | 1 |
| Candido, A | 1 |
| Rossi, P | 1 |
| Tartaglione, R | 1 |
| Alfano, G | 1 |
| Menichella, G | 1 |
| Mango, G | 1 |
| Zambetti, M | 1 |
| Bajetta, E | 1 |
| Bidoli, P | 1 |
| Verusio, C | 1 |
| Paul, AK | 1 |
| Masterton, G | 1 |
| Schofield, CB | 1 |
| Tait, IB | 1 |
| Palmer, HM | 1 |
| Beardwell, CG | 1 |
| Howard, PJ | 1 |
| Assaf, RA | 1 |
| Samuel, IO | 1 |
| Johnson, AG | 1 |
| McMurray, GN | 1 |
| Howard, FA | 1 |
| Sharp, DS | 1 |
| McGarry, J | 1 |
| Robinson, OP | 1 |
| Middleton, RS | 1 |
| Bloch, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial[NCT02135510] | Phase 3 | 249 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay[NCT02956616] | Phase 2 | 118 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section[NCT01216410] | 306 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial[NCT04252521] | 150 participants (Actual) | Interventional | 2019-07-03 | Completed | |||
| Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial[NCT02760069] | Phase 4 | 122 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin[NCT03237611] | Phase 2 | 15 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Expired IRB approval on 2/11/21) | ||
| Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial[NCT00869310] | Phase 3 | 303 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to we terminated the study before enrolling 303/560 due to a slow accrual) | ||
| Isopropyl Alcohol Inhalation as Anti-emetic Therapy in the Emergency Department[NCT04464915] | 0 participants (Actual) | Interventional | 2020-07-31 | Withdrawn (stopped due to Given the COVID-19 pandemic, there has been a temporary suspension of study activities, therefore the study has not yet been initiated.) | |||
| Effect of Ketamine Versus Sevoflurane On The Right Ventricular Pressure During Congenital Pulmonary Stenosis Balloon Dilatation[NCT05582213] | 40 participants (Actual) | Interventional | 2022-10-01 | Completed | |||
| Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)[NCT03125811] | Early Phase 1 | 121 participants (Actual) | Interventional | 2017-07-17 | Completed | ||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326] | 300 participants (Anticipated) | Interventional | 2012-03-01 | Completed | |||
| Do Peri-operative High Doses of Intravenous Glucocorticoids Improve Short-term Functional Outcome After Direct Anterior Total Hip Arthroplasty? A Randomized, Single Surgeon, Placebo Controlled, Double Blind Study[NCT04317872] | 70 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | |||
| Ondansetron Vs Metoclopramide in the Treatment of Vomiting in Gastroenteritis Patients: A Randomized Controlled Trial[NCT01165866] | Phase 4 | 170 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Comparison of Gastric Volumes by Gastric Ultrasound in Term Parturients Undergoing Scheduled Elective Cesarean Delivery With and Without Metoclopramide[NCT05033041] | Phase 4 | 72 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | ||
| Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy[NCT01980160] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Did not receive IRB approval from our institution therefore the study was closed.) | |||
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer[NCT04669132] | Phase 2 | 50 participants (Actual) | Interventional | 2020-12-17 | Completed | ||
| A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis[NCT00003213] | Phase 3 | 267 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.[NCT00825071] | Phase 4 | 180 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery[NCT02115529] | Phase 2 | 331 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Is Intra-operative Acupuncture Point P6 Stimulation as Effective as Traditional Pharmacotherapy in Reducing Nausea and Vomiting During Cesarean Section With Regional Anesthesia?[NCT02959840] | Phase 4 | 180 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase III, Randomized, Open-label, Active-controlled, Two-arm, Parallel-design, Interventional Clinical Trial Evaluating the Efficacy and Safety of Ondansetron 8 mg IV/ IM Injection Compared to Metoclopramide 10 mg in the Management of Nausea and Vomiti[NCT05876585] | Phase 3 | 126 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Aromatherapy for Management of Chemotherapy-induced Symptoms[NCT02670941] | Early Phase 1 | 31 participants (Actual) | Interventional | 2016-01-31 | Terminated (stopped due to Slow accrual; Received grant funding for a similar but different study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients discharged on postoperative Day #2 (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Enhanced Recovery | 5 |
| Routine Perioperative Care | 2 |
Postoperative Length of Hospital Stay in Hours from time of surgery (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Hours (Median) |
|---|---|
| Enhanced Recovery | 73.58 |
| Routine Perioperative Care | 75.50 |
The amount of postoperative pain medication required for each patient in Morphine Milligram Equivalents (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Morphine Milligram Equivalents (Mean) |
|---|---|
| Enhanced Recovery | 117.16 |
| Routine Perioperative Care | 119.38 |
All patients will be queried regarding whether breastfeeding was initiated after cesarean birth and how soon after birth (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Breastfeeding | Bottlefeeding | Both Breastfeeding and Bottlefeeding | |
| Enhanced Recovery | 39 | 4 | 15 |
| Routine Perioperative Care | 29 | 2 | 29 |
Comparison of intraoperative nausea and vomiting between the 3 groups. (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants (Number) |
|---|---|
| Combination Group | 23 |
| Metoclopramide | 31 |
| Phenylephrine Infusion | 49 |
The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants with SBP< 20 % baseline (Number) |
|---|---|
| Combination Group | 16 |
| Metoclopramide | 19 |
| Phenylephrine Infusion | 16 |
(NCT01216410)
Timeframe: 0-24 hrs
| Intervention | participants (Number) |
|---|---|
| Combination Group | 95 |
| Metoclopramide | 93 |
| Phenylephrine Infusion | 97 |
1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted. (NCT01216410)
Timeframe: 24 h
| Intervention | participants (Number) |
|---|---|
| Combination Group | 94 |
| Metoclopramide | 85 |
| Phenylephrine Infusion | 87 |
(NCT01216410)
Timeframe: 0-2h, 2-6h, 6-24h
| Intervention | participants (Number) | ||
|---|---|---|---|
| 0-2 hrs PONV | 2-6 hrs PONV | 6-24 hrs PONV | |
| Combination Group | 20 | 28 | 22 |
| Metoclopramide | 33 | 35 | 26 |
| Phenylephrine Infusion | 39 | 41 | 22 |
Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea. (NCT02760069)
Timeframe: 30 minutes post intervention
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 23 |
| Inhaled ISO + Oral Placebo | 19 |
| Inhaled Placebo + Oral Ondansetron | 42 |
Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record. (NCT02760069)
Timeframe: Study duration (up to 5 hours post intervention)
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 11 |
| Inhaled ISO + Oral Placebo | 10 |
| Inhaled Placebo + Oral Ondansetron | 18 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the first cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 11 | 10 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the first cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 9 | 9 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the second cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the second cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 44 |
| Metoclopramide, Ondansetron | 14 |
| Acupressure Point P6 Stimulator | 22 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage I. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 33 |
| Metoclopramide, Ondansetron | 7 |
| Acupressure Point P6 Stimulator | 14 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage II. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 12 |
| Metoclopramide, Ondansetron | 6 |
| Acupressure Point P6 Stimulator | 5 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage III. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 16 |
| Metoclopramide, Ondansetron | 8 |
| Acupressure Point P6 Stimulator | 14 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage IV. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 3 |
| Metoclopramide, Ondansetron | 4 |
| Acupressure Point P6 Stimulator | 0 |
Patients are asked their overall anesthetic care satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 53 |
| Metoclopramide, Ondansetron | 58 |
| Acupressure Point P6 Stimulator | 56 |
Patients are asked their anti-emetic treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 49 |
| Metoclopramide, Ondansetron | 58 |
| Acupressure Point P6 Stimulator | 55 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 27 |
| Metoclopramide, Ondansetron | 10 |
| Acupressure Point P6 Stimulator | 8 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage I. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 20 |
| Metoclopramide, Ondansetron | 5 |
| Acupressure Point P6 Stimulator | 4 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage II. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 10 |
| Metoclopramide, Ondansetron | 1 |
| Acupressure Point P6 Stimulator | 3 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage III. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 9 |
| Metoclopramide, Ondansetron | 4 |
| Acupressure Point P6 Stimulator | 6 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage IV. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 0 |
| Metoclopramide, Ondansetron | 2 |
| Acupressure Point P6 Stimulator | 0 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
91 reviews available for metoclopramide and Emesis
| Article | Year |
|---|---|
Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Metoclopramide; Nausea; Odds Ratio; Pregnancy | 2021 |
Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting.
Topics: Adult; Analgesics, Opioid; Antiemetics; Female; Humans; Male; Metoclopramide; Nausea; Vomiting | 2022 |
Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Dexamethasone; Diarrhea; Dimenhydrinate; Domper | 2020 |
Should Antiemetics be Given Prophylactically with Intravenous Opioids While Treating Acute Pain in the Emergency Department?: Clinical Practice Paper Approved by American Academy of Emergency Medicine Clinical Guidelines Committee.
Topics: Acute Pain; Analgesics, Opioid; Antiemetics; Emergency Medicine; Emergency Service, Hospital; Humans | 2020 |
MASCC antiemetics in advanced cancer updated guideline.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Neoplasms; Vomiting | 2021 |
Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery).
Topics: Adrenal Cortex Hormones; Adult; Chlorpromazine; Dexamethasone; Humans; Indoles; Metoclopramide; Naus | 2017 |
[Vomiting].
Topics: Antineoplastic Agents; Feeding Behavior; Gastric Emptying; Gastritis; Gastroparesis; Humans; Metoclo | 2017 |
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzodiazepines; Chemoradiotherapy; Dexamethasone; Disord | 2018 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2013 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cannabinoids; Chlorpromazine; Dizziness; Domperidone; Eup | 2015 |
Cannabinoid hyperemesis syndrome: a guide for the practising clinician.
Topics: Adult; Antiemetics; Cannabinoids; Cannabis; Disease Management; Dronabinol; Humans; Male; Marijuana | 2015 |
The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials.
Topics: Chi-Square Distribution; Critical Illness; Diarrhea; Domperidone; Dopamine Antagonists; Enteral Nutr | 2016 |
Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Substance P; Treatmen | 2009 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Metoclopra | 2009 |
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Dexamethasone; Dose-Response Relations | 1998 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2010 |
Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Radiotherapy; Randomized Controlled Trials as Topic; Se | 2012 |
Nausea and vomiting in early pregnancy.
Topics: Acupressure; Administration, Oral; Domperidone; Female; Humans; Metoclopramide; Nausea; Phytotherapy | 2009 |
Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Disease; Analgesics, Opioid; Antiemetics; Dopamine Agonists; Emergencies; Humans; Injections, | 2011 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2011 |
Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis.
Topics: Anesthesia, Conduction; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Female; Humans; Intr | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
Treatment of pediatric migraine in the emergency room.
Topics: Adolescent; Age Distribution; Age of Onset; Analgesics; Antiemetics; Child; Child, Preschool; Dihydr | 2012 |
[Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].
Topics: Antiemetics; Antipsychotic Agents; Chronic Disease; Domperidone; Dopamine Antagonists; Drug Therapy, | 2012 |
Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anorexia; Antiemetics; Delayed-Action Preparat | 2002 |
Anti-emetics.
Topics: Antiemetics; Domperidone; Dopamine Antagonists; Humans; Metoclopramide; Migraine Disorders; Nausea; | 2001 |
[Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; H | 2004 |
Best evidence topic reports. Metoclopramide versus placebo with opioid.
Topics: Analgesics, Opioid; Antiemetics; Evidence-Based Medicine; Humans; Male; Metoclopramide; Middle Aged; | 2004 |
Antiemetic therapy in patients treated with cisplatin chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Controlled Clinical Trials as Topic; Double-Blind Met | 1989 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Drug Therapy, Combination; Humans; Isoquinoline | 2007 |
Pharmacologic treatment of chemotherapy-induced nausea and vomiting.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Butyrophenones; Chemoreceptor Cells; Dr | 1984 |
Advances in anti-emetic therapy.
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Clinical Trials as Topic; Dexamethasone; Do | 1984 |
Anaesthesia and emesis. II: Prevention and management.
Topics: Anesthesia; Antiemetics; Butyrophenones; Domperidone; Histamine H1 Antagonists; Humans; Metocloprami | 1984 |
Treatment of nausea and vomiting caused by cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cannabinoids; Dronabinol; Humans; Metoclopramide; Nausea; Vomiti | 1982 |
Metoclopramide. An updated review of its pharmacological properties and clinical use.
Topics: Animals; Drug Interactions; Gastrointestinal Diseases; Humans; Kinetics; Metoclopramide; Vomiting | 1983 |
Nausea and vomiting.
Topics: Analgesics; Anesthetics; Domperidone; Humans; Metoclopramide; Nausea; Phenothiazines; Piperazines; S | 1984 |
Dopamine antagonists in the upper gastrointestinal tract.
Topics: Diabetic Neuropathies; Digestive System; Domperidone; Dopamine Antagonists; Duodenum; Dyspepsia; Eso | 1984 |
Disorders of gastrointestinal motility associated with diabetes mellitus.
Topics: Autonomic Nervous System Diseases; Bethanechol Compounds; Constipation; Diabetes Complications; Diab | 1983 |
Drug therapy. Metoclopramide.
Topics: Dopamine Antagonists; Esophagitis; Gastric Emptying; Gastroesophageal Reflux; Gastrointestinal Motil | 1981 |
Review of a new gastrointestinal drug--metoclopramide.
Topics: Diabetes Complications; Gastric Emptying; Humans; Metoclopramide; Stomach Diseases; Vomiting | 1981 |
[Pharmacological and clinical characteristics of metoclopramide].
Topics: Endocrine Glands; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; Metoclopramide; Musc | 1981 |
Antiemetics in children receiving cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Humans; Metoclopramide; Nausea; Neoplasms; | 1994 |
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1994 |
Cost-effectiveness analysis of antiemetic treatment.
Topics: Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Dexamethasone; Europe; European Union; | 1994 |
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Huma | 1994 |
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Metoclopramide; Nausea; Ondan | 1994 |
Delayed emesis: a dilemma in antiemetic control.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Forecasti | 1993 |
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Child; Cisplatin; Clinical Trials, Phase I as To | 1994 |
[An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Topics: Antineoplastic Agents; Granisetron; Humans; Metoclopramide; Nausea; Ondansetron; Serotonin Antagonis | 1993 |
The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action.
Topics: Animals; Antiemetics; Dogs; Ferrets; Humans; Metoclopramide; Ondansetron; Receptors, Serotonin; Sero | 1993 |
Emesis and anti-emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Rabbits; Receptors, Serotonin; | 1994 |
Optimal control of acute cisplatin-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dopamine Antagonists; Humans; Metoclopramide; Nausea; | 1996 |
Postoperative nausea and vomiting in children.
Topics: Anesthetics, Inhalation; Antiemetics; Child; Droperidol; Humans; Incidence; Metoclopramide; Nausea; | 1996 |
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Granisetron | 1996 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
[Recent improvements in antiemetic therapy].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron | 1997 |
Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Topics: Administration, Oral; Age Factors; Antiemetics; Dexamethasone; Humans; Indoles; Injections, Intraven | 1997 |
[Effectiveness and cost of 5-HT3-antagonists in acute chemotherapy-induced emesis. Health-economic analysis based on current meta-analytic data].
Topics: Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Germany; Humans; Metoclopramide; Selectiv | 1997 |
Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
Topics: Adult; Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Humans; Metoclopramide; Neoplasms; | 1998 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Metoclopramide.
Topics: Animals; Digestive System; Gastrointestinal Motility; Humans; Metoclopramide; Muscle, Smooth; Nausea | 1979 |
Some aspects of medical management of gastrointestinal disease. I.
Topics: Diarrhea; Disaccharides; Endoscopy; Esophagitis; Gastric Juice; Gastric Mucosa; Gastrointestinal Dis | 1975 |
Metoclopramide: a review of its pharmacological properties and clinical use.
Topics: Animals; Basal Ganglia Diseases; Cardiovascular System; Central Nervous System; Clinical Trials as T | 1976 |
Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
Topics: Antiemetics; Cisplatin; Clinical Trials as Topic; Female; Humans; Imidazoles; Male; Metoclopramide; | 1992 |
Antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Imi | 1992 |
5-HT3 antagonists in postoperative nausea and vomiting.
Topics: Aged; Anesthesia, General; Humans; Male; Metoclopramide; Nausea; Ondansetron; Postoperative Complica | 1992 |
Ondansetron. Therapeutic use as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Metoclopramide; Nausea; Ondansetron; Radiati | 1991 |
Emerging differences between 5-HT3 receptor antagonists.
Topics: Animals; Antiemetics; Gastrointestinal Motility; Humans; Metoclopramide; Serotonin Antagonists; Vomi | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
5HT3-antagonist receptors: their role in drug-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Dexamethasone; Dopamine Antagonists; Drug | 1990 |
[Nausea and vomiting during treatment with cytostatics].
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Metoclop | 1991 |
Management of chemotherapy-induced nausea and vomiting.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Benzodiazepines; Butyrophenones; Cannab | 1990 |
Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dogs; Dopamine Antagonists; Female; Ferrets; | 1990 |
[Nausea and vomiting induced by chemotherapy: bases to a rational treatment].
Topics: Antiemetics; Antineoplastic Agents; Butyrophenones; Drug Therapy, Combination; Metoclopramide; Nause | 1989 |
Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 1989 |
The control of cancer chemotherapy-induced nausea and vomiting.
Topics: Adrenal Cortex Hormones; Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Antipsychotic Agen | 1985 |
Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy.
Topics: Antiemetics; Antipsychotic Agents; Dicyclomine; Diphenhydramine; Doxylamine; Drug Combinations; Fema | 1986 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
Combination antiemetics for cisplatin chemotherapy.
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Droperidol; Drug Evaluation; Drug Therapy, C | 1988 |
Metoclopramide--a review.
Topics: Anxiety; Digestive System; Dopamine Antagonists; Drug Interactions; Female; Gastric Emptying; Gastro | 1986 |
[The treatment of vomiting caused by the administration of cytostatic agents].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Loraz | 1986 |
[Progress in the management of vomiting associated with antineoplastic agents].
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Evaluation; Drug Therapy, Combination; Human | 1985 |
[The control of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Chlorpromazine; Cisplatin; Domperidone; Hum | 1985 |
Recent advances in the prevention or reduction of cytotoxic-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cannabinoids; Drug Evaluation; Glucocorticoids; | 1985 |
382 trials available for metoclopramide and Emesis
| Article | Year |
|---|---|
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Met | 2022 |
The efficacy of prophylactic metoclopramide in preventing nausea and vomiting in patients with acute pain treated with intravenous tramadol: a randomized double-blinded, placebo-controlled trial.
Topics: Acute Pain; Analgesics, Opioid; Antiemetics; Double-Blind Method; Humans; Metoclopramide; Nausea; Tr | 2023 |
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 2020 |
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Humans; Male; Metoclop | 2021 |
A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastr
Topics: Adult; Critical Illness; Enteral Nutrition; Erythromycin; Female; Gastric Emptying; Gastrointestinal | 2016 |
Effect of metoclopramide on nausea and emesis in dogs premedicated with morphine and dexmedetomidine.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dexmedetomidine; Dogs; Dopamine Antagonists; Female; Male; | 2018 |
Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; G | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Female; Hysterectomy; Male; Metoclopra | 2017 |
Metoclopramide as intermittent and continuous infusions in critically ill patients: a pilot randomized clinical trial.
Topics: Adult; Aged; Antiemetics; Critical Illness; Drug Administration Schedule; Energy Intake; Enteral Nut | 2017 |
Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs.
Topics: Animals; Antiemetics; Dog Diseases; Dogs; Female; Male; Metoclopramide; Ondansetron; Parvoviridae In | 2017 |
Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiemetics; Chi-Square Distribution; Contrast Me | 2009 |
Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Meto | 2008 |
Antiemetic activity of megestrol acetate in patients receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Drug Therapy | 2011 |
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doub | 2012 |
Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery.
Topics: Acupressure; Adolescent; Adult; Antiemetics; Child; Combined Modality Therapy; Double-Blind Method; | 2011 |
Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dopamine Antagonists; Double-Blind Method; Female; | 2011 |
Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Emergency Medical Services; Emergency Service, Hospit | 2011 |
Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea.
Topics: Adult; Antiemetics; Double-Blind Method; Female; Humans; Metoclopramide; Nausea; Placebos; Pregnancy | 2011 |
Adjunctive atropine versus metoclopramide: can we reduce ketamine-associated vomiting in young children? a prospective, randomized, open, controlled study.
Topics: Anesthetics, Dissociative; Antiemetics; Atropine; Child, Preschool; Female; Humans; Infant; Ketamine | 2012 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cis | 2013 |
Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anorexia; Antiemetics; Delayed-Action Preparat | 2002 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2002 |
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2003 |
A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; | 2003 |
Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy.
Topics: Adult; Antiemetics; Drug Therapy, Combination; Female; Humans; Hyperemesis Gravidarum; Metoclopramid | 2003 |
Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Humans; Male; Met | 2003 |
Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Emergency | 2004 |
Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Topics: Adult; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2004 |
Effectiveness of pre-emptive metoclopramide infusion in alleviating pain, discomfort and nausea associated with nasogastric tube insertion: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Gagging; Human | 2005 |
Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Female; | 2006 |
Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine.
Topics: Adult; Apomorphine; Betamethasone; Dopamine Agonists; Dopamine Antagonists; Female; Glucocorticoids; | 2006 |
Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; F | 2006 |
Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Child; Dimenhydrinate; Female; Grani | 2006 |
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 2007 |
Advances in anti-emetic therapy.
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Clinical Trials as Topic; Dexamethasone; Do | 1984 |
Antiemetics for patients treated with antitumor chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Cyclizine; Dronabinol; Drug Therapy, Combination; F | 1980 |
Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Dronabinol; Human | 1984 |
[Metoclopramide in the prevention of postoperative nausea and vomiting].
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Metocloprami | 1983 |
Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; Drug Syn | 1983 |
[Domperidone and metoclopramide in the prevention of postoperative nausea and vomiting].
Topics: Abortion, Induced; Adolescent; Adult; Clinical Trials as Topic; Domperidone; Double-Blind Method; Fe | 1983 |
[Prevention of cytostatic-induced vomiting. High-dosage metoclopramide versus an antiemetic combination in a controlled comparison].
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 1983 |
Nausea and vomiting during spinal anaesthesia. Effect of metoclopramide and domperidone: a double-blind trial.
Topics: Aged; Anesthesia, Spinal; Blood Pressure; Clinical Trials as Topic; Domperidone; Double-Blind Method | 1984 |
Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1984 |
A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 1984 |
[Symptomatic therapy of vomiting in children. Clinical study of a new preparation with anti-emetic activity (Clebopride)].
Topics: Benzamides; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; Female; | 1984 |
Preanesthetic cimetidine and metoclopramide for acid aspiration prophylaxis in elective surgery.
Topics: Adult; Anesthesia; Cimetidine; Clinical Trials as Topic; Gastric Acid; Gastric Juice; Humans; Inhala | 1984 |
Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study.
Topics: Adult; Amitriptyline; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doub | 1984 |
Emesis due to cancer chemotherapy: results of a prospective, randomised, double-blind trial of varying doses of metoclopramide in the management of cis-platinum-induced vomiting.
Topics: Adolescent; Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1984 |
Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Male; Methylprednisolo | 1984 |
Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy.
Topics: Cisplatin; Dacarbazine; Female; Humans; Lorazepam; Male; Metoclopramide; Middle Aged; Vomiting | 1984 |
Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Humans; Metoc | 1984 |
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Drug Evaluati | 1984 |
Antiemetic efficacy of high-dose corticosteroids and droperidol in cisplatin-induced emesis: a controlled trial with droperidol and metoclopramide.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Droperidol; Drug | 1984 |
[Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Appetite; Double-Blind Method; Female; Humans; Male; Metoclopr | 1983 |
Vomiting after anaesthesia for termination of pregnancy in Chinese.
Topics: Abortion, Induced; Anesthesia, Obstetrical; China; Ethnicity; Female; Humans; Metoclopramide; Preane | 1983 |
[Metoclopramide and cisplatin].
Topics: Cisplatin; Drug Evaluation; Humans; Metoclopramide; Random Allocation; Vomiting | 1983 |
[Clinical evaluation of antiemetics for vomiting due to cancer chemotherapy in children].
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; D | 1982 |
[Prevention of cytostatic-induced vomiting with high-dose metoclopramide].
Topics: Antineoplastic Agents; Humans; Metoclopramide; Vomiting | 1983 |
Postoperative vomiting treated with domperidone. A double-blind comparison with metoclopramide and a placebo.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Clinical Trials as Topic; Domperidone; Double-Blind Method | 1980 |
[Domperidone as an anti-emetic in antineoplastic chemotherapy].
Topics: Aged; Antineoplastic Agents; Benzimidazoles; Clinical Trials as Topic; Domperidone; Female; Gastroin | 1981 |
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Metoclo | 1981 |
[Study of cipropride in the treatment of digestive disorders induced by anticancer chemotherapy. Double-blind study using metoclopramide].
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1981 |
[Comparative study of antiemetic properties of clebopride and metoclopramide in vomiting produced by cis-platinum (author's transl)].
Topics: Antiemetics; Benzamides; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Humans; Metoclopr | 1981 |
Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; | 1982 |
Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Hum | 1982 |
Reduction of postoperative vomiting by preoperative administration of oral metoclopramide.
Topics: Adolescent; Adult; Double-Blind Method; Female; Gastrointestinal Motility; Humans; Intraoperative Ca | 1980 |
Metoclopramide therapy in fifty-five patients with delayed gastric emptying.
Topics: Adolescent; Adult; Aged; Diabetes Complications; Drainage; Female; Gastric Emptying; Humans; Male; M | 1980 |
Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children.
Topics: Adolescent; Age Factors; Antiemetics; Blood Pressure; Body Weight; Child; Child, Preschool; Double-B | 1995 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
On the mechanism of radiation-induced emesis: the role of serotonin.
Topics: Dexamethasone; Drug Therapy, Combination; Female; Hemibody Irradiation; Humans; Hydroxyindoleacetic | 1994 |
Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Granisetron; Humans; Injections, Intravenous; Male; Met | 1995 |
Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Dru | 1995 |
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Akathisia, Drug-Induced; Consciousness; Double-Blind Method; Droperidol; Female; Humans; Hypotension | 1995 |
Antiemetic efficacy of a droperidol-morphine combination in patient-controlled analgesia.
Topics: Adolescent; Adult; Analgesia, Patient-Controlled; Dose-Response Relationship, Drug; Double-Blind Met | 1995 |
Granisetron in the prevention of irradiation-induced emesis.
Topics: Adult; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gra | 1995 |
Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine.
Topics: Administration, Cutaneous; Adult; Aged; Cholecystectomy, Laparoscopic; Dizziness; Female; Humans; In | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Eating; Female; Humans; Male | 1994 |
The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery.
Topics: Administration, Oral; Adolescent; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Child; | 1995 |
[Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting].
Topics: Adult; Double-Blind Method; Female; Genital Diseases, Female; Humans; Injections, Intravenous; Metoc | 1995 |
Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Droperidol; Female; | 1995 |
Propofol injection pain: comparing the addition of lignocaine or metoclopramide.
Topics: Adult; Anesthesia Recovery Period; Anesthesia, Intravenous; Blood Pressure; Extrapyramidal Tracts; F | 1994 |
Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Cross-Over Studies; Female; Humans; Infusions, Intravenous; Mal | 1994 |
A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Granis | 1994 |
Sustained release metoclopramide for prophylaxis of post-operative nausea and vomiting.
Topics: Administration, Oral; Adult; Delayed-Action Preparations; Double-Blind Method; Elective Surgical Pro | 1994 |
Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study.
Topics: Administration, Intranasal; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; | 1994 |
Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial.
Topics: Adult; Cisplatin; Clemastine; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lorazepam; M | 1995 |
Effect of nabilone on nausea and vomiting after total abdominal hysterectomy.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Dronabinol; Drug Administration Schedule; Female; Hum | 1994 |
Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.
Topics: Acetaminophen; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Humans | 1994 |
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
Antiemetic efficacy of metoclopramide when included in a patient-controlled analgesia infusion.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Double-Blind Method; Female; Gynecology; Humans; Metoclo | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Administration, Oral; Adult; Aged; Chi-Square Distribution; Cisplatin; Constipation; Dexamethasone; | 1994 |
Evaluation of two antiemetic agents during outpatient gynaecological surgery.
Topics: Abortion, Induced; Adult; Ambulatory Surgical Procedures; Analysis of Variance; Anesthesia, General; | 1994 |
The roles of patient and observer assessments in anti-emetic trials.
Topics: Cross-Over Studies; Double-Blind Method; Humans; Lorazepam; Metoclopramide; Nurses; Observer Variati | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Huma | 1994 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem | 1994 |
[Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
Topics: Anesthesia, Epidural; Child; Child, Preschool; Female; Humans; Male; Metoclopramide; Nausea; Ondanse | 1994 |
Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Femal | 1994 |
Rectal indomethacin for analgesia after appendicectomy in children.
Topics: Administration, Rectal; Analgesia; Analgesia, Patient-Controlled; Appendectomy; Child; Double-Blind | 1994 |
Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis.
Topics: Acute Disease; Adult; Aged; Chi-Square Distribution; Cisplatin; Female; Humans; Infusions, Intraveno | 1994 |
Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Droperidol; Female; Humans; | 1993 |
Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Female; Gynecology; Humans; | 1994 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Diphenh | 1994 |
Prophylactic antiemetic therapy with patient-controlled analgesia: a double-blind, placebo-controlled comparison of droperidol, metoclopramide, and tropisetron.
Topics: Analgesia, Patient-Controlled; Antiemetics; Double-Blind Method; Droperidol; Elective Surgical Proce | 1994 |
Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, General; Double-Blind | 1994 |
Zingiber officinale (ginger)--an antiemetic for day case surgery.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Humans; Metoclopram | 1993 |
[Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin].
Topics: Adult; Aged; Anorexia; Cisplatin; Domperidone; Drug Therapy, Combination; Female; Granisetron; Human | 1993 |
Propofol anaesthesia reduces early postoperative emesis after paediatric strabismus surgery.
Topics: Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthesia, Intr | 1993 |
Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Diphenhydramin | 1993 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Female; | 1993 |
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Genita | 1994 |
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Indoles; Male; Metoclopramid | 1994 |
The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1994 |
Open placebo controlled comparison of the antiemetic effect of droperidol, metoclopramide or a combination of both in pediatric strabismus surgery.
Topics: Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Drug Administration Schedule; | 1993 |
Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lorazepam; M | 1993 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug The | 1993 |
Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.
Topics: Adult; Aged; Alprazolam; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non | 1993 |
The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Drug Utilization Review; Female; Hospitals | 1993 |
Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen.
Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neo | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Postoperative nausea and vomiting: a comparison of anti-emetic drugs used alone or in combination.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Drug Combinations; Humans; Metoclopramide; Naus | 1993 |
Tiapride versus metoclopramide: comparison after minor gynaecological surgery.
Topics: Abortion, Incomplete; Abortion, Missed; Adolescent; Adult; Dilatation and Curettage; Double-Blind Me | 1993 |
Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Drug Therapy, Combin | 1996 |
Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplas | 1996 |
Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Therapy, Combination; Female; Granis | 1995 |
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1995 |
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combine | 1995 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Dexamethasone; Drug | 1996 |
Management of cyclophosphamide-induced emesis over repeat courses.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cyclophosphamide; Dexamethasone; | 1996 |
Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 1996 |
Erythromycin as a prokinetic agent in children.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Double-Blind Method; Erythromycin; Gastr | 1996 |
Tropisetron and metoclopramide in the prevention of postoperative nausea and vomiting. A comparative, placebo controlled study in patients undergoing ophthalmic surgery.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Humans; Indo | 1996 |
Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Female; Granisetron; Hematopoietic Stem Cell | 1996 |
The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial.
Topics: Antiemetics; Antineoplastic Agents; Asian People; Cisplatin; Cross-Over Studies; Dexamethasone; Diph | 1996 |
[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cathartics; Cisapride | 1996 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 1996 |
Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Humans; Male; Metoclopramide; Middle Ag | 1996 |
Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Granisetron; H | 1996 |
Posttonsillectomy vomiting. Ondansetron or metoclopramide during paediatric tonsillectomy: are two doses better than one?
Topics: Analysis of Variance; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, Inhalation; Anes | 1996 |
Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen.
Topics: Aged; Antiemetics; Antineoplastic Agents; Female; Humans; Male; Metoclopramide; Nausea; Neoplasms; R | 1996 |
Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Hysterectom | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Adrenergic Agonists; Adult; Antiemetics; Atropine; Chemoprevention; Cholecystectomy, Laparoscopic; C | 1996 |
A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, | 1996 |
Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis.
Topics: Adenoidectomy; Analgesics; Anesthesia, Inhalation; Anesthetics, Inhalation; Antiemetics; Child; Chil | 1996 |
Antiemetic efficacy of granisetron and metoclopramide in children undergoing ophthalmic or ENT surgery.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Double-Blind Method; Granisetron; Humans; Metoc | 1996 |
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Com | 1997 |
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Topics: Acute Disease; Alcoholism; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Cisplatin; Do | 1997 |
Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section.
Topics: Acupressure; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Doub | 1997 |
Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 1996 |
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neurosu | 1996 |
Antiemetic activity of ondansetron in acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Diarrhea; Female; Fluid Therapy; Gastroenteriti | 1997 |
Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine.
Topics: Aged; Analgesics, Opioid; Antiemetics; Blood Pressure; Double-Blind Method; Female; Hip; Humans; Inj | 1997 |
A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dopamine Antagonists; Double-Bl | 1994 |
Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Drug Therapy, | 1994 |
Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dopamine Antagonists; Femal | 1994 |
Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Drug Therapy, | 1994 |
Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Granisetron; Humans; Hydroxyi | 1997 |
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children.
Topics: Age Distribution; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; | 1997 |
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?].
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Female; Humans; Male; Metoclopramide; Nausea; | 1996 |
Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.
Topics: Antiemetics; Cisplatin; Dexamethasone; Female; Granisetron; Humans; Lung Neoplasms; Male; Metoclopra | 1997 |
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Humans; Male; | 1997 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Humans; Metoclopramide; Mi | 1997 |
Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Cataract Extraction; C | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Administration S | 1997 |
A randomized, double-blind, placebo controlled comparison of droperidol, ondansetron, and metoclopramide for the prevention of vomiting following outpatient strabismus surgery in children.
Topics: Ambulatory Surgical Procedures; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperido | 1997 |
Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Double-Blind Method; F | 1997 |
Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Humans; Indoles; Male; Metoclopramide; Nausea; | 1997 |
Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
Topics: Administration, Oral; Aerosols; Antiemetics; Carbon Dioxide; Disease-Free Survival; Dose Fractionati | 1997 |
Comparison of ondansetron, metoclopramide, and placebo in the prevention of postoperative emesis in children undergoing ophthalmic surgery.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Eye Diseases; Humans; Infant; Metoclopramide; Onda | 1997 |
Ondansetron dose response curve in high-risk pediatric patients.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Prevention of nausea and vomiting in female patients undergoing breast surgery: a comparison with granisetron, droperidol, metoclopramide and placebo.
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Droperidol; Female; Granisetron; Humans; | 1998 |
Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis.
Topics: Adult; Double-Blind Method; Droperidol; Female; Gastrointestinal Agents; Granisetron; Humans; Metocl | 1998 |
International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Gynecologic Surgic | 1998 |
Prophylactic therapy with granisetron in the prevention of vomiting after paediatric surgery. A randomized, double-blind comparison with droperidol and metoclopramide.
Topics: Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Granisetron; Humans; | 1998 |
Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Gr | 1998 |
Prevention of postoperative nausea and vomiting in female patients during menstruation: comparison of droperidol, metoclopramide and granisetron.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Gynecologic Surgical Proce | 1998 |
Prophylactic metoclopramide administered immediately after the induction of anesthesia has no effect on the incidence of postoperative emesis after strabismus surgery.
Topics: Anesthesia, General; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; Double-Blind Met | 1998 |
Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer.
Topics: Adult; Aged; Antiemetics; Chlorpromazine; Dexamethasone; Drug Therapy, Combination; Female; Humans; | 1998 |
Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Hu | 1998 |
Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Topics: Antiemetics; Antineoplastic Agents; Child; Diphenhydramine; Drug Therapy, Combination; Female; Human | 1998 |
Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Topics: Abdominal Pain; Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisapride; Cisplatin | 1999 |
Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Co | 1999 |
Granisetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting after thyroidectomy.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Humans; Metoclopramide; Mi | 1999 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
Sulpiride versus metoclopramide in nononcologic patients with vomiting or nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Bl | 1999 |
[Postoperative nausea and vomiting after laparoscopic cholecystectomy].
Topics: Adult; Antiemetics; Cholecystectomy, Laparoscopic; Humans; Metoclopramide; Middle Aged; Nausea; Post | 1999 |
Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Male; Methylprednisolone; Metoclopramide; Middle | 1999 |
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Fe | 1999 |
Granisetron, droperidol, and metoclopramide for the treatment of established postoperative nausea and vomiting in women undergoing gynecologic surgery.
Topics: Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Gynec | 2000 |
Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; C | 1996 |
Prophylactic metoclopramide is unnecessary with intravenous analgesia in the ED.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Antiemetics; Double-Blind | 2000 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemoth | 2000 |
Effects of i.v. metoclopramide, atropine and their combination on gastric insufflation in children anaesthetized with sevoflurane and nitrous oxide.
Topics: Anesthesia, General; Anesthetics, Inhalation; Antiemetics; Atropine; Child; Double-Blind Method; Dru | 2001 |
Gastric residual volume in children: a study comparing efficiency of erythromycin and metoclopramide as prokinetic agents.
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Erythro | 2001 |
Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chi-Square Distribution; Cisplatin; Dexamethasone; | 2001 |
A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cost | 2000 |
Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Metoclopram | 2002 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
Letter: Metoclopramide in parkinsonism.
Topics: Clinical Trials as Topic; Humans; Levodopa; Metoclopramide; Nausea; Parkinson Disease; Promethazine; | 1975 |
Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Topics: Antiemetics; Antineoplastic Agents; Child; Clinical Trials as Topic; Double-Blind Method; Dronabinol | 1979 |
Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.
Topics: Aged; Blood Pressure; Bromocriptine; Clinical Trials as Topic; Female; Growth Hormone; Humans; Male; | 1978 |
Improvement of life quality in cancer patients undergoing chemotherapy.
Topics: Alopecia; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Clinical Trials as Topic; C | 1979 |
A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children.
Topics: Antiemetics; Benzimidazoles; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; | 1979 |
Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide.
Topics: Antiemetics; Benzimidazoles; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Dou | 1979 |
Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthesia, Obstetrical; Benzimidazoles; Cli | 1979 |
Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Benzimidazoles; Child; Child, Preschool; Female; Hum | 1979 |
Metoclopramide: a review of its pharmacological properties and clinical use.
Topics: Animals; Basal Ganglia Diseases; Cardiovascular System; Central Nervous System; Clinical Trials as T | 1976 |
Oral premedication: diazepam, metoclopramide and a drink.
Topics: Administration, Oral; Adult; Atropine; Diazepam; Drinking; Female; Humans; Injections, Intramuscular | 1977 |
The use of metoclopramide in acute pyloric obstruction. A clinical trial.
Topics: Adolescent; Adult; Aged; Barium Sulfate; Clinical Trials as Topic; Duodenal Ulcer; Female; Follow-Up | 1975 |
[Clinical experience with Paspertin in gastroenterology].
Topics: Biliary Dyskinesia; Clinical Trials as Topic; Gastrointestinal Diseases; Gastrointestinal Motility; | 1975 |
Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy | 1992 |
A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Therapy, Combinati | 1992 |
Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man.
Topics: Adult; Double-Blind Method; Fats; Gamma Cameras; Gastric Emptying; Half-Life; Humans; Indoles; Infus | 1992 |
Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Clinical Protocols; De | 1992 |
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Indoles; Lorazepam; Male; Metoclopramide; Middl | 1992 |
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazo | 1992 |
Ondansetron in the treatment of postoperative vomiting: a randomized, double-blind comparison with droperidol and metoclopramide.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Antiemetics; Dilatation and Curettage; Double-B | 1992 |
A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Female; H | 1992 |
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Cisplatin; Double-Blind Method; Humans; Injections, Intravenous; Male; Metoclopra | 1992 |
Lignocaine vs bupivacaine in prominent ear correction: a controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Anesthesia, General; Anesthesia, Local; Bupivacaine; Child; Child, | 1992 |
Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Dose-Response | 1992 |
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
Topics: Adult; Aged; Antineoplastic Agents; Costs and Cost Analysis; Double-Blind Method; Drug Industry; Fem | 1992 |
Metoclopramide reduces the incidence of vomiting after tonsillectomy in children.
Topics: Adolescent; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Female; Huma | 1992 |
Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Comb | 1992 |
A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery.
Topics: Adolescent; Ambulatory Surgical Procedures; Child; Child, Preschool; Double-Blind Method; Droperidol | 1992 |
Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dexamethasone; Diphenhydramine; Double- | 1992 |
Comparison of antiemetic effect among ephedrine, droperidol and metoclopramide in pediatric inguinal hernioplasty.
Topics: Antiemetics; Child; Child, Preschool; Droperidol; Drug Evaluation; Ephedrine; Hernia, Inguinal; Huma | 1992 |
[Droperidol versus metoclopramide. Prevention of emesis following strabismus surgery in children].
Topics: Child; Child, Preschool; Double-Blind Method; Droperidol; Humans; Metoclopramide; Postoperative Comp | 1992 |
Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Resp | 1991 |
Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1991 |
Outpatient cholecystectomy simulated in an inpatient population.
Topics: Abdomen; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Analgesics; An | 1991 |
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male | 1990 |
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; D | 1991 |
Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.
Topics: Antiemetics; Cisplatin; Dexamethasone; Humans; Lorazepam; Metoclopramide; Nausea; Prospective Studie | 1991 |
Metoclopramide does not decrease the incidence of nausea and vomiting after alfentanil for outpatient anaesthesia.
Topics: Adult; Alfentanil; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; | 1991 |
Nausea and vomiting after termination of pregnancy as day surgery cases: comparison of 3 different doses of droperidol and metoclopramide as anti-emetic prophylaxis.
Topics: Abortion, Induced; Adult; Ambulatory Surgical Procedures; Dose-Response Relationship, Drug; Droperid | 1991 |
A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting.
Topics: Delayed-Action Preparations; Domperidone; Double-Blind Method; Female; Humans; Male; Metoclopramide; | 1991 |
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Injections, Intr | 1991 |
Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis.
Topics: Cisplatin; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Administration Schedule; Drug T | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Progress in the control of acute and delayed emesis induced by cisplatin.
Topics: Akathisia, Drug-Induced; Cisplatin; Dystonia; Humans; Imidazoles; Metoclopramide; Ondansetron; Serot | 1991 |
Effects of ondansetron on chemotherapy-induced acute and delayed emesis--a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biperiden; Cisplatin; Dexa | 1991 |
The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdominal Neoplasms; Adult; Aged; Antiemetics; Double-Blind Method; Humans; Imidazoles; Metocloprami | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Does propofol have an anti-emetic effect? A prospective study of the anti-emetic effect of propofol following laparoscopy.
Topics: Adult; Antiemetics; Blood Pressure; Female; Humans; Laparoscopy; Metoclopramide; Nausea; Postoperati | 1991 |
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Humans; Infusions, Intravenous; Metoclo | 1991 |
Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
Topics: Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Methyl | 1991 |
Low dose, oral lorazepam: a safe and effective adjuvant to antiemetic therapy.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemothera | 1991 |
Diphenhydramine for nausea and vomiting related to cancer chemotherapy with cisplatin.
Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Humans; Mal | 1991 |
Cinnarizine for prevention of nausea and vomiting during platin chemotherapy.
Topics: Adult; Aged; Carboplatin; Cinnarizine; Cisplatin; Combined Modality Therapy; Female; Humans; Lorazep | 1991 |
The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Drug Therapy, Comb | 1991 |
Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine. Randomized open parallel study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dexamethasone; Diphenhydramine; Droperidol; Drug The | 1991 |
A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis.
Topics: Adult; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 1991 |
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study.
Topics: Cisplatin; Dexamethasone; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Sex Factors; Vo | 1991 |
Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprazolam; Antineoplastic Combined Chemotherapy Protoco | 1991 |
High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Droperidol; Drug Therapy, Combination; Female; Humans; | 1991 |
Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients.
Topics: Activities of Daily Living; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethaso | 1991 |
[Antiemetic treatments associated with antineoplastic chemotherapy].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; | 1990 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dou | 1990 |
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazoles; Male; Metoclop | 1990 |
Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
Topics: Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Headache; Humans; Indazole | 1990 |
Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Diazepam; Diphenhydramine; Drug Therapy, Combination; Humans; | 1990 |
A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Evaluation; Female; Humans; Lorazep | 1990 |
Ginger root--a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Aged; Analgesics; Antiemetics; Double-Blind Method; Female; Genital Diseases, Fem | 1990 |
Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
Topics: Administration, Cutaneous; Cisplatin; Female; Genital Neoplasms, Female; Humans; Infusions, Intraven | 1990 |
Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methyl | 1990 |
Comparison of antiemetic activity of chloropromazine and high doses of metoclopramide in cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Drug Adminis | 1990 |
Metoclopramide reduces the incidence of vomiting following strabismus surgery in children.
Topics: Adolescent; Ambulatory Surgical Procedures; Child; Child, Preschool; Double-Blind Method; Humans; Me | 1990 |
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1989 |
Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting.
Topics: Acupuncture Points; Acupuncture Therapy; Adolescent; Adult; Anesthesia, General; Cyclizine; Electroa | 1989 |
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; D | 1989 |
Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study.
Topics: Adolescent; Adult; Aged; Antiemetics; Chlorpromazine; Cisplatin; Clinical Trials as Topic; Dexametha | 1989 |
Dose-ranging antiemetic trial of high-dose oral metoclopramide.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Clinical Trials as Topic; Diphenhydramine; Drug | 1989 |
Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone.
Topics: Adolescent; Antineoplastic Agents; Benztropine; Child; Child, Preschool; Chlorpromazine; Clinical Tr | 1989 |
Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Therapy, Combinat | 1989 |
[A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Clorazepate Dipotassium; Cosyntropin; Dexamethason | 1989 |
Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section.
Topics: Adult; Akathisia, Drug-Induced; Anesthesia, Epidural; Anesthesia, Obstetrical; Cesarean Section; Dou | 1989 |
The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1989 |
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
Topics: Age Factors; Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Drug Administration Schedule; D | 1989 |
Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; F | 1989 |
Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research.
Topics: Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolon | 1989 |
Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum?
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Diazepam; Double-Blind Method; Drug Evaluation; Dru | 1989 |
Effective control of moderate-dose cisplatin-induced emesis by a short-course regimen including metoclopramide, chlorpromazine and hydrocortisone: results of a randomized trial with metoclopramide alone.
Topics: Adolescent; Adult; Aged; Antiemetics; Chlorpromazine; Cisplatin; Drug Therapy, Combination; Female; | 1989 |
[Comparative study on the tolerance and efficacy of high doses of metoclopramide and clebopride in vomiting induced by cisplatin].
Topics: Adult; Aged; Antiemetics; Benzamides; Cisplatin; Drug Evaluation; Female; Humans; Male; Metocloprami | 1989 |
Betamethasone-dixyrazine combination versus high-dose metoclopramide as antiemetic treatment in doxorubicin and cisplatin chemotherapy.
Topics: Antiemetics; Betamethasone; Cisplatin; Double-Blind Method; Doxorubicin; Female; Humans; Male; Metoc | 1989 |
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dronabinol | 1988 |
[Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach].
Topics: Adult; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasm | 1988 |
Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Amnesia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lor | 1989 |
Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Infus | 1989 |
Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery.
Topics: Abdomen; Adult; Antiemetics; Clinical Trials as Topic; Domperidone; Droperidol; Female; Humans; Hyst | 1986 |
[Randomized controlled study of high-dose metoclopramide and dexamethasone in the prevention of CDDP-induced emesis].
Topics: Adult; Aged; Anorexia; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dr | 1986 |
A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dexameth | 1988 |
Betamethasone-dixyrazine versus metoclopramide as antiemetic treatment in cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Betamethasone; Clinical Trials as Topic; Double-Blind Method; Hu | 1988 |
A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; | 1988 |
[The effect of metoclopramide on postoperative nausea and vomiting].
Topics: Abortion, Therapeutic; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1988 |
Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost-effectiveness.
Topics: Cisplatin; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Infusions, Intravenous; Metoclop | 1987 |
[Effect of medical vagotomy on the CDDP induced nausea and vomiting evaluated by the chemotherapy-vomiting time (CV time)].
Topics: Acetaminophen; Adult; Cisplatin; Female; Humans; Metoclopramide; Middle Aged; Nausea; Ovarian Neopla | 1988 |
Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Diphenhydra | 1988 |
A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adolescent; Adult; Aged; Cisplatin; Clinical Trials as Topic; Costs and Cost Analysis; Female; Human | 1987 |
High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. A randomized double-blind study.
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; | 1987 |
Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dexamethasone; | 1987 |
A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1987 |
[Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as | 1987 |
High-dose metoclopramide and chlorpromazine in the treatment of cisplatin-induced emesis.
Topics: Adult; Aged; Chlorpromazine; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Kinetic | 1987 |
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
[A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1987 |
Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Diphenhydramine; Double-Blind Metho | 1987 |
Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen.
Topics: Administration, Cutaneous; Antiemetics; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; | 1987 |
High-dose metoclopramide by infusion: a double-blind study of plasma concentration-effect relationships in patients receiving cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doub | 1987 |
[The effect of metoclopramide, dexamethasone and antihistamine in the prevention of PAC chemotherapy-induced emesis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; D | 1988 |
High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma.
Topics: Adult; Aged; Cisplatin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Metoc | 1988 |
High-dose dexamethasone and high-dose metoclopramide versus high-dose dexamethasone and sulpiride in the management of cisplatin-induced emesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; | 1988 |
Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Female; Humans; Infusions, Intravenous; Injections, Intra | 1988 |
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1988 |
Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1986 |
[Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1986 |
Enhancement of the antiemetic action of metoclopramide against cisplatin-induced emesis by transdermal electrical nerve stimulation.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Electric Stimulation; Female; | 1986 |
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Do | 1986 |
Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone | 1986 |
The antiemetic efficacy of secobarbital and chlorpromazine compared to metoclopramide, diphenhydramine, and dexamethasone. A randomized trial.
Topics: Adult; Chlorpromazine; Cisplatin; Clinical Trials as Topic; Dexamethasone; Diphenhydramine; Drug Adm | 1986 |
The value of dexamethasone when added to combination drug therapy in the prevention of cisplatin-induced nausea and vomiting, evaluated by time-lapse video technology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dexamethasone; | 1986 |
Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following gynaecological surgery in day cases.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Clinical Trials as Topic; Dila | 1986 |
[Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy].
Topics: Aged; Cisplatin; Clinical Trials as Topic; Droperidol; Drug Therapy, Combination; Female; Humans; Lu | 1986 |
[The treatment of vomiting caused by the administration of cytostatic agents].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Loraz | 1986 |
Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
Topics: Antineoplastic Agents; Anxiety; Gastrointestinal Diseases; Humans; Methylprednisolone; Methylprednis | 1986 |
Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1987 |
High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis.
Topics: Cisplatin; Clinical Trials as Topic; Droperidol; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ma | 1986 |
Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Dru | 1987 |
Antiemetic therapy in patients treated with high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Cytarabine; Drug Therapy, | 1987 |
Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial.
Topics: Adult; Aged; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Methylpred | 1986 |
Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein.
Topics: Female; Fluorescein Angiography; Humans; Male; Metoclopramide; Middle Aged; Nausea; Vomiting | 1987 |
[Metoclopramide plus diphenhydramine compared with chlorpromazine in cisplatin-induced vomiting. Randomized, crossed and double-blind study].
Topics: Adult; Aged; Chlorpromazine; Cisplatin; Diphenhydramine; Double-Blind Method; Drug Therapy, Combinat | 1987 |
Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; C | 1987 |
[Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy].
Topics: Adult; Aged; Cisplatin; Droperidol; Drug Administration Schedule; Female; Humans; Male; Methylpredni | 1986 |
Antiemetic combination for cisplatin-induced emesis. Results from a controlled study.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Hum | 1986 |
Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae.
Topics: Adolescent; Adult; Droperidol; Drug Evaluation; Female; Humans; Intraoperative Care; Metoclopramide; | 1986 |
Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens.
Topics: Adult; Cisplatin; Female; Half-Life; Humans; Kinetics; Male; Metoclopramide; Middle Aged; Neoplasms; | 1986 |
Oral bioavailability of high-dose metoclopramide.
Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Half-Life; Humans; Kinetics; Metoclopra | 1986 |
Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Parenteral; Male; Metoclopramide; Middle Aged; Na | 1986 |
[Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy].
Topics: Aged; Cisplatin; Dexamethasone; Female; Humans; Lorazepam; Lung Neoplasms; Male; Metoclopramide; Mid | 1987 |
Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Double-Blind Method | 1986 |
The effect of administration rate on cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1985 |
[Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Metoc | 1985 |
The evaluation of domperidone and metoclopramide as antiemetics in day care abortion patients.
Topics: Abortion, Therapeutic; Adolescent; Adult; Anesthesia, General; Anesthesia, Obstetrical; Clinical Tri | 1985 |
Combination antiemetic therapy in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Ge | 1985 |
Comparative evaluation of two outpatient antiemetic regimens for cancer chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Humans; Metoclopramide; Nausea; Neop | 1985 |
Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1985 |
[Metoclopramide in the prevention of nausea and vomiting caused by cytostatics].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Mal | 1985 |
Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Age Factors; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; | 1985 |
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Cisplatin; Clinical Trials as | 1985 |
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
Topics: Chlorpromazine; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Injections | 1985 |
Comparison of the antiemetics metoclopramide and promethazine in labour.
Topics: Clinical Trials as Topic; Consciousness; Double-Blind Method; Female; Humans; Meperidine; Metoclopra | 1985 |
Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis.
Topics: Adult; Aged; Cisplatin; Diuresis; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Male; | 1985 |
[Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis].
Topics: Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Metoclopramide; Middle Aged; Nausea; | 1986 |
[Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
Topics: Cisplatin; Dose-Response Relationship, Drug; Haloperidol; Humans; Metoclopramide; Neoplasms; Risk; T | 1985 |
The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Me | 1985 |
Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide.
Topics: Adult; Cisplatin; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Humans; Male; Met | 1985 |
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Metoclopramid | 1985 |
Studies of drugs given before anaesthesia. XXII: Metoclopramide.
Topics: Adult; Blood Pressure; Consciousness; Diazepam; Gastrointestinal Motility; Humans; Hypnotics and Sed | 1974 |
Flatulent dyspepsia.
Topics: Clinical Trials as Topic; Dyspepsia; Female; Flatulence; Gastroesophageal Reflux; Heartburn; Humans; | 1973 |
An evaluation of metoclopramide as an anti-emetic in seasickness.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clinical Trials as Topic; Female; Humans; Hypnotics a | 1973 |
The effect of intra-muscular metoclopramide on gastric emptying during labour.
Topics: Anesthesia, Obstetrical; Clinical Trials as Topic; Female; Gastrointestinal Motility; Humans; Inject | 1973 |
The anti-emetic effect of metoclopramide with an account of some experiments to assess the effect of the drug on gastric emptying in early labour.
Topics: Anesthesia, Obstetrical; Female; Gastrointestinal Motility; Humans; Inhalation; Labor, Obstetric; Me | 1973 |
276 other studies available for metoclopramide and Emesis
| Article | Year |
|---|---|
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
Topics: Animals; Antiemetics; Benzamides; Benzofurans; Binding, Competitive; Bridged Bicyclo Compounds; Brid | 1992 |
Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
Topics: Amides; Animals; Antiemetics; Benzamides; Benzofurans; Bridged Bicyclo Compounds; Bridged Bicyclo Co | 1992 |
Extrapyramidal signs following a single intravenous dose of metoclopramide in an English Bulldog.
Topics: Administration, Intravenous; Animals; Antiemetics; Basal Ganglia Diseases; Dog Diseases; Dogs; Metoc | 2021 |
GC-MS analysis of organic fractions of Chrozophora tinctoria (L.) A.Juss. and their prokinetic propensity in animal models.
Topics: Acetylcholinesterase; Animals; Anti-Bacterial Agents; Antifungal Agents; Antioxidants; Dimenhydrinat | 2022 |
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Biperiden; Clonazepam; Dopamine; Humans; M | 2022 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Metoclopramide-induced acute dystonic reaction: A pediatric case report.
Topics: Child; Dyskinesias; Humans; Male; Metoclopramide; Torticollis; Vomiting; Whooping Cough | 2023 |
Comparison of metoclopramide and promethazine for the treatment of postoperative nausea and vomiting in the post-anesthesia care unit: A retrospective database analysis.
Topics: Anesthesia; Antiemetics; Double-Blind Method; Humans; Metoclopramide; Ondansetron; Postoperative Nau | 2020 |
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.
Topics: Antiemetics; Humans; Male; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.
Topics: Antiemetics; Double-Blind Method; Humans; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Ondansetron use in early pregnancy and the risk of miscarriage.
Topics: Abortion, Spontaneous; Antiemetics; Female; Humans; Metoclopramide; Ondansetron; Pregnancy; Vomiting | 2021 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Controversies in Gastroparesis: Discussing the Sticky Points.
Topics: Abdominal Pain; Antiemetics; Chronic Disease; Diabetes Complications; Diagnosis, Differential; Diagn | 2021 |
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Female; Humans; M | 2019 |
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice.
Topics: Adrenal Cortex Hormones; Adult; Analgesics, Opioid; Antiemetics; Antipsychotic Agents; Cross-Section | 2019 |
Intractable Vomiting in a 20-Month-Old Boy.
Topics: Antiemetics; Drug Resistance; Failure to Thrive; Gastric Outlet Obstruction; Gastroscopy; Humans; In | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository.
Topics: Administration, Rectal; Animals; Antiemetics; Delayed-Action Preparations; Dopamine Antagonists; Dru | 2013 |
Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
Topics: Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 2013 |
Long-lasting adverse effects after short-term low-dose treatment with metoclopramide for vomiting.
Topics: Adult; Antiemetics; Diphenhydramine; Dyskinesias; Female; Gastroenteritis; Humans; Injections, Intra | 2014 |
Confidence-interval construction for rate ratio in matched-pair studies with incomplete data.
Topics: Antiemetics; Clinical Trials as Topic; Confidence Intervals; Humans; Likelihood Functions; Matched-P | 2014 |
Managing reflux in infants: lifestyle modifications or medications?
Topics: Antiemetics; Child Development; Disease Management; Esophagitis, Peptic; Gastroesophageal Reflux; Hi | 2014 |
Does Braun enteroenterostomy reduce delayed gastric emptying after pancreaticoduodenectomy?
Topics: Abdominal Abscess; Acupuncture; Anastomotic Leak; Antiemetics; Domperidone; Enterostomy; Erythromyci | 2014 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
Topics: Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Nausea; Ondansetron; | 2014 |
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Chemoprevention; Domperidone; Health Care Surveys; | 2015 |
[Phytotherapy for control of nausea and vomiting].
Topics: Drug Recalls; Drug Substitution; Humans; Metoclopramide; Nausea; Phytotherapy; Plant Extracts; Plant | 2015 |
Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study.
Topics: Ambulances; Antiemetics; Emergency Medical Services; Female; Humans; Male; Metoclopramide; Nausea; O | 2016 |
Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lora | 2016 |
Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
Topics: Adult; Antiemetics; Emergency Service, Hospital; Female; Humans; Logistic Models; Male; Metocloprami | 2016 |
Emergency department management of gastro-enteritis in Australia and New Zealand.
Topics: Acute Disease; Antiemetics; Australia; Data Collection; Dehydration; Diarrhea; Emergency Medicine; E | 2008 |
Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antiemetics; Disease Mo | 2008 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
The safety of metoclopramide use in the first trimester of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cohort Studies; Female; Fetus; Humans; Infant, Low Birth W | 2009 |
Circulatory collapse in a patient with gastrinoma after metoclopramide administration.
Topics: Adolescent; Dopamine Antagonists; Gastrinoma; Humans; Male; Metoclopramide; Nausea; Pancreatic Neopl | 2009 |
Nausea and vomiting in advanced cancer.
Topics: Algorithms; Antiemetics; Causality; Decision Trees; Drug Therapy, Combination; Evidence-Based Medici | 2010 |
Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Health Care Surveys; Humans | 2011 |
Effects of metoclopramide on emesis in cats sedated with xylazine hydrochloride.
Topics: Animals; Antiemetics; Cat Diseases; Cats; Female; Hypnotics and Sedatives; Male; Metoclopramide; Sod | 2010 |
Methylprednisolone reduces postoperative nausea in total knee and hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Arthroplasty, Replacement, Hip; Arthroplasty, Replaceme | 2010 |
Comparison the effects of metoclopramide and dropridol associated with dexamethasone on post operative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Antiemetics; Dexamethasone; Droperidol; Female; Humans; Male; Metoclopramid | 2010 |
Treatment and assessment of emergency department nausea and vomiting in Australasia: a survey of anti-emetic management.
Topics: Antiemetics; Australia; Clinical Protocols; Cross-Sectional Studies; Dopamine Antagonists; Emergency | 2011 |
Type I Brugada electrocardiogram pattern induced by metoclopramide.
Topics: Brugada Syndrome; Dizziness; Dopamine Antagonists; Flecainide; Humans; Male; Metoclopramide; Middle | 2011 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Tolerance to enteral nutrition therapy in traumatic brain injury patients.
Topics: Adult; Aged; Antiemetics; Brain Injuries; Cross-Sectional Studies; Domperidone; Enteral Nutrition; E | 2012 |
Hypoglossal nerve palsy after extensive vomiting.
Topics: Adult; Antiemetics; Early Diagnosis; Female; Humans; Hypoglossal Nerve Diseases; Hypoglossal Nerve I | 2012 |
Conservative management in a rare case of spontaneous bilateral cerebellar haemorrhage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetazolamide; Adult; Antiemetics; Cerebellum; Diuretics, O | 2012 |
Antiemetics for acute gastroenteritis-related vomiting in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Dimenhydrinate; Gastroenteritis; Humans; Metocloprami | 2012 |
Impact of data by Fujii and colleagues on the meta-analysis of metoclopramide for antiemetic prophylaxis in women undergoing Caesarean delivery under neuraxial anaesthesia.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Female; Humans; Intraope | 2012 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Metoclopramide-induced supersensitivity psychosis.
Topics: Aged; Antiemetics; Antipsychotic Agents; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Hallucina | 2002 |
Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study.
Topics: Adolescent; Adult; Antiemetics; Brazil; Canada; Case-Control Studies; Congenital Abnormalities; Dopa | 2002 |
Low incidence of nausea and vomiting with intravenous opiate analgesia in the ED.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Em | 2002 |
[A new vomiting animal model--mink].
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper Sulfate; Disease Models, Animal; Male; Metoclop | 2003 |
[With evidence-based phytotherapy. Takes away gastric and intestinal irritation].
Topics: Antiemetics; Cisapride; Clinical Trials as Topic; Dopamine Antagonists; Evidence-Based Medicine; Gas | 2003 |
Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Butanols; Capsaicin; Cyclooxygenase Inhibitors; Dihydroergotamine; Diphenhydra | 2005 |
Tolerability of the compound ABHR in hospice patients.
Topics: Aged; Antiemetics; Cohort Studies; Diphenhydramine; Drug Combinations; Female; Haloperidol; Hospice | 2005 |
Value of mink vomit model in study of anti-emetic drugs.
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper Sulfate; Disease Models, Animal; Enterochromaff | 2006 |
Anaphylaxis during treatment of nausea and vomiting: IgE-mediated metoclopramide allergy.
Topics: Adult; Anaphylaxis; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Immunoglobulin E | 2006 |
A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.
Topics: Adolescent; Antiemetics; Diphenhydramine; Dopamine Antagonists; Dystonia; Female; Fundoplication; Hi | 2006 |
Please treat me with metoclopramide.
Topics: Adult; Antiemetics; Humans; Male; Metoclopramide; Patient Participation; Pyloric Stenosis; Treatment | 2007 |
Metoclopramide: extrapyramidal symptoms in children.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Child; Humans; Metoclopramide; Nausea; Netherlands; Vo | 2007 |
Antiemetics.
Topics: Age Factors; Aged; Antiemetics; Cisplatin; Dronabinol; Humans; Metoclopramide; Vomiting | 1984 |
Can metoclopramide reveal Huntington's disease?
Topics: Adolescent; Female; Humans; Huntington Disease; Male; Metoclopramide; Pedigree; Suppositories; Vomit | 1982 |
Management of chemotherapy-induced nausea and emesis.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Butyrophenones; Cannabinoids; Histamine | 1983 |
[Vomiting accompanying cytostatic treatment, and its control].
Topics: Antiemetics; Antineoplastic Agents; Dronabinol; Drug Evaluation; Histamine H1 Antagonists; Humans; M | 1984 |
[Pharmacotherapy of emesis caused by cytostatic agents].
Topics: Antiemetics; Antineoplastic Agents; Domperidone; Dronabinol; Humans; Metoclopramide; Phenothiazines; | 1982 |
[Is there a proven methods for the prevention of cytostatic-induced vomiting?].
Topics: Antiemetics; Appetite; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Humans; Metoclopramide | 1982 |
An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting.
Topics: Adult; Antiemetics; Dronabinol; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Radiother | 1984 |
Antiemetics and cytotoxic drugs.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Metoclopramide; Premedication; Vomiting | 1983 |
Antiemetics and cytotoxic drugs.
Topics: Cisplatin; Humans; Metoclopramide; Vomiting | 1983 |
Antiemetics and cytotoxic drugs.
Topics: Adult; Antiemetics; Cisplatin; Humans; Metoclopramide; Vomiting | 1983 |
Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1984 |
Combination metoclopramide and dexamethasone: an effective antiemetic regimen in outpatients receiving non-cisplatin chemotherapy.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Ad | 1984 |
[A new solution for orthograde intestinal lavage].
Topics: Colonic Diseases; Humans; Intubation, Gastrointestinal; Metoclopramide; Nausea; Polyethylene Glycols | 1984 |
Control of cancer chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Butyrophenones; Cannabinoids; Drug Therapy, Combination; Glucocorticoids; Hum | 1984 |
Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting.
Topics: Adolescent; Adult; Antineoplastic Agents; Humans; Infusions, Parenteral; Kinetics; Metoclopramide; M | 1984 |
Optimizing metoclopramide control of cisplatin-induced emesis.
Topics: Adult; Aged; Body Weight; Chromatography, High Pressure Liquid; Cisplatin; Diarrhea; Drug Administra | 1984 |
Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide.
Topics: Administration, Oral; Adult; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1984 |
Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diazepam; Dip | 1984 |
[Metoclopramide plasma levels following oral administration of high doses for prophylaxis of emesis in cytostatic therapy].
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Metoclopramide; Vomiting | 1984 |
Metoclopramide: a brief review.
Topics: Drug Interactions; Humans; Metoclopramide; Nausea; Vomiting | 1983 |
Metoclopramide therapy for chemotherapy -- induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Nausea; Vomiting | 1983 |
Pharmacist on call: I.V. metoclopramide--relief for cancer chemotherapy patients.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Vomiting | 1984 |
[Primperan].
Topics: Adult; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Metoclopramide; Vomiting | 1984 |
Metoclopramide.
Topics: Animals; Atropine; Cat Diseases; Cats; Central Nervous System; Digestive System; Dog Diseases; Dogs; | 1983 |
[Emesis due to cytostatic drugs. Update and review of our experiences].
Topics: Antineoplastic Agents; Dexamethasone; Haloperidol; Humans; Metoclopramide; Prochlorperazine; Vomitin | 1983 |
Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Dystonia; Female; Humans; Male; Metoclopramide; Nau | 1984 |
Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation.
Topics: Antineoplastic Agents; Diarrhea; Drug Administration Schedule; Drug Evaluation; Humans; Infusions, P | 1984 |
Gastric emptying in patients with diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Food; Gastric Emptying; Humans; Male; Metoclopramide; Midd | 1984 |
[New aspects in the antiemetic therapy of cytostatic drug-induced vomiting].
Topics: Antiemetics; Antineoplastic Agents; Cannabinoids; Chemoreceptor Cells; Dose-Response Relationship, D | 1984 |
Chronic intestinal pseudo-obstruction.
Topics: Adult; Aged; Celiac Disease; Chronic Disease; Female; Humans; Intestinal Obstruction; Intestinal Pse | 1981 |
High dose metoclopramide as an antiemetic for patients receiving chemotherapy with cis-platinum.
Topics: Adult; Cisplatin; Drug Evaluation; Humans; Metoclopramide; Nausea; Neoplasms; Vomiting | 1982 |
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Male; Melanoma; Metoclopramide; Middle Aged; Mycobacteriu | 1980 |
Enhanced gastroduodenal motility in children.
Topics: Adolescent; Child; Child, Preschool; Diabetic Neuropathies; Gastrointestinal Motility; Humans; Infan | 1982 |
Metoclopramide (Reglan).
Topics: Antineoplastic Agents; Drug Interactions; Gastric Emptying; Humans; Metoclopramide; Vomiting | 1982 |
Acute dystonic reaction to Maxolon (metoclopramide)
Topics: Child; Female; Humans; Metoclopramide; Muscle Cramp; Torticollis; Vomiting | 1982 |
High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Vomiting | 1982 |
High-dose metoclopramide: control of dacarbazine-induced emesis in a preliminary trial.
Topics: Adult; Aged; Dacarbazine; Humans; Metoclopramide; Middle Aged; Vomiting | 1982 |
[High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Therapy, Combination; Female; | 1982 |
Cisplatin-induced emesis in the Ferret: a new animal model.
Topics: Animals; Carnivora; Castration; Cisplatin; Disease Models, Animal; Ferrets; Male; Metoclopramide; Vo | 1982 |
A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma.
Topics: Antineoplastic Agents; Cisplatin; Droperidol; Drug Therapy, Combination; Female; Humans; Metoclopram | 1981 |
Experimental study on bromopride pharmacology in vivo. antiemetic activity, effects on intestinal transit, on bloating and on gastric ulcers; basal effects on CNS and interferences with the spontaneous motor activity.
Topics: Animals; Antiemetics; Central Nervous System; Dogs; Female; Gastric Emptying; Male; Metoclopramide; | 1980 |
High-dose metoclopramide for chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Nausea; Vomiting | 1981 |
[Acetonemic vomiting. Treatment and prevention of recurrence].
Topics: Acetone; Child; Humans; Metoclopramide; Recurrence; Vomiting | 1980 |
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Droperi | 1995 |
Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Child; Female; Humans; | 1995 |
Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.
Topics: Adult; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Hydroxyindoleacet | 1993 |
Ondansetron or metoclopramide in children undergoing tonsillectomy.
Topics: Child; Humans; Metoclopramide; Ondansetron; Tonsillectomy; Vomiting | 1995 |
Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
Topics: Animals; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; | 1994 |
Re-examination of clinical aspects of pharmacoeconomic analysis.
Topics: Antineoplastic Agents; Economics, Pharmaceutical; Humans; Metoclopramide; Ondansetron; Pharmacology, | 1994 |
On the relationship between nausea and vomiting in patients undergoing chemotherapy. Italian Group for Antiemetic Research.
Topics: Antiemetics; Cisplatin; Confounding Factors, Epidemiologic; Dexamethasone; Diphenhydramine; Factor A | 1994 |
Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Humans; Indo | 1994 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Metocloprami | 1994 |
Effective control of cisplatin induced emesis by combination drug regimen.
Topics: Adult; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Combinations; Female; Follow-Up | 1994 |
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Topics: Adult; Cisplatin; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Metoclopramide; Na | 1994 |
Cost-effectiveness, not cost containment.
Topics: Cisplatin; Cost Control; Cost-Benefit Analysis; Drug Evaluation; Humans; Metoclopramide; Nausea; Ond | 1994 |
Effects of cholinoceptor and 5-hydroxytryptamine3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis.
Topics: Animals; Atropine; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; C | 1993 |
The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis.
Topics: Administration, Oral; Animals; Antiemetics; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, He | 1993 |
Antiemetic-induced akathisia in cancer patients receiving chemotherapy.
Topics: Akathisia, Drug-Induced; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male; Met | 1994 |
[Prokinetic drugs in digestive disorders].
Topics: Antineoplastic Agents; Cisapride; Domperidone; Esophageal Motility Disorders; Gastroesophageal Reflu | 1993 |
The effects of different antiemetic agents on morphine-induced emesis in ferrets.
Topics: Anesthesia; Animals; Antiemetics; Droperidol; Ferrets; Granisetron; Injections, Intravenous; Isoflur | 1993 |
Ondansetron versus metoclopramide and droperidol: an unfair comparison.
Topics: Anesthesiology; Droperidol; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications | 1993 |
Drugs for vomiting caused by cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Humans; Metoclopramide; Ondansetron; Vomiting | 1993 |
Gastroparesis: an important cause of hospitalization in continuous ambulatory peritoneal dialysis patients and the role of erythromycin.
Topics: Cisapride; Diabetes Mellitus, Type 1; Erythromycin; Female; Gastric Emptying; Hospitalization; Human | 1993 |
Adverse drug reaction to metoclopramide hydrochloride in a macaw with proventricular dilatation syndrome.
Topics: Animals; Bird Diseases; Dilatation, Pathologic; Diphenhydramine; Female; Metoclopramide; Nervous Sys | 1993 |
Potential for combination therapy with the new antiserotonergic agents.
Topics: Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1993 |
Bionursing: the management of migraine and vomiting.
Topics: Aged; Antiemetics; Female; Humans; Methysergide; Metoclopramide; Migraine Disorders; Occupational He | 1996 |
Adverse reactions to metoclopramide (Reglan) presenting as depression in a bone marrow transplant patient.
Topics: Adult; Akathisia, Drug-Induced; Antiemetics; Antineoplastic Agents; Bone Marrow Transplantation; Dep | 1995 |
Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine.
Topics: Adult; Analgesia, Epidural; Analgesics, Opioid; Anesthesia, Epidural; Anesthetics, Local; Antiemetic | 1996 |
Metoclopramide in trauma CT scanning: preventing emesis of oral radiographic contrast.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Contrast Media; Glasg | 1996 |
Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs.
Topics: Animals; Antiemetics; Apomorphine; Benzamides; Benzyl Compounds; Dogs; Domperidone; Dopamine Antagon | 1996 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Suspected herbicide toxicosis in a dog.
Topics: 2-Methyl-4-chlorophenoxyacetic Acid; Abdominal Pain; Animals; Anorexia; Antidotes; Antiemetics; Atax | 1996 |
Can vomiting after squint surgery be prevented?
Topics: Adult; Antiemetics; Child, Preschool; Female; Humans; Male; Metoclopramide; Ondansetron; Postoperati | 1997 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Droperidol; Drug Therapy, Combination; Humans; Metoclopr | 1997 |
Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Granisetron; Humans; Injections, Intraven | 1997 |
Biphasic emetic response of cyclophosphamide in the ferret.
Topics: Animals; Antiemetics; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dose-Response Relationshi | 1997 |
Correct choice of anti-emetic.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1997 |
Ondansetron compared with metoclopramide in the treatment of PONV.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative C | 1998 |
Respiratory failure following oral administration of metoclopramide.
Topics: Administration, Oral; Adult; Antiemetics; Female; Humans; Metoclopramide; Nausea; Respiratory Insuff | 1998 |
An audit of antiemetic use with CMF chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1998 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Metoclopramide and acute porphyria.
Topics: Antiemetics; Humans; Metoclopramide; Porphyria, Acute Intermittent; Vomiting | 1997 |
Gastroesophageal reflux and pulmonary complication in a neonate.
Topics: Antiemetics; Apnea; Cisapride; Follow-Up Studies; Gastroesophageal Reflux; Gastrointestinal Agents; | 1998 |
Use of placebos in delayed-emesis studies.
Topics: Antiemetics; Dexamethasone; Humans; Metoclopramide; Neurokinin-1 Receptor Antagonists; Vomiting | 1999 |
Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Topics: Adult; Antiemetics; Domperidone; Drug Administration Schedule; Female; Humans; Incidence; Indoles; M | 1999 |
Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist.
Topics: Acetals; Antiemetics; Aprepitant; Cisplatin; Dexamethasone; Humans; Metoclopramide; Morpholines; Neu | 1999 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Huma | 2000 |
Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.
Topics: Acute Disease; Age Factors; Antiemetics; Antineoplastic Agents; Body Weights and Measures; Chlorprom | 2000 |
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
Topics: Aged; Antiemetics; Humans; Iloprost; Infusions, Intravenous; Male; Metoclopramide; Nausea; Ondansetr | 2001 |
[Pheochromocytoma with severe paralytic ileus occurred from acute pulmonary edema caused by metoclopramide].
Topics: Adrenal Gland Neoplasms; Adult; Antiemetics; Female; Humans; Intestinal Pseudo-Obstruction; Metoclop | 2001 |
An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Dexamet | 2002 |
Diseases of the alimentary system; Nausea and vomiting.
Topics: Antiemetics; Female; Histamine H1 Antagonists; Humans; Metoclopramide; Motion Sickness; Nausea; Phen | 1976 |
Metoclopramide and renal failure.
Topics: Dystonia Musculorum Deformans; Humans; Metoclopramide; Uremia; Vomiting | 1979 |
Chlorpromazine, lithium, and metoclopramide: unrecognised synergistic and antagonistic effects.
Topics: Adult; Antiemetics; Bipolar Disorder; Chlorpromazine; Drug Antagonism; Drug Synergism; Female; Human | 1979 |
Antagonism of cisplatin induced emesis in the dog.
Topics: Animals; Antiemetics; Chlorpromazine; Cisplatin; Dogs; Dronabinol; Female; Haloperidol; Indoles; Mal | 1979 |
A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man.
Topics: Cisplatin; Humans; Metoclopramide; Vomiting | 1978 |
Metoclopramide in young children.
Topics: Child, Preschool; Dystonia; Humans; Infant; Metoclopramide; Vomiting | 1978 |
[Present status of Primperan in the surgical milieu].
Topics: Digestion; Humans; Metoclopramide; Postoperative Complications; Preanesthetic Medication; Vomiting | 1976 |
Pharmacological studies of caerulein. II. The possibility of mediation through the central nervous system.
Topics: Animals; Apomorphine; Atropine; Blood Pressure; Central Nervous System; Ceruletide; Chlorpromazine; | 1975 |
Letter: Metoclopramide therapy following Ramstedt pyloromyotomy.
Topics: Humans; Infant, Newborn; Male; Metoclopramide; Postoperative Care; Pyloric Stenosis; Pylorus; Vomiti | 1975 |
Clinical studies with dopamine-receptor stimulants.
Topics: Adult; Apomorphine; Blood Pressure; Dopamine; Female; Hallucinations; Humans; Male; Metoclopramide; | 1975 |
[L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
Topics: Aged; Drug Combinations; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Nausea; Parkin | 1976 |
Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism.
Topics: Adult; Apomorphine; Drug Therapy, Combination; Haloperidol; Humans; Male; Metoclopramide; Parkinson | 1976 |
Diphenhydramine for nausea and vomiting related to cancer chemotherapy with cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Combination; Female; Humans; M | 1992 |
Control of cisplatin induced emesis--a multidisciplinary intervention strategy.
Topics: Adult; Aged; Biperiden; Cisplatin; Female; Humans; Lorazepam; Metoclopramide; Middle Aged; Nausea; O | 1992 |
Prevention of cisplatin-induced emesis. The Italian Group for Antiemetic Research.
Topics: Cisplatin; Humans; Metoclopramide; Vomiting | 1992 |
Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs.
Topics: Afferent Pathways; Animals; Cisplatin; Dogs; Female; Indoles; Male; Metoclopramide; Receptors, Serot | 1992 |
Tardive dyskinesia associated with use of metoclopramide in a child.
Topics: Child, Preschool; Chronic Disease; Combined Modality Therapy; Drug Therapy, Combination; Dyskinesia, | 1992 |
Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
Topics: Animals; Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic | 1992 |
Postoperative nausea and vomiting in day-case surgery.
Topics: Ambulatory Surgical Procedures; Child; Droperidol; Female; Humans; Male; Metoclopramide; Nausea; Pos | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy.
Topics: Adenocarcinoma; Antiemetics; Female; Humans; Metoclopramide; Middle Aged; Nausea; Neuroleptic Malign | 1992 |
Management of theophylline overdose patients in the intensive care unit.
Topics: Absorption; Adolescent; Adult; Arrhythmias, Cardiac; Charcoal; Critical Care; Drug Overdose; Female; | 1992 |
[Control of cisplatin-induced delayed emesis].
Topics: Cisplatin; Dexamethasone; Female; Humans; Metoclopramide; Time Factors; Vomiting | 1991 |
Acute and delayed emesis after cisplatin-based regimen: description and prevention.
Topics: Acute Disease; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lora | 1991 |
Antiemetic efficacy of alprazolam in carboplatin-induced emesis.
Topics: Administration, Oral; Aged; Alprazolam; Carboplatin; Drug Therapy, Combination; Female; Humans; Infu | 1991 |
Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.
Topics: Animals; Antiemetics; Benzimidazoles; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocy | 1991 |
[Improved control of cisplatin-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam].
Topics: Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lorazepam; Metoclopramide; Vomi | 1991 |
Serotonin antagonists: a new class of antiemetic agents.
Topics: Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Granise | 1991 |
General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride.
Topics: Animals; Apomorphine; Bethanechol Compounds; Cisapride; Conditioning, Operant; Diarrhea; Dogs; Gastr | 1991 |
Compounding nausea aid.
Topics: Benztropine; Chemistry, Pharmaceutical; Dexamethasone; Diphenhydramine; Drug Combinations; Drug Comp | 1991 |
Vomiting and chemotherapy.
Topics: Adult; Age Factors; Antiemetics; Child; Cisplatin; Humans; Metoclopramide; Middle Aged; Vomiting | 1990 |
The actions of fenfluramine and interaction with 5-HT3 receptor-antagonists to inhibit emesis in the ferret.
Topics: Animals; Antiemetics; Cisplatin; Fenclonine; Fenfluramine; Ferrets; Indoles; Male; Metoclopramide; R | 1990 |
Familial dyskinesia following single dose metoclopramide.
Topics: Adult; Diet, Vegetarian; Dyskinesia, Drug-Induced; Female; Humans; Male; Metoclopramide; Middle Aged | 1990 |
[Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 1990 |
Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret.
Topics: Administration, Oral; Animals; Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo C | 1990 |
[A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis].
Topics: Administration, Oral; Adult; Aged; Alprazolam; Antineoplastic Combined Chemotherapy Protocols; Carci | 1990 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diphenhydramine; Drug Eval | 1990 |
A nursing narrative.
Topics: Acute Disease; Adult; Humans; Male; Metoclopramide; Nausea; Pancreatitis; Seizures; Vomiting | 1990 |
The neuroleptic malignant syndrome.
Topics: Adult; Female; Haloperidol; Humans; Metoclopramide; Neuroleptic Malignant Syndrome; Postoperative Co | 1990 |
Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Droperidol; Evaluation Studies as Topic; Huma | 1990 |
[Trial with a new anti-nausea regime].
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Humans; Metoclopramide | 1990 |
Combination metoclopramide and diphenhydramine short infusion for prevention of chemotherapy-induced emesis.
Topics: Diphenhydramine; Drug Therapy, Combination; Humans; Metoclopramide; Vomiting | 1990 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and acupuncture in women treated with cisplatin.
Topics: Acupuncture Therapy; Adult; Aged; Cisplatin; Combined Modality Therapy; Dexamethasone; Diphenhydrami | 1990 |
Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret.
Topics: Animals; Antiemetics; Behavior, Animal; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compo | 1990 |
Prevention of cisplatin-induced vomiting in patients with cancer. A pilot study with a multiagent protocol.
Topics: Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Neoplasms; Pilot Project | 1990 |
[Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting].
Topics: Adult; Antiemetics; Cisplatin; Clonazepam; Dexamethasone; Diphenhydramine; Female; Humans; Metoclopr | 1990 |
[Intrapleural administration of CDDP against malignant pleural effusions in breast cancer].
Topics: Aged; Breast Neoplasms; Cisplatin; Female; Humans; Hydrocortisone; Infusions, Intravenous; Mastectom | 1990 |
Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Metoclopramide; Nausea; Neoplas | 1989 |
[Antiemetic efficacy of betamethasone versus betamethasone combined with metoclopramide in cisplatin-treated cancer patients].
Topics: Adult; Aged; Antiemetics; Betamethasone; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Fema | 1989 |
[Management of vomiting induced by polychemotherapy in Hodgkin's disease].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Halop | 1989 |
[The antiemetic effect and clinical evaluation of metoclopramide alone and combined with betamethasone in children with malignant tumor].
Topics: Adolescent; Adrenal Cortex; Antineoplastic Agents; Betamethasone; Child; Child, Preschool; Drug Eval | 1989 |
Hormonal responses of metoclopramide-treated subjects experiencing nausea or emesis during parabolic flight.
Topics: Adrenocorticotropic Hormone; Adult; Arginine Vasopressin; Epinephrine; Humans; Metoclopramide; Motio | 1987 |
Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge.
Topics: Adolescent; Adrenocorticotropic Hormone; Arginine Vasopressin; Child, Preschool; Clonidine; Dinopros | 1988 |
Treatment of common minor ailments.
Topics: Acetaminophen; Antacids; Antiemetics; Aspirin; Dyspepsia; Female; Heartburn; Histamine H1 Antagonist | 1986 |
[Emesis induced by cisplatin and sulfato-1, sulfato-1,2-diaminocyclohexane platinum in dogs and their antiemetics].
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Diphenhydramine; Dogs; Drug Therapy, Combina | 1986 |
BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Cyclophosphamide; Dogs; Doxorubicin; Female; Ferrets; | 1988 |
The use of metoclopramide in treatment of cisplatin-induced emesis.
Topics: Cisplatin; Humans; Metoclopramide; Vomiting | 1986 |
The action of dazopride to enhance gastric emptying and block emesis.
Topics: Animals; Benzamides; Callitrichinae; Dopamine Antagonists; Electric Stimulation; Ferrets; Gastric Em | 1987 |
[Effect of metoclopramide in a subject at risk for Huntington's chorea].
Topics: Adolescent; Female; Humans; Huntington Disease; Metoclopramide; Pedigree; Risk; Vomiting | 1985 |
[Metoclopramide].
Topics: Humans; Metoclopramide; Vomiting | 1988 |
Domperidone: an alternative to metoclopramide.
Topics: Acute Disease; Adolescent; Adult; Child; Domperidone; Humans; Metoclopramide; Nausea; Vomiting | 1988 |
Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.
Topics: Animals; Antineoplastic Agents; Apomorphine; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Ci | 1987 |
The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret.
Topics: Animals; Antiemetics; Apomorphine; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Carnivora; C | 1988 |
Managing chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Infusions, Parenteral; Injections, Subcutaneous; Metoclopramide; Vomi | 1988 |
Silent regurgitation in day case gynaecological patients.
Topics: Adult; Ambulatory Surgical Procedures; Female; Gastroesophageal Reflux; Genital Diseases, Female; Hu | 1988 |
Emesis and cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans | 1988 |
Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin.
Topics: Adolescent; Adult; Age Factors; Aged; Cisplatin; Diphenhydramine; Female; Humans; Male; Metocloprami | 1988 |
Combination of glucagon and low-dose metoclopramide in management of cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Drug Therapy, Combination; Glucagon; Humans; Metoclopramide; Nausea; Vomiting | 1988 |
[Antiemetic efficacy of high-dose metoclopramide, diphenhydramine, methylprednisolone and diazepam on chemotherapy-induced emesis in gynecological malignancy].
Topics: Adult; Aged; Cisplatin; Diazepam; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neopla | 1988 |
Effects of preoperative metoclopramide and droperidol on postoperative nausea and vomiting in ambulatory surgery patients.
Topics: Adult; Ambulatory Surgical Procedures; Droperidol; Female; Humans; Metoclopramide; Nausea; Postopera | 1988 |
[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dex | 1987 |
[Metoclopramide, methylprednisolone and flunitrazepam in cytostatic-induced vomiting].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Flun | 1987 |
Safety and antiemetic effects of metoclopramide in metrizamide myelography.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Metoclopramide; Metrizamide; Myelography; Nausea; | 1987 |
Treatment of pseudopregnancy with bromocriptin, an ergot alkaloid.
Topics: Animals; Bromocriptine; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Lactation; Metoclopra | 1986 |
A comparison of metoclopramide vs. droperidol/phenobarbital for emesis induced by chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Droperido | 1987 |
Administration of metoclopramide for prevention of nausea and vomiting during epidural anesthesia for elective cesarean section.
Topics: Anesthesia, Epidural; Cesarean Section; Female; Fentanyl; Gestational Age; Humans; Metoclopramide; M | 1987 |
Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Cisplatin; Dose-Response Relationship, Drug; Humans | 1986 |
[Effectiveness of high-dose metoclopramide in the control of acute emesis induced by chemotherapy].
Topics: Antineoplastic Agents; Humans; Metoclopramide; Vomiting | 1987 |
Vomiting after ophthalmic surgery. Effects of intra-operative antiemetics and postoperative oral fluid restriction.
Topics: Adult; Antiemetics; Drinking; Droperidol; Female; Humans; Male; Metoclopramide; Middle Aged; Ophthal | 1987 |
Evaluation of ethanol as an antiemetic in patients receiving cisplatin.
Topics: Cisplatin; Ethanol; Female; Humans; Infusions, Intravenous; Male; Metoclopramide; Nausea; Neoplasms; | 1987 |
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1987 |
Metoclopramide-induced neuroleptic malignant syndrome.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Metoclopramide; Nausea; Neuroleptic Malignant Synd | 1987 |
Efficacy of continuous high-dose metoclopramide in patients receiving daily cisplatin infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 1987 |
Prochlorperazine and vomiting after eye surgery.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Droperidol; Drug Therapy, Combination; Humans; Inf | 1987 |
Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, efficacy, patient preference, and cost reduction.
Topics: Cisplatin; Humans; Infusions, Intravenous; Metoclopramide; Nausea; Neoplasms; Vomiting | 1987 |
Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility.
Topics: Animals; Benzamides; Cisplatin; Dogs; Dose-Response Relationship, Drug; Female; Gastrointestinal Mot | 1986 |
Effect of diphenhydramine on the antiemetic action of metoclopramide against cisplatin-induced emesis in dogs.
Topics: Animals; Behavior, Animal; Central Nervous System Diseases; Cisplatin; Diphenhydramine; Dogs; Metocl | 1986 |
[Antiemetic inefficacy of high intravenous doses of metoclopramide by short-term infusion in vomiting induced by antineoplastic chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Parenteral; Metoclop | 1986 |
Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Combinations; Female; Humans; Male; Metoclopramide; Midd | 1986 |
Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases.
Topics: Adult; Aged; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Metoclopramide; | 1986 |
5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.
Topics: Animals; Antiemetics; Cisplatin; Ferrets; Indoles; Male; Metoclopramide; Receptors, Serotonin; Tropi | 1986 |
Diabetes mellitus: gastrointestinal complications.
Topics: Blood Glucose; Cholecystitis; Cholelithiasis; Diabetes Complications; Diabetic Neuropathies; Esophag | 1986 |
[Evaluation of an antiemetic regimen with a high-dose metoclopramide, dexamethasone and diphenhydramine combination in chemotherapy regimens with cisplatin].
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Combination; Humans; Metoclopr | 1986 |
[Experimental study on the control of cisplatin-induced emesis in dogs].
Topics: Analysis of Variance; Animals; Cisplatin; Dogs; Metoclopramide; Nausea; Vagotomy; Vomiting | 1987 |
Metoclopramide versus chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
Topics: Chlorpromazine; Humans; Metoclopramide; Nausea; Vomiting | 1985 |
Metoclopramide as an antiemetic agent in pediatric oncology patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Humans; Male; Metoclopramide; Neoplasms; Vo | 1986 |
Antiemetic effect of high-dose metoclopramide.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Vomiting | 1986 |
Continuous infusion of metoclopramide for prevention of chemotherapy-induced emesis.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Dacarbazine; Female; Humans; Infusions, Parenteral; M | 1986 |
Anaesthesia and emesis. Clinical usefulness of metoclopramide.
Topics: Adult; Anesthesia; Humans; Metoclopramide; Postoperative Complications; Vomiting | 1985 |
[Primperan: recent pharmacological data on its gastromotor effect].
Topics: Gastrointestinal Motility; Humans; Metoclopramide; Vomiting | 1985 |
[Primperan during pregnancy].
Topics: Female; Heartburn; Humans; Metoclopramide; Pneumonia, Aspiration; Pregnancy; Pregnancy Complications | 1985 |
[Value of primperan in digestive studies].
Topics: Biopsy; Digestive System; Endoscopy; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; I | 1985 |
Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis.
Topics: Adult; Cisplatin; Dose-Response Relationship, Drug; Humans; Infusions, Parenteral; Kinetics; Male; M | 1985 |
[Cisplatin drug therapy. Antiemetic treatment. Experiences with the use of high-dose metoclopramide combined with chlopromazine and prochlorperazine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Dose-Response Relat | 1985 |
Parkinsonism following i.v. administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Cisplatin; Female; Humans; Metoclopramide; Nausea; Ovaria | 1985 |
High-dose metoclopramide as an antiemetic in patients receiving cis-platinum-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Female; Humans; Male; Metoclopr | 1985 |
High-dose intravenous metoclopramide and intermittent intramuscular prochlorperazine and diazepam in the management of emesis induced by cis-dichlorodiammineplatinum.
Topics: Antiemetics; Cisplatin; Diazepam; Drug Therapy, Combination; Humans; Injections, Intramuscular; Meto | 1985 |
Lack of antiemetic effect of high-dose metoclopramide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; | 1985 |
[Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting].
Topics: Aged; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lung Neopl | 1985 |
Review of the current status of prokinetic agents in gastroenterology.
Topics: Benzamides; Chemical Phenomena; Chemistry; Cisapride; Dexamethasone; Digestive System; Domperidone; | 1985 |
The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum.
Topics: Cisplatin; Humans; Kinetics; Metoclopramide; Nausea; Vomiting | 1985 |
Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis.
Topics: Basal Ganglia Diseases; Cisplatin; Dose-Response Relationship, Drug; Hemodynamics; Humans; Metoclopr | 1985 |
Sequential therapy with lithium in chemotherapy-induced vomiting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Domperidone; Drug Evaluatio | 1985 |
Metoclopramide in prevention of postanaesthetic vomiting.
Topics: Adolescent; Adult; Aged; Anesthesia, Inhalation; Female; Humans; Male; Metoclopramide; Middle Aged; | 1985 |
Triple tetracycline ('Deteclo') as a single dose oral treatment of uncomplicated gonorrhoea in the male.
Topics: Administration, Oral; Adolescent; Adult; Chlortetracycline; Demeclocycline; Diarrhea; Drug Combinati | 1973 |
Hyperthyroidism presenting with acute abdominal symptoms.
Topics: Abdomen, Acute; Adult; Antacids; Body Weight; Carbimazole; Colic; Diarrhea; Female; Goiter; Hemateme | 1974 |
Studies of drugs given before anaesthesia. XXIV: Metocloramide with morphine and pethidine.
Topics: Adult; Anxiety; Female; Humans; Infant, Newborn; Meperidine; Metoclopramide; Morphine; Nausea; Prean | 1974 |
The premedicant and anti-emetic action of metoclopramide.
Topics: Atropine; Diazepam; Female; Humans; Hypnotics and Sedatives; Meperidine; Metoclopramide; Nausea; Pre | 1973 |
Metoclopramide--a new pharmacological approach?
Topics: Animals; Antiemetics; Gastroesophageal Reflux; Gastrointestinal Motility; Humans; Metoclopramide; Vo | 1973 |
The use of metoclopramide in the elderly.
Topics: Aged; Digitalis; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Geriatrics; Hiccup; Humans; | 1973 |
[Incorrect use of metoclopramide].
Topics: Humans; Infant; Meningitis; Metoclopramide; Vomiting | 1974 |